<Publications>
<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30125371</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>69</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r.</ArticleTitle>
            <Pagination>
                <MedlinePgn>513-523</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.30225</ELocationID>
            <Abstract>
                <AbstractText>Hepatitis C virus (HCV) genotype 4 is highly heterogeneous. HCV subtype 4r has been suggested to be less responsive to direct-acting antiviral (DAA) drug treatment than other genotype 4 subtypes. Among 537 DAA-treated patients who experienced a virological failure (VF) in France between 2015 and 2018, 121 (22.5%) were infected with genotype 4 and 27 of them (22.3%) with subtype 4r; subtype 4r was thus over-represented as compared to its prevalence in the French general population. Population sequencing of the nonstructural protein (NS) 3, NS5A, and NS5B genes was performed in all subtype 4r patients at treatment failure and in 6 at baseline, whereas full-length HCV genome sequencing was performed in two baseline and three treatment failure samples by means of an original shotgun metagenomics method based on deep sequencing. At treatment failure, all subtype 4r patients harbored two to three dominant NS5A resistance-associated substitutions (RASs), including at least L28A/C/I/M/V and L30R. Among 13 patients exposed to sofosbuvir and an NS5A inhibitor (daclatasvir, ledipasvir, or velpatasvir), 5 (38.5%) also harbored NS5B S282C/T RASs at treatment failure. An additional patient harbored S282C/T RASs at treatment failure by deep sequencing. Prevalence of S282C/T RASs at treatment failure was significantly higher in patients infected with genotype 4r than with other genotypes, including other subtypes of genotype 4. Conclusion: The lower rates of sustained virological response in patients infected with subtype 4r are related to the frequent preexistence at treatment baseline and subsequent selection by DAA treatment of both NS5A and NS5B S282 RASs. Our study suggests that these patients should be identified and receive a triple DAA combination regimen as first-line treatment.</AbstractText>
                <CopyrightInformation>© 2018 by the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fourati</LastName>
                    <ForeName>Slim</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rodriguez</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soulier</LastName>
                    <ForeName>Alexandre</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruiz</LastName>
                    <ForeName>Isaac</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poiteau</LastName>
                    <ForeName>Lila</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chevaliez</LastName>
                    <ForeName>Stéphane</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pawlotsky</LastName>
                    <ForeName>Jean-Michel</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>National Agency for Research on AIDS and Viral Hepatitis</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30125371</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.30225</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30107485</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1537-6591</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>68</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
                <ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.</ArticleTitle>
            <Pagination>
                <MedlinePgn>569-576</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciy547</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">This study was performed to investigate the efficacy and safety of grazoprevir-elbasvir guided by baseline resistance-associated substitutions (RASs) in the Swiss HCVree Trial.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We performed hepatitis C virus (HCV) RNA screening among all men who have sex with men (MSM) enrolled in the Swiss HIV Cohort Study. Individuals with replicating HCV genotype 1 or 4 infection were eligible for grazoprevir-elbasvir treatment. Genotype 1a-infected individuals with baseline RASs and genotype 4-infected individuals with prior failure of HCV treatment received 16 weeks of grazoprevir-elbasvir combined with ribavirin. All other individuals received 12 weeks of grazoprevir-elbasvir alone. Patients reporting unprotected sex with occasional partners were offered a HCV risk reduction-oriented behavioral intervention.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">We screened 3722 MSM and identified 177 (4.8%) with replicating infection. A total of 122 individuals (3.3%) were eligible for study treatment. Six of 76 patients infected with genotype 1a (7.3%) harbored baseline RASs. Sustained virological response after 12 weeks of follow-up was achieved in 121 patients (99%), including all with genotype 1a infection. Overall, 8 serious adverse events occurred, none of which was related to the study drug. Seventy-five percent of eligible MSM participated in the risk counseling program.</AbstractText>
                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Grazoprevir-elbasvir for 12 or 16 weeks, with or without ribavirin, achieved high cure rates and had an excellent safety profile. Unique to other studies, the treatment duration was guided by the presence of baseline RASs among genotype 1a-infected individuals, and the treatment phase was accompanied by an HCV risk reduction-oriented behavioral intervention. This successful population-wide treatment approach lays the groundwork to achieve HCV elimination in coinfected MSM.</AbstractText>
                <AbstractText Label="Clinical Trials Registration" NlmCategory="UNASSIGNED">NCT02785666.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Braun</LastName>
                    <ForeName>Dominique L</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Virology, University of Zurich.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hampel</LastName>
                    <ForeName>Benjamin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Virology, University of Zurich.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kouyos</LastName>
                    <ForeName>Roger</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Virology, University of Zurich.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Huyen</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>Cyril</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Virology, University of Zurich.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flepp</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center of Infectious Diseases Zurich.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stöckle</LastName>
                    <ForeName>Marcel</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases &amp; Hospital Epidemiology, University Hospital Basel, University of Basel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conen</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases and Hospital Hygiene, Cantonal Hospital Aarau.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Béguelin</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Bern University Hospital, University of Bern.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Künzler-Heule</LastName>
                    <ForeName>Patrizia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Nursing Science, University Hospital Basel, University of Basel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nicca</LastName>
                    <ForeName>Dunja</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Nursing Science, University Hospital Basel, University of Basel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmid</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Cantonal Hospital St Gallen.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delaloye</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Intensive Care Unit, Department of Intensive Care Medicine, University of Lausanne and University Hospital Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rougemont</LastName>
                    <ForeName>Mathieu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, University Hospital Geneva.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernasconi</LastName>
                    <ForeName>Enos</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Regional Hospital Lugano.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rauch</LastName>
                    <ForeName>Andri</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Bern University Hospital, University of Bern.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Günthard</LastName>
                    <ForeName>Huldrych F</ForeName>
                    <Initials>HF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Virology, University of Zurich.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Böni</LastName>
                    <ForeName>Jürg</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Virology, University of Zurich.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fehr</LastName>
                    <ForeName>Jan S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Swiss HIV Cohort Study </CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02785666</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Infect Dis</MedlineTA>
            <NlmUniqueID>9203213</NlmUniqueID>
            <ISSNLinking>1058-4838</ISSNLinking>
        </MedlineJournalInfo>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Anagnostopoulos</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Battegay</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>B</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>B</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>B</LastName>
                <ForeName>D L</ForeName>
                <Initials>DL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bucher</LastName>
                <ForeName>H C</ForeName>
                <Initials>HC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Calmy</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cavassini</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ciuffi</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dollenmaier</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Egger</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Elzi</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>F</LastName>
                <ForeName>J S</ForeName>
                <Initials>JS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fellay</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Furrer</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fux</LastName>
                <ForeName>C A</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>G</LastName>
                <ForeName>H F</ForeName>
                <Initials>HF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Haerry</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hasse</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hirsch</LastName>
                <ForeName>H H</ForeName>
                <Initials>HH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoffmann</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hösli</LastName>
                <ForeName>I</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Huber</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kahlert</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kaiser</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Keiser</LastName>
                <ForeName>O</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klimkait</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>K</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kovari</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ledergerber</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martinetti</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martinez de Tejada</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marzolini</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Metzner</LastName>
                <ForeName>K J</ForeName>
                <Initials>KJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Müller</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>N</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paioni</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pantaleo</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perreau</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>R</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rudin</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scherrer</LastName>
                <ForeName>A U</ForeName>
                <Initials>AU</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>S</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Speck</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>S</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tarr</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trkola</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vernazza</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wandeler</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weber</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yerly</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30107485</ArticleId>
            <ArticleId IdType="pii">5071945</ArticleId>
            <ArticleId IdType="doi">10.1093/cid/ciy547</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29599611</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">2219-2840</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Mar</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of gastroenterology</Title>
                <ISOAbbreviation>World J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1361-1372</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v24.i12.1361</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess daclatasvir plus asunaprevir (DUAL) in treatment-naïve patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype 1b infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients were randomly assigned (3:1) to receive 24 wk of treatment with DUAL (daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily) beginning on day 1 of the treatment period (immediate treatment arm) or following 12 wk of matching placebo (placebo-deferred treatment arm). The primary endpoint was a comparison of sustained virologic response at posttreatment week 12 (SVR12) compared with the historical SVR rate for peg-interferon plus ribavirin (70%) among patients in the immediate treatment arm. The first 12 wk of the study were blinded. Safety was assessed in DUAL-treated patients compared with placebo patients during the first 12 wk (double-blind phase), and during 24 wk of DUAL in both arms combined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 207 patients were randomly assigned to immediate (<i>n</i> = 155) or placebo-deferred (<i>n</i> = 52) treatment. Most patients were Asian (86%), female (59%) and aged &lt; 65 years (90%). Among them, 13% had cirrhosis, 32% had <i>IL28B</i> non-CC genotypes and 53% had baseline HCV RNA levels of ≥ 6 million IU/mL. Among patients in the immediate treatment arm, SVR12 was achieved by 92% (95% confidence interval: 87.2-96.0), which was significantly higher than the historical comparator rate (70%). SVR12 was largely unaffected by cirrhosis (89%), age ≥ 65 years (92%), male sex (90%), baseline HCV RNA ≥ 6 million (89%) or <i>IL28B</i> non-CC genotypes (96%), although SVR12 was higher among patients without (96%) than among those with (53%) baseline NS5A resistance-associated polymorphisms (at L31 or Y93H). During the double-blind phase, aminotransferase elevations were more common among placebo recipients than among patients receiving DUAL. During 24 wk of DUAL therapy (combined arms), the most common adverse events (≥ 10%) were elevated alanine aminotransferase and upper respiratory tract infection; emergent grade 3-4 laboratory abnormalities were infrequently observed, and all grade 3-4 aminotransferase abnormalities (alanine aminotransferase, <i>n</i> = 9; aspartate transaminase, <i>n</i> = 6) reversed within 8-11 d. Two patients discontinued DUAL treatment; one due to aminotransferase elevations, nausea, and jaundice and the other due to a fatal adverse event unrelated to treatment. There were no treatment-related deaths.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DUAL was well-tolerated during this phase 3 study, and SVR12 with DUAL treatment (92%) exceeded the historical SVR rate for peg-interferon plus ribavirin of 70%.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Lai</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peking University People's Hospital and Peking University Hepatology Institute, Beijing 100044, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Fu-Sheng</ForeName>
                    <Initials>FS</Initials>
                    <AffiliationInfo>
                        <Affiliation>302 Military Hospital of China, Beijing 100039, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Ming-Xiang</ForeName>
                    <Initials>MX</Initials>
                    <AffiliationInfo>
                        <Affiliation>the Sixth People's Hospital of Shenyang, Shenyang 110006, Liaoning Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Ji-Dong</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yakovlev</LastName>
                    <ForeName>Alexey A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Saint-Petersburg State Healthcare Institution 'Clinical Infectious Hospital n.a. S.P. Botkin', Saint-Petersburg 191167, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burnevich</LastName>
                    <ForeName>Eduard</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niu</LastName>
                    <ForeName>Jun-Qi</ForeName>
                    <Initials>JQ</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Hospital of Jilin University, Jilin 1300021, Jilin Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Yong Jin</ForeName>
                    <Initials>YJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>SMG-SNU Boramae Medical Center, Seoul 07061, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Xiang-Jun</ForeName>
                    <Initials>XJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Qingdao Municipal Hospital, Qingdao 266011, Shandong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Guangzhou No. 8 People's Hospital, Guangzhou 510060, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xin-Yue</ForeName>
                    <Initials>XY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Ruijin Hospital, Jiaotong University School of Medicine, Shenyang 200025, Liaoning Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>TheFirst Affiliated Hospital with Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>Jin-Lin</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dou</LastName>
                    <ForeName>Xiao-Guang</ForeName>
                    <Initials>XG</Initials>
                    <AffiliationInfo>
                        <Affiliation>China Medical University, Shengjing Hospital, Shenyang 110004, Liaoning Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gandhi</LastName>
                    <ForeName>Yash</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ 08540, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Wen-Hua</ForeName>
                    <Initials>WH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ 08540, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT 06492, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noviello</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ 08540, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Treitel</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ 08540, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Shanghai 200040, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deng</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Shanghai 200040, China. daniel.deng@bms.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>World J Gastroenterol</MedlineTA>
            <NlmUniqueID>100883448</NlmUniqueID>
            <ISSNLinking>1007-9327</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S9X0KRJ00S</RegistryNumber>
                <NameOfSubstance UI="C571889">asunaprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056910" MajorTopicYN="N">Republic of Korea</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012426" MajorTopicYN="N">Russia</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Asunaprevir</Keyword>
            <Keyword MajorTopicYN="N">Chronic hepatitis C</Keyword>
            <Keyword MajorTopicYN="N">Daclatasvir</Keyword>
            <Keyword MajorTopicYN="N">Direct-acting antiviral</Keyword>
            <Keyword MajorTopicYN="N">Genotype 1b</Keyword>
            <Keyword MajorTopicYN="N">Liver disease</Keyword>
            <Keyword MajorTopicYN="N">NS3</Keyword>
            <Keyword MajorTopicYN="N">NS5A</Keyword>
        </KeywordList>
        <CoiStatement>Conflict-of-interest statement: All authors have no conflicts of interest for this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29599611</ArticleId>
            <ArticleId IdType="doi">10.3748/wjg.v24.i12.1361</ArticleId>
            <ArticleId IdType="pmc">PMC5871831</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Hippokratia. 2009 Oct;13(4):211-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20011084</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Ther. 2015 Jul;32(7):637-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26155891</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol Hepatol. 2016 Nov;31(11):1860-1867</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27003037</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatol Int. 2015 Jul;9(3):378-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26071238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Drug Saf. 2011 Jul;10 (4):529-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21345149</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2014;19(5):479-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24448487</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22869577</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol Hepatol. 2016 Jan;31(1):14-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26252875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Nov 1;384(9954):1597-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25078304</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virol J. 2017 Feb 23;14 (1):41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28231805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2016 Oct;20:99-105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27741441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Ther. 2016 Jul;33(7):1169-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27287851</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Comp Eff Res. 2015 Nov;4(6):593-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26159375</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 1996 Nov;25(5):591-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8938532</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2011 Jul;31 Suppl 2:61-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21651703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 19;366(3):216-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22256805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2013;18(7):885-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23804631</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2016 Oct;36(10 ):1433-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27009831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2016 Jul;36(7):954-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26683763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Zhonghua Gan Zang Bing Za Zhi. 2015 Dec;23(12):906-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26739465</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2017 Jan;37(1):5-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27473533</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2083-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24604476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Mar;60(3):490-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24444658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Medicine (Baltimore). 2016 Jul;95(28):e4151</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27428205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Value Health Reg Issues. 2017 May;12 :1-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28648305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterol Clin North Am. 2015 Dec;44(4):793-805</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26600220</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Apr;57(4):1333-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23172780</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">29504692</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1386-6346</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>48</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology research : the official journal of the Japan Society of Hepatology</Title>
                <ISOAbbreviation>Hepatol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen.</ArticleTitle>
            <Pagination>
                <MedlinePgn>802-809</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/hepr.13074</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The therapeutic benefit of adding ribavirin (RBV) to 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) for patients who experienced failure of a previous nonstructural protein (NS) 5A inhibitor-containing regimen is unclear.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 29 genotype 1b HCV patients who had failed prior daclatasvir (DCV) plus asunaprevir (ASV) treatment were retreated for 12 weeks of LDV/SOF, with or without RBV. Antiviral efficacy and predictive factors associating with a sustained virological response at 24 weeks (SVR24) were evaluated retrospectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">SVR24 was achieved in 67% (10/15) of patients who received LDV/SOF with, and 64% (9/14) without, RBV. The SVR24 rates were 80% in patients with, and 58% without, mild fibrosis (FIB-4 &lt; 3.25). The SVR24 rate was lower with unfavorable IL28B rs8099917 SNP genotypes; specifically, the TT, TG and GG had SVR24 rates of 78%, 50% and 40%. The SVR24 rate was lower with a poor response to prior DCV plus ASV, where relapse, viral breakthrough and no response had SVR24 rates 71%, 58% and 0%. The SVR24 rate was lower with the number of NS5A resistance-associated substitutions (RAS), where 2, 3, 4 and 5 RAS had SVR24 rates of 78%, 67%, 50% and 0%. A patient with an NS5A-P32 deletion, which shows resistance to next-generation NS5A inhibitors, was retreated with LDV/SOF with RBV and achieved SVR24.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The addition of RBV to 12 weeks of LDV/SOF has little therapeutic benefit when retreating patients in whom a prior NS5A inhibitor-containing regimen had failed.</AbstractText>
                <CopyrightInformation>© 2018 The Japan Society of Hepatology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ikeda</LastName>
                    <ForeName>Hiroki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>Tsunamasa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimizu</LastName>
                    <ForeName>Hirohito</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepato-Biliary-Pancreatic Center, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hiraishi</LastName>
                    <ForeName>Tetsuya</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Kawasaki Municipal Tama Hospital, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaneko</LastName>
                    <ForeName>Rena</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Japan Labour Health and Welfare Organization Kanto Rosai Hospital, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baba</LastName>
                    <ForeName>Toshiyuki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Hideaki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsunaga</LastName>
                    <ForeName>Kotaro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>Nobuyuki</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yasuda</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4547-5213</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okuse</LastName>
                    <ForeName>Chiaki</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Kawasaki Municipal Tama Hospital, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iwabuchi</LastName>
                    <ForeName>Shogo</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepato-Biliary-Pancreatic Center, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Michihiro</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Kawasaki Municipal Tama Hospital, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itoh</LastName>
                    <ForeName>Fumio</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, school of medicine, Kawasaki, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Hepatol Res</MedlineTA>
            <NlmUniqueID>9711801</NlmUniqueID>
            <ISSNLinking>1386-6346</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">P32 deletion</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="N">ledipasvir</Keyword>
            <Keyword MajorTopicYN="N">nonstructural protein 5A inhibitor</Keyword>
            <Keyword MajorTopicYN="N">retreatment</Keyword>
            <Keyword MajorTopicYN="N">ribavirin</Keyword>
            <Keyword MajorTopicYN="N">sofosbuvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29504692</ArticleId>
            <ArticleId IdType="doi">10.1111/hepr.13074</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29473975</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>67</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>06</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2113-2126</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.29852</ELocationID>
            <Abstract>
                <AbstractText>Many direct-acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis. The C-ISLE study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) in compensated cirrhotic participants with GT3 infection. This was a phase 2, randomized, open-label study. Treatment-naive participants received EBR/GZR + SOF + RBV for 8 weeks or EBR/GZR + SOF for 12 weeks, and peginterferon/RBV treatment-experienced participants received EBR/GZR + SOF ± RBV for 12 weeks or EBR/GZR + SOF for 16 weeks. The primary endpoint was HCV RNA &lt;15 IU/mL 12 weeks after the end of treatment (sustained virologic response at 12 weeks [SVR12]). Among treatment-naive participants, SVR12 was 91% (21/23) in those treated with RBV for 8 weeks and 96% (23/24) in those treated for 12 weeks. Among treatment-experienced participants, SVR12 was 94% (17/18) and 100% (17/17) in the 12-week arm, with and without RBV, respectively, and 94% (17/18) in the 16-week arm. Five participants failed to achieve SVR: 2 relapsed (both in the 8-week arm), 1 discontinued due to vomiting/cellulitis (16-week arm), and 2 discontinued (consent withdrawn/lost to follow-up). SVR12 was not affected by the presence of resistance-associated substitutions (RASs). There was no consistent change in insulin resistance, and 5 participants reported serious adverse events (pneumonia, chest pain, opiate overdose, cellulitis, decreased creatinine). High efficacy was demonstrated in participants with HCV GT3 infection and cirrhosis. Treatment beyond 12 weeks was not required, and efficacy was maintained regardless of baseline RASs.</AbstractText>
                <AbstractText Label="CONCLUSION">Data from this study support the use of EBR/GZR plus SOF for 12 weeks without RBV for treatment-naive and peginterferon/RBV-experienced people with GT3 infection and cirrhosis (ClinicalTrials.gov NCT02601573). (Hepatology 2018;67:2113-2126).</AbstractText>
                <CopyrightInformation>© 2018 by the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Foster</LastName>
                    <ForeName>Graham R</ForeName>
                    <Initials>GR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Queen Mary University, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agarwal</LastName>
                    <ForeName>Kosh</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Liver Studies, Kings College Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cramp</LastName>
                    <ForeName>Matthew E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>South West Liver Unit, Derriford Hospital and Peninsula Schools of Medicine and Dentistry, Plymouth, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moreea</LastName>
                    <ForeName>Sulleman</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bradford Teaching Hospitals Foundation Trust, Bradford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barclay</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Glasgow Royal Campus, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collier</LastName>
                    <ForeName>Jane</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>John Radcliffe Hospital, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Ashley S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ryder</LastName>
                    <ForeName>Stephen D</ForeName>
                    <Initials>SD</Initials>
                    <AffiliationInfo>
                        <Affiliation>NIHR Biomedical Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospital NHS Trust and The University of Nottingham, Nottingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ustianowski</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>North Manchester General Hospital, Manchester, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forton</LastName>
                    <ForeName>Daniel M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>St. Georges University of London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fox</LastName>
                    <ForeName>Ray</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gartnavel General Hospital, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Joint Clinical Research Unit, Bristol, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenberg</LastName>
                    <ForeName>William M</ForeName>
                    <Initials>WM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Liver and Digestive Health, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mutimer</LastName>
                    <ForeName>David J</ForeName>
                    <Initials>DJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>QE Hospital, Birmingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Jiejun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilbert</LastName>
                    <ForeName>Christopher L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asante-Appiah</LastName>
                    <ForeName>Ernest</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haber</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02601573</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000611265">elbasvir-grazoprevir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29473975</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.29852</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">29461687</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-3231</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>38</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>09</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
                <ISOAbbreviation>Liver Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1583-1591</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.13727</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">The aim of this integrated analysis was to assess the efficacy of the once-daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without ribavirin in HCV genotype 4 (GT4)-infected participants enrolled in the Phase 2/3 clinical programme with elbasvir/grazoprevir.</AbstractText>
                <AbstractText Label="METHODS">Treatment-naïve and treatment-experienced participants 18 years of age or older with chronic HCV GT4 infection and baseline HCV RNA ≥10 000 IU/mL were included in the analysis. The analysis population was the full analysis set (FAS; all participants who received at least 1 dose of study medication) and a total of 155 HCV GT4 participants were evaluated. The primary endpoint was sustained virologic response at week 12 (SVR12; HCV RNA less than the lower limit of quantitation at 12 weeks after the completion of study therapy).</AbstractText>
                <AbstractText Label="RESULTS">Overall, among GT4-infected participants treated with 12 or 16 weeks of elbasvir/grazoprevir ± ribavirin, the SVR12 efficacy rates were 96.4% (107/111) in treatment-naïve participants and 88.6% (39/44) in treatment-experienced participants. The SVR12 rates were 96.0% (97/101) in treatment-naïve participants treated with 12 weeks of elbasvir/grazoprevir and 100% (8/8) in treatment-experienced participants treated with 16 weeks of elbasvir/grazoprevir plus ribavirin. Efficacy was not impacted by GT4 subtype.</AbstractText>
                <AbstractText Label="CONCLUSIONS">The regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. Baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir in GT4-infected participants.</AbstractText>
                <CopyrightInformation>© 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Asselah</LastName>
                    <ForeName>Tarik</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">0000-0002-0024-0595</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Department, AP-HP, University Paris Diderot, INSERM UMR1149, Beaujon Hospital, Clichy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reesink</LastName>
                    <ForeName>Hendrik</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">0000-0002-5298-2494</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gerstoft</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Ledinghen</LastName>
                    <ForeName>Victor</ForeName>
                    <Initials>V</Initials>
                    <Identifier Source="ORCID">0000-0001-6414-1951</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Service d'Hépato-Gastroentérologie, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pockros</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Peggy</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asante-Appiah</LastName>
                    <ForeName>Ernest</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Bach-Yen</ForeName>
                    <Initials>BY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Talwani</LastName>
                    <ForeName>Rohit</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serfaty</LastName>
                    <ForeName>Lawrence</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Saint-Antoine Hospital, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01932762</AccessionNumber>
                        <AccessionNumber>NCT02105467</AccessionNumber>
                        <AccessionNumber>NCT02105662</AccessionNumber>
                        <AccessionNumber>NCT02105688</AccessionNumber>
                        <AccessionNumber>NCT02252016</AccessionNumber>
                        <AccessionNumber>NCT02251990</AccessionNumber>
                        <AccessionNumber>NCT02105701</AccessionNumber>
                        <AccessionNumber>NCT02358044</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Liver Int</MedlineTA>
            <NlmUniqueID>101160857</NlmUniqueID>
            <ISSNLinking>1478-3223</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">elbasvir</Keyword>
            <Keyword MajorTopicYN="Y">genotype 4</Keyword>
            <Keyword MajorTopicYN="Y">grazoprevir</Keyword>
            <Keyword MajorTopicYN="Y">hepatitis C</Keyword>
            <Keyword MajorTopicYN="Y">ribavirin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29461687</ArticleId>
            <ArticleId IdType="doi">10.1111/liv.13727</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29454794</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>154</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>06</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2194-2208.e12</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(18)30212-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2018.02.017</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Chronic liver diseases caused by hepatitis C virus (HCV) genotype 6 are prevalent in Asia, and millions of people require treatment with direct-acting antiviral regimens, such as NS5A inhibitor velpatasvir combined with the NS5B polymerase inhibitor sofosbuvir. We developed infectious cell culture models of HCV genotype 6a infection to study the effects of these inhibitors and the development of resistance.</AbstractText>
                <AbstractText Label="METHODS">The consensus sequences of strains HK2 (MG717925) and HK6a (MG717928), originating from serum of patients with chronic HCV infection, were determined by Sanger sequencing of genomes amplified by reverse-transcription polymerase chain reaction. In vitro noninfectious full-length clones of these 6a strains were subsequently adapted in Huh7.5 cells, primarily by using substitutions identified in JFH1-based Core-NS5A and Core-NS5B genotype 6a recombinants. We studied the efficacy of NS5A and NS5B inhibitors in concentration-response assays. We examined the effects of long-term culture of Huh7.5 cells incubated with velpatasvir and sofosbuvir singly or combined following infection with passaged full-length HK2 or HK6a recombinant viruses. Resistance-associated substitutions (RAS) were identified by Sanger and next-generation sequencing, and their effects on viral fitness and in drug susceptibility were determined in reverse-genetic experiments.</AbstractText>
                <AbstractText Label="RESULTS">Adapted full-length HCV genotype 6a recombinants HK2cc and HK6acc had fast propagation kinetics and high infectivity titers. Compared with an HCV genotype 1a recombinant, HCV genotype 6a recombinants of strains HK2 and HK6a were equally sensitive to daclatasvir, elbasvir, velpatasvir, pibrentasvir, and sofosbuvir, but less sensitive to ledipasvir, ombitasvir, and dasabuvir. Long-term exposure of HCV genotype 6a-infected Huh7.5 cells with a combination of velpatasvir and sofosbuvir resulted in clearance of the virus, but the virus escaped the effects of single inhibitors via emergence of the RAS L31V in NS5A (conferring resistance to velpatasvir) and S282T in NS5B (conferring resistance to sofosbuvir). Engineered recombinant genotype 6a viruses with single RAS mediated resistance to velpatasvir or sofosbuvir. HCV genotype 6a viruses with RAS NS5A-L31V or NS5B-S282T were however, able to propagate and escape in Huh7.5 cells exposed to the combination of velpatasvir and sofosbuvir. Further, HCV genotype 6a with NS5A-L31V was able to propagate and escape in the presence of pibrentasvir with emergence of NS5A-L28S, conferring a high level of resistance to this inhibitor.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Strains of HCV genotype 6a isolated from patients can be adapted to propagate in cultured cells, permitting studies of the complete life cycle for this important genotype. The combination of velpatasvir and sofosbuvir is required to block propagation of original HCV genotype 6a, which quickly becomes resistant to single inhibitors via the rapid emergence and persistence of RAS. These features of HCV genotype 6a could compromise treatment.</AbstractText>
                <CopyrightInformation>Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pham</LastName>
                    <ForeName>Long V</ForeName>
                    <Initials>LV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramirez</LastName>
                    <ForeName>Santseharay</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gottwein</LastName>
                    <ForeName>Judith M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fahnøe</LastName>
                    <ForeName>Ulrik</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yi-Ping</ForeName>
                    <Initials>YP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pedersen</LastName>
                    <ForeName>Jannie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bukh</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: jbukh@sund.ku.dk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000622691">pibrentasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>KCU0C7RS7Z</RegistryNumber>
                <NameOfSubstance UI="C000604171">velpatasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">DAA</Keyword>
            <Keyword MajorTopicYN="Y">Escape Variants</Keyword>
            <Keyword MajorTopicYN="Y">In Vitro System</Keyword>
            <Keyword MajorTopicYN="Y">Nucleotide Analog</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29454794</ArticleId>
            <ArticleId IdType="pii">S0016-5085(18)30212-9</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2018.02.017</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29453451</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Feb</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
                <ISOAbbreviation>Sci Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3199</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-21303-2</ELocationID>
            <Abstract>
                <AbstractText>Baseline resistance-associated substitutions (RASs) have variable impacts in clinical trials but their prevalence and impact in real-world patients remains unclear. We performed baseline resistance testing using a commercial assay (10% cutoff) for 486 patients treated with LDV/SOF or SMV/SOF, with or without ribavirin, in the multi-center, observational HCV-TARGET cohort. Linkage of RASs was evaluated in selected samples using a novel quantitative single variant sequencing assay. Our results showed that the prevalence of NS3, NS5A, NS5B RASs was 45%, 13%, and 8%, respectively, and 10% of patients harbored RASs in 2 or more drug classes. Baseline LDV RASs in GT1a, TE, and cirrhosis LDV/SOF subgroup was associated with 2-4% lower SVR12 rates. SMV RASs was associated with lower SVR12 rates in GT1a, treatment-experienced, cirrhotics SMV/SOF subgroup. Pooled analysis of all patients with baseline RASs revealed that SVR12 was 100% (19/19) in patients treated for longer than 98 days but was 87% (81/93) in patients treated for shorter than 98 days. These results demonstrate that RASs prevalence and their impact in real world practice are in general agreement with registration trials, and suggest that longer treatment duration may overcome the negative impact of baseline RASs on SVR12 rates in clinical practice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Gary P</ForeName>
                    <Initials>GP</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, USA. gary.wang@medicine.ufl.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>North Florida/South Georgia Veterans Health System, Gainesville, USA. gary.wang@medicine.ufl.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Terrault</LastName>
                    <ForeName>Norah</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California, San Francisco, San Francisco, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reeves</LastName>
                    <ForeName>Jacqueline D</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Monogram Biosciences, South San Francisco, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Lin</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Joseph K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Yale University School of Medicine, New Haven, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morelli</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuo</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Virginia Mason Medical Center, Seattle, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levitsky</LastName>
                    <ForeName>Josh</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Northwestern University Feinberg School of Medicine, Chicago, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sherman</LastName>
                    <ForeName>Kenneth E</ForeName>
                    <Initials>KE</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Cincinnati, Cincinnati, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frazier</LastName>
                    <ForeName>Lynn M</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Wellness Center, Little Rock, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramani</LastName>
                    <ForeName>Ananthakrishnan</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Columbia Memorial Hospital (Mountainview Medical Center), Hudson, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peter</LastName>
                    <ForeName>Joy</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akuskevich</LastName>
                    <ForeName>Lucy</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of North Carolina, Chapel Hill, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fried</LastName>
                    <ForeName>Michael W</ForeName>
                    <Initials>MW</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of North Carolina, Chapel Hill, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA016086</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 DK078392</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 TR001863</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29453451</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-018-21303-2</ArticleId>
            <ArticleId IdType="pii">10.1038/s41598-018-21303-2</ArticleId>
            <ArticleId IdType="pmc">PMC5816647</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Nov 15;384(9956):1756-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25078309</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2017 Jun 1;376(22):2134-2146</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28564569</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2018 Jan 25;378(4):354-369</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29365309</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2016 Feb 04;6:20310</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26842909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2017 Jan;66(1):153-194</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27667367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20166-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22135472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2017 Oct;66(4):1090-1101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28504842</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2009 Apr;49(4):1335-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19330875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2016 Jun 24;11(6):e0157438</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27341031</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1999 Aug 19;341(8):556-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10451460</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Dec 31;373(27):2599-607</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26571066</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2012 May;86(10):5915-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22438535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 Aug;64(2):360-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26704148</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Aug 20;373(8):705-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26196665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Viruses. 2015 Dec 18;7(12):6716-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26694454</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Nov;62(5):1623-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Jul 29;8(7):e69698</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23922778</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2014 Oct;58(10):6079-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25092699</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virol J. 2015 Nov 14;12:186</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26577836</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28404132</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 May;54(5):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20176898</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Dec;151(6):1131-1140.e5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27565882</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19861128</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Sep;151(3):501-512.e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27296509</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2016 Mar 25;60(4):2402-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26856832</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biotechniques. 1993 Jul;15(1):120-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8363827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015 Aug 28;10(8):e0134395</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26317755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2017 May;66(5):910-918</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28108232</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29425404</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>68</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>07</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>380-383</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.29836</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Doi</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hikita</LastName>
                    <ForeName>Hayato</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">0000-0003-2488-7315</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakamori</LastName>
                    <ForeName>Ryotaro</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tahata</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kai</LastName>
                    <ForeName>Yugo</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamada</LastName>
                    <ForeName>Ryoko</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yakushijin</LastName>
                    <ForeName>Takayuki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mita</LastName>
                    <ForeName>Eiji</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohkawa</LastName>
                    <ForeName>Kazuyoshi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imai</LastName>
                    <ForeName>Yasuharu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ikeda Municipal Hospital, Ikeda, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furuta</LastName>
                    <ForeName>Kunimaro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kodama</LastName>
                    <ForeName>Takahiro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tatsumi</LastName>
                    <ForeName>Tomohide</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takehara</LastName>
                    <ForeName>Tetsuo</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>013TE6E4WV</RegistryNumber>
                <NameOfSubstance UI="C586541">ledipasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29425404</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.29836</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">29425396</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Feb</Month>
                        <Day>09</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.29837</ELocationID>
            <Abstract>
                <AbstractText>Hepatitis C virus (HCV) genotype (gt) 3 is highly prevalent globally, with non-gt3a subtypes common in Southeast Asia. Resistance-associated substitutions (RASs) have been shown to play a role in treatment failure. However, the role of RASs in gt3 is not well understood. We report the prevalence of RASs in a cohort of direct-acting antiviral treatment-naive, gt3-infected patients, including those with rarer subtypes, and evaluate the effect of these RASs on direct-acting antivirals in vitro. Baseline samples from 496 gt3 patients enrolled in the BOSON clinical trial were analyzed by next-generation sequencing after probe-based enrichment for HCV. Whole viral genomes were analyzed for the presence of RASs to approved direct-acting antivirals. The resistance phenotype of RASs in combination with daclatasvir, velpatasvir, pibrentasvir, elbasvir, and sofosbuvir was measured using the S52 ΔN gt3a replicon model. The nonstructural protein 5A A30K and Y93H substitutions were the most common at 8.9% (n = 44) and 12.3% (n = 61), respectively, and showed a 10-fold and 11-fold increase in 50% effect concentration for daclatasvir compared to the unmodified replicon. Paired RASs (A30K + L31M and A30K + Y93H) were identified in 18 patients (9 of each pair); these combinations were shown to be highly resistant to daclatasvir, velpatasvir, elbasvir, and pibrentasvir. The A30K + L31M combination was found in all gt3b and gt3g samples.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study reveals high frequencies of RASs to nonstructural protein 5A inhibitors in gt3 HCV; the paired A30K + L31M substitutions occur in all patients with gt3b and gt3g virus, and in vitro analysis suggests that these subtypes may be inherently resistant to all approved nonstructural protein 5A inhibitors for gt3 HCV. (Hepatology 2018).</AbstractText>
                <CopyrightInformation>© 2018 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7778-7137</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Magri</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Oxford Martin School, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonsall</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ip</LastName>
                    <ForeName>Camilla L C</ForeName>
                    <Initials>CLC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trebes</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piazza</LastName>
                    <ForeName>Palo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowden</LastName>
                    <ForeName>Rory</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8596-0366</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Dung</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ansari</LastName>
                    <ForeName>M Azim</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Oxford Martin School, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simmonds</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barnes</LastName>
                    <ForeName>Eleanor</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>STOP-HCV Consortium</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MR/K01532X/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29425396</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.29837</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">29404477</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2471-254X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>08</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology communications</Title>
                <ISOAbbreviation>Hepatol Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>538-549</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep4.1060</ELocationID>
            <Abstract>
                <AbstractText>S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF-based regimen. Here, the emergence and fitness of the S282T substitution in virologic failure patients administered SOF-based regimens across the SOF and ledipasvir (LDV)/SOF phase 2 and 3 programs was evaluated. Plasma samples collected at baseline and at virologic failure were amplified and deep sequenced (1% cutoff). To date, over 12,000 patients have been treated in SOF or LDV/SOF phase 2 and 3 studies. Of these, deep sequencing was available at baseline in 8598 patients (62.4% genotype [GT] 1, 10.7% GT2, 20.9% GT3, and 6.0% GT4-6) and at virologic failure in 901 patients. In the 8598 patients, no S282T substitution was detected at baseline; at virologic failure, 10 of the 901 (1%) patients had S282T detected. The SOF-based regimen associated with treatment-emergent S282T was SOF monotherapy in two patients, retreatment with LDV/SOF in prior LDV/SOF failures in three patients, LDV/SOF for 8 weeks in 1 GT1 patient, LDV/SOF for 12 weeks in 1 patient each with GT3, GT4, and GT5, and LDV/SOF + ribavirin for 12 weeks in 1 GT6 patient. Nine of 10 patients with emergent S282T received an SOF-based retreatment regimen, eight of whom achieved sustained virologic response 12 weeks after treatment and one of whom failed retreatment. <i>Conclusion</i>: The emergence of S282T substitution was rare in patients who fail SOF-based regimens. Successful retreatment of prior SOF failure patients is possible in the presence of S282T substitution with SOF in combination with various direct-acting antiviral agents. (<i>Hepatology Communications</i> 2017;1:538-549).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Auckland Clinical Studies Auckland New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Metivier</LastName>
                    <ForeName>Sophie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre Hospitalier Universitaire-Purpan Toulouse France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahass</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>ID Care, Inc Hillsborough NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ryan</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Liver Disease Specialists Norfolk VA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stedman</LastName>
                    <ForeName>Catherine A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Christchurch Hospital and University of Otago Christchurch New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia S</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doehle</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hedskog</LastName>
                    <ForeName>Charlotte</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jenny C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc Foster City CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine Baltimore MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Younes</LastName>
                    <ForeName>Ziad</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastro One Germantown TN.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute University of Texas Health Science Center San Antonio TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatol Commun</MedlineTA>
            <NlmUniqueID>101695860</NlmUniqueID>
            <ISSNLinking>2471-254X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29404477</ArticleId>
            <ArticleId IdType="doi">10.1002/hep4.1060</ArticleId>
            <ArticleId IdType="pii">HEP41060</ArticleId>
            <ArticleId IdType="pmc">PMC5678900</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 May;53(5):1742-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21374691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2016 Feb 04;6:20310</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26842909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2015 Sep;15(9):1049-1054</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26187031</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Transl Med. 2010 May 5;2(30):30ra32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20445200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 May;60(5):920-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24434503</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2014 Dec 15;59(12):1666-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25266287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2013 May;13(5):401-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23499158</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2014 Nov 4;161(9):634-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25364884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jun;61(6):1793-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25846014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 Feb;52(2):458-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17999967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Feb 8;383(9916):515-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24209977</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2013 Feb;87(3):1544-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23152524</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2015 Jan;35(1):79-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24814388</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2012 Oct;50(10):3267-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22837328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2016;21(5):447-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26789637</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2005 Sep;5(9):558-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16122679</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22430955</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1993-2001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24795201</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2012 Jul;57(1):24-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22314425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2016 Apr;16(4):459-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26803446</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2016 Apr 15;213(8):1240-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26603202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Sep;151(3):501-512.e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27296509</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2015 Nov;22(11):871-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25784085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2014 Mar 1;209(5):668-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24154738</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2016 Jan 11;60(3):1847-1853</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26824950</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2011 Sep;55(9):4196-203</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21746939</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2010 Feb;138(2):447-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20006612</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 Oct;64(4):1049-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27351341</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 Jan 3;368(1):34-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23281974</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29274866</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>154</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>04</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1435-1448</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(17)36720-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2017.12.015</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Inhibitors of the hepatitis C virus (HCV) NS5A protein are a key component of effective treatment regimens, but the genetic heterogeneity of HCV has limited the efficacy of these agents and mutations lead to resistance. We directly compared the efficacy of all clinically relevant NS5A inhibitors against HCV genotype 1-7 prototype isolates and resistant escape variants, and investigated the effects of pre-existing resistance-associated substitutions (RAS) on HCV escape from treatment.</AbstractText>
                <AbstractText Label="METHODS">We measured the efficacy of different concentrations of daclatasvir, ledipasvir, ombitasvir, elbasvir, ruzasvir, velpatasvir, and pibrentasvir in cultured cells infected with HCV recombinants expressing genotype 1-7 NS5A proteins with or without RAS. We engineered HCV variants that included RAS identified in escape experiments, using recombinants with or without T/Y93H and daclatasvir, or that contained RAS previously reported from patients.</AbstractText>
                <AbstractText Label="RESULTS">NS5A inhibitors had varying levels of efficacy against original and resistant viruses. Only velpatasvir and pibrentasvir had uniform high activity against all HCV genotypes tested. RAS hotspots in NS5A were found at amino acids 28, 30, 31, and 93. Engineered escape variants had high levels of fitness. Pibrentasvir had the highest level of efficacy against variants; viruses with RAS at amino acids 28, 30, or 31 had no apparent resistance to pibrentasvir, and HCV with RAS at amino acid 93 had a low level of resistance to this drug. However, specific combinations of RAS and deletion of amino acid 32 led to significant resistance to pibrentasvir. For the remaining NS5A inhibitors tested, RAS at amino acids 28 and 93 led to high levels of resistance. Among these inhibitors, velpatasvir was more effective against variants with RAS at amino acid 30 and some variants with RAS at amino acid 31 than the other agents. Variants with the pre-existing RAS T/Y93H acquired additional NS5A changes during escape experiments, resulting in HCV variants with specific combinations of RAS, showing high fitness and high resistance.</AbstractText>
                <AbstractText Label="CONCLUSIONS">We performed a comprehensive comparison of the efficacy of the 7 clinically relevant inhibitors of HCV NS5A and identified variants associated with resistance to each agent. These findings could improve treatment of patients with HCV infection.</AbstractText>
                <CopyrightInformation>Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gottwein</LastName>
                    <ForeName>Judith M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: jgottwein@sund.ku.dk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pham</LastName>
                    <ForeName>Long V</ForeName>
                    <Initials>LV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mikkelsen</LastName>
                    <ForeName>Lotte S</ForeName>
                    <Initials>LS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghanem</LastName>
                    <ForeName>Lubna</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramirez</LastName>
                    <ForeName>Santseharay</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scheel</LastName>
                    <ForeName>Troels K H</ForeName>
                    <Initials>TKH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carlsen</LastName>
                    <ForeName>Thomas H R</ForeName>
                    <Initials>THR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bukh</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: jbukh@sund.ku.dk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">DAA</Keyword>
            <Keyword MajorTopicYN="Y">Direct Acting Antiviral</Keyword>
            <Keyword MajorTopicYN="Y">Drug Resistance</Keyword>
            <Keyword MajorTopicYN="Y">Liver Disease</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29274866</ArticleId>
            <ArticleId IdType="pii">S0016-5085(17)36720-3</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2017.12.015</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29274188</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2893</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>05</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of viral hepatitis</Title>
                <ISOAbbreviation>J. Viral Hepat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.</ArticleTitle>
            <Pagination>
                <MedlinePgn>535-542</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jvh.12850</ELocationID>
            <Abstract>
                <AbstractText>It is unclear whether multiple nonstructural (NS) 5A resistance-associated substitutions (RASs) correlate with the outcome of sofosbuvir (SOF) and ledipasvir (LDV) therapy. We investigated the effects of multiple NS5A RASs in NS5A inhibitor-naïve patients with chronic hepatitis C virus genotype 1b infection treated with SOF/LDV. In 313 patients treated with SOF/LDV, we assessed the effects of multiple NS5A RASs on the sustained virological response (SVR). RASs at L28, R30, L31, Q54, P58, Q62, A92, and Y93 in the NS5A region were examined by direct sequencing. The prevalence of RASs was as follows: 2.6% at L28, 8.7% at R30, 6.1% at L31, 48.7% at Q54, 9.9% at P58, 9.9% at Q62, 5.1% at A92, 13.8% at Y93, and 19.2% at L31 or Y93. A total of 133 patients had no RASs. SVR was achieved in 98.7% of the patients. SVR rates significantly differed between patients with and without the L31 or Y93 RAS (93.0% [53/57] vs 100% [250/250], P = .0011). In addition, among patients with the L31 or Y93 RAS, 29.8%, 45.6% and 24.6% had one, two and three or more NS5A RASs, respectively. The SVR rate was significantly lower in patients with the L31 or Y93 RAS with more than three NS5A RASs compared to those with fewer than three NS5A RASs (71.4% [10/14] vs 100% [43/43], P = .0025). Although the prevalence of multiple NS5A RASs at baseline was low in NS5A inhibitor-naïve patients, the presence of multiple NS5A RASs was associated with the effectiveness of SOF/LDV therapy.</AbstractText>
                <CopyrightInformation>© 2017 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kozuka</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">0000-0002-0763-6760</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hai</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Motoyama</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hagihara</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujii</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uchida-Kobayashi</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morikawa</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Enomoto</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murakami</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawada</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamori</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0001-9119-4864</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Viral Hepat</MedlineTA>
            <NlmUniqueID>9435672</NlmUniqueID>
            <ISSNLinking>1352-0504</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>013TE6E4WV</RegistryNumber>
                <NameOfSubstance UI="C586541">ledipasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">direct-acting antiviral</Keyword>
            <Keyword MajorTopicYN="Y">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="Y">nonstructural 5A</Keyword>
            <Keyword MajorTopicYN="Y">resistance-associated substitutions</Keyword>
            <Keyword MajorTopicYN="Y">sustained virological response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29274188</ArticleId>
            <ArticleId IdType="doi">10.1111/jvh.12850</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">29271114</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2036</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>47</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>03</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Alimentary pharmacology &amp; therapeutics</Title>
                <ISOAbbreviation>Aliment. Pharmacol. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.</ArticleTitle>
            <Pagination>
                <MedlinePgn>665-673</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.14478</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">The combination of sofosbuvir (SOF) plus an NS5A inhibitor for 12 weeks is highly efficacious in patients with chronic hepatitis C. As the costs of generic production of sofosbuvir and NS5A inhibitor are rapidly decreasing, the combination of these DAAs will be the standard treatment in most low- to middle-income countries in the future.</AbstractText>
                <AbstractText Label="AIM">To identify key predictors of response that can be used to tailor treatment decisions.</AbstractText>
                <AbstractText Label="METHODS">A cohort of 216 consecutive patients infected with HCV genotype 1 (1a: n = 57; 1b: n = 77), 2 (n = 4), 3 (n = 33) or 4 (n = 44) were treated with sofosbuvir (SOF) + daclatasvir (n = 176) or SOF + ledipasvir (n = 40) for 12 weeks. The viral kinetics was analysed using the biphasic model and the cure boundary was used to predict time to clear HCV.</AbstractText>
                <AbstractText Label="RESULTS">The overall SVR rate was high (94.4%; n = 204), regardless of the time to viral suppression or low-level viraemia at the end of treatment. The model-based predicted HCV RNA levels at the end of treatment could not differentiate patients who did from those who did not achieve SVR. The presence of NS5A resistance-associated substitutions [position 28 (OR = 70.3, P&lt;.001) and/or 31 (OR = 61.6, P = .002)] at baseline was predictive of virological failure in cirrhotic patients but was not associated with on-treatment viral kinetics.</AbstractText>
                <AbstractText Label="CONCLUSION">This real-world study confirms the excellent results of clinical trials with therapies based on a combination of SOF plus an NS5A inhibitor. It suggests that a personalized approach including baseline NS5A inhibitor resistance testing may inform treatment decisions in cirrhotic patients.</AbstractText>
                <CopyrightInformation>© 2017 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fourati</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0002-1236-5467</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Henri Mondor Hospital, National Reference Center for Viral Hepatitis B, C and D, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guedj</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U1137, IAME, Paris, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chevaliez</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Henri Mondor Hospital, National Reference Center for Viral Hepatitis B, C and D, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>T H T</ForeName>
                    <Initials>THT</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U1137, IAME, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roudot-Thoraval</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Public Health, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruiz</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soulier</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Henri Mondor Hospital, National Reference Center for Viral Hepatitis B, C and D, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scoazec</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varaut</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poiteau</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Henri Mondor Hospital, National Reference Center for Viral Hepatitis B, C and D, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Francois</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mallat</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Henri Mondor Hospital, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pawlotsky</LastName>
                    <ForeName>J-M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Henri Mondor Hospital, National Reference Center for Viral Hepatitis B, C and D, University of Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Aliment Pharmacol Ther</MedlineTA>
            <NlmUniqueID>8707234</NlmUniqueID>
            <ISSNLinking>0269-2813</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000595958">ledipasvir, sofosbuvir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29271114</ArticleId>
            <ArticleId IdType="doi">10.1111/apt.14478</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29221887</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-0641</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>68</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hepatology</Title>
                <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>895-903</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0168-8278(17)32476-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2017.11.032</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">The fixed-dose combination of sofosbuvir/velpatasvir was highly efficacious in patients infected with genotype (GT)1-6 hepatitis C virus (HCV) in the ASTRAL studies. This analysis evaluated the impact of baseline resistance-associated substitutions (RASs) on treatment outcome and emergence of RASs in patients infected with HCV GT1-6 who were treated with sofosbuvir/velpatasvir.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Non-structural protein 5A and 5B (NS5A and NS5B) deep sequencing was performed at baseline and at the time of relapse for all patients treated with sofosbuvir/velpatasvir for 12 weeks (n = 1,778) in the ASTRAL-1-3, ASTRAL-5 and POLARIS-2-3 studies.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with 37 known and 19 novel HCV subtypes were included in these analyses. Overall, 28% (range 9% to 61% depending on genotype) had detectable NS5A class RASs at baseline, using a 15% sequencing assay cut-off. There was no significant effect of baseline NS5A class RASs on sustained virologic response at week 12 (SVR12) with sofosbuvir/velpatasvir; the SVR12 rate in the presence of NS5A class RASs was 100% and 97%, in patients with GT1a and GT1b infection, respectively, and 100% in patients with GT2 and GT4-6 infections. In GT3 infection, the SVR rate was 93% and 98% in patients with and without baseline NS5A class RASs, respectively. The overall virologic failure rate was low (20/1,778 = 1.1%) in patients treated with sofosbuvir/velpatasvir. Single NS5A class resistance was observed at virologic failure in 17 of the 20 patients.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sofosbuvir/velpatasvir taken for 12 weeks once daily resulted in high SVR rates in patients infected with GT1-6 HCV, irrespective of baseline NS5A RASs. NS5A inhibitor resistance, but not sofosbuvir resistance, was detected in the few patients with virologic failure. These data highlight the high barrier to resistance of this regimen for the treatment of chronic HCV across all genotypes in the vast majority of patients.</AbstractText>
                <AbstractText Label="LAY SUMMARY" NlmCategory="UNASSIGNED">Sofosbuvir/velpatasvir taken once daily for 12 weeks resulted in high sustained virologic response rates in patients infected with HCV, irrespective of the presence of NS5A resistance-associated variants prior to treatment. Single class NS5A inhibitor resistance, but not sofosbuvir resistance, was detected in the few patients with virologic failure. These data highlight the high barrier to resistance of this regimen for the treatment of chronic HCV across all genotypes in the vast majority of patients.</AbstractText>
                <CopyrightInformation>Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hezode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reau</LastName>
                    <ForeName>Nancy</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia S</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA. Electronic address: jenny.svarovskaia@gilead.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doehle</LastName>
                    <ForeName>Brian P</ForeName>
                    <Initials>BP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shanmugam</LastName>
                    <ForeName>Ragavi</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hedskog</LastName>
                    <ForeName>Charlotte</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McNally</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osinusi</LastName>
                    <ForeName>Anu</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roberts</LastName>
                    <ForeName>Stuart K</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Alfred Health and Monash University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Leary</LastName>
                    <ForeName>Jacqueline G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor University Medical Center at Dallas, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shafran</LastName>
                    <ForeName>Stephen D</ForeName>
                    <Initials>SD</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Alberta, Edmonton, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeuzem</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Hepatol</MedlineTA>
            <NlmUniqueID>8503886</NlmUniqueID>
            <ISSNLinking>0168-8278</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ASTRAL-1</Keyword>
            <Keyword MajorTopicYN="N">ASTRAL-2</Keyword>
            <Keyword MajorTopicYN="N">ASTRAL-3</Keyword>
            <Keyword MajorTopicYN="N">ASTRAL-5</Keyword>
            <Keyword MajorTopicYN="N">Direct-acting antivirals</Keyword>
            <Keyword MajorTopicYN="N">POLARIS-2</Keyword>
            <Keyword MajorTopicYN="N">POLARIS-3</Keyword>
            <Keyword MajorTopicYN="N">Sofosbuvir/velpatasvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29221887</ArticleId>
            <ArticleId IdType="pii">S0168-8278(17)32476-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.11.032</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29152781</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>67</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>04</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1253-1260</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.29671</ELocationID>
            <Abstract>
                <AbstractText>Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options. MAGELLAN-1 Part 2 was a randomized, open-label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and past VF on at least one NS3/4A protease and/or NS5A inhibitor-containing therapy. Patients with compensated liver disease, with or without cirrhosis, and HCV genotype (GT) 1, 4, 5, or 6 were randomized 1:1 to receive 12 or 16 weeks of G/P. The primary endpoint was sustained virological response (SVR) at 12 weeks posttreatment (SVR12). Among 91 patients treated, 87 had GT1 and 4 had GT4 infection. SVR12 was achieved by 89% (39 of 44) and 91% (43 of 47) of patients who received 12 and 16 weeks of G/P, respectively. Virological relapse occurred in 9% (4 of 44) of patients treated with 12 weeks of G/P; there were no relapses with 16 weeks of treatment. Past treatment history with one class of inhibitor (protease or NS5A) had no impact on SVR12, whereas past treatment with both classes of inhibitors was associated with lower SVR12 rate. The most common adverse event (AE) was headache (≥10% of patients), and there were no serious AEs assessed as related to study drugs or AEs leading to discontinuation.</AbstractText>
                <AbstractText Label="CONCLUSION">Sixteen weeks of G/P treatment achieved a high SVR12 rate in patients with HCV GT1 infection and past failure to regimens containing either NS5A inhibitors or NS3 protease inhibitors. (Hepatology 2018;67:1253-1260).</AbstractText>
                <CopyrightInformation>© 2017 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Poordad</LastName>
                    <ForeName>Fred</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Texas Liver Institute, University of Texas Health, San Antonio, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asatryan</LastName>
                    <ForeName>Armen</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buti</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vall d'Hebron University Hospital and CiBERHED del Instituto Carlos III, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaw</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Royal Adelaide Hospital, Adelaide, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Henri Mondor, Université Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Felizarta</LastName>
                    <ForeName>Franco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Private Practice, Bakersfield, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reindollar</LastName>
                    <ForeName>Robert W</ForeName>
                    <Initials>RW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Stuart C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Henry Ford Health System, Detroit, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pianko</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Monash Health and Monash University, Caulfield South, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fried</LastName>
                    <ForeName>Michael W</ForeName>
                    <Initials>MW</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of North Carolina, Chapel Hill, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernstein</LastName>
                    <ForeName>David E</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>North Shore University Hospital, Manhasset, NY.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallant</LastName>
                    <ForeName>Joel</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Southwest CARE Center, Santa Fe, NM.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Chih-Wei</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lei</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Teresa I</ForeName>
                    <Initials>TI</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krishnan</LastName>
                    <ForeName>Preethi</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kopecky-Bromberg</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kort</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mensa</LastName>
                    <ForeName>Federico J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000612853">ABT-493</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000622691">pibrentasvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29152781</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.29671</ArticleId>
            <ArticleId IdType="pmc">PMC5901397</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2017 Jun 1;376(22):2134-2146</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28564569</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2017 Jan;66(1):153-194</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27667367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2016 Jan 1;62(1):32-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26371152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 May;146(5):1176-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24631495</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Viruses. 2015 Dec 18;7(12):6716-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26694454</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Sep;62(3):932-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26111063</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2017 Jun 1;64(11):1615-1618</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28369411</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2017 Apr 24;61(5):</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28193664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2017 Aug;66(2):389-397</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28128852</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29146520</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>154</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>03</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.</ArticleTitle>
            <Pagination>
                <MedlinePgn>976-988.e4</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(17)36353-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2017.11.007</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Little is known about substitutions that mediate resistance of hepatitis C virus (HCV) to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments.</AbstractText>
                <AbstractText Label="METHODS">We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (nonstructural protein [NS]3, NS5A, NS5B) targeted by DAAs. We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe with DAA failure with sequences from 2322 DAA-naïve patients, infected with HCV genotypes 1 to 4. We considered RASs to be relevant if they were associated with DAA failure in patients or conferred a greater than twofold change in susceptibility compared with a reference strain in in vitro replicon assays. Data were collected on pretreatment status, DAA regimen, the treatment initiation date and duration, and virologic response. Patients who received at least 4 weeks of antiviral treatment were included in the analysis.</AbstractText>
                <AbstractText Label="RESULTS">RASs in NS3 associated with simeprevir or paritaprevir failure include R155K and D168E/V. In addition, several RASs were specifically associated with failure of simeprevir (Q80K/R in patients with genotype 1a or 4) or paritaprevir (Y56H in combination with D168V in patients with genotype 1b). Y93H in NS5A was the RAS most frequently associated with failure of daclatasvir, ledipasvir, or ombitasvir in patients with genotype 1b infection, and L31M was associated with failure of daclatasvir or ledipasvir, but not ombitasvir. RASs in NS5A were heterogeneous among patients with HCV genotype 1a or genotype 4 infections. In patients with HCV genotype 3, Y93H was associated with resistance to daclatasvir, but no RASs were associated with ledipasvir failure, pointing to a limited efficacy of ledipasvir in patients with genotype 3. Among patients failed by sofosbuvir-containing regimens, L159F was enriched in patients with genotype 1b (together with C316N) or genotype 3 infection, whereas the RAS S282T was rarely observed.</AbstractText>
                <AbstractText Label="CONCLUSIONS">We compared RASs in NS3, NS5A, and NS5B among patients failed by DAA therapy. Theses varied with the HCV genotype and subtype, and the different drug classes. These findings might be used to select salvage therapies.</AbstractText>
                <CopyrightInformation>Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dietz</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany, German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Susser</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany, German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vermehren</LastName>
                    <ForeName>Johannes</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany, German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peiffer</LastName>
                    <ForeName>Kai-Henrik</ForeName>
                    <Initials>KH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany, German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grammatikos</LastName>
                    <ForeName>Georgios</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany, German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berger</LastName>
                    <ForeName>Annemarie</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Medical Virology, University Hospital Frankfurt, Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferenci</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buti</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Müllhaupt</LastName>
                    <ForeName>Beat</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Swiss Hepato-Pancreato-Biliary Center and Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hunyady</LastName>
                    <ForeName>Bela</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hinrichsen</LastName>
                    <ForeName>Holger</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Practice of Gastroenterology, Kiel, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mauss</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Practice of Gastroenterology, Düsseldorf, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petersen</LastName>
                    <ForeName>Jörg</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Interdisciplinary Medicine IFI, Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buggisch</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Interdisciplinary Medicine IFI, Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Felten</LastName>
                    <ForeName>Gisela</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Practice of Hepatology, Herne, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hüppe</LastName>
                    <ForeName>Dietrich</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Practice of Hepatology, Herne, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knecht</LastName>
                    <ForeName>Gaby</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infektiologikum, Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lutz</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infektiologikum, Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schott</LastName>
                    <ForeName>Eckart</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berg</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine I, University of Tübingen, Tübingen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spengler</LastName>
                    <ForeName>Ulrich</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine I, University of Bonn, Bonn, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>von Hahn</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany; German Center for Infection Research (DZIF), Hannover-Braunschweig Site, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berg</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeuzem</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany, German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sarrazin</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany, German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany; Medizinische Klinik II, St. Josefs-Hospital, Wiesbaden, Germany. Electronic address: sarrazin@em.uni-frankfurt.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>European HCV Resistance Study Group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C084422">NS3 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">DAA</Keyword>
            <Keyword MajorTopicYN="Y">HCV</Keyword>
            <Keyword MajorTopicYN="Y">RASs</Keyword>
            <Keyword MajorTopicYN="Y">Virologic Treatment Failure</Keyword>
        </KeywordList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Antoni</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vogelmann</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ebert</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Backhus</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seufferlein</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Balavoine</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Giostra</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berg</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cornberg</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wedemeyer</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manns</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Gottardi</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Esteban</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Discher</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Roeb</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gress</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Günther</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wietzke-Braun</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Herrmann</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stallmach</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoffmann</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klinker</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kodal</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lammert</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Löbermann</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schulze Zur Wiesch</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>von Felden</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Piecha</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lohse</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Götze</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Malfertheiner</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mayerle</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moradpour</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moreno</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Neumann-Haefelin</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thimme</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reinhardt</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ellenrieder</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schattenberg</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sprinzl</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Galle</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schmidt</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schott</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Epple</LastName>
                <ForeName>H-J</ForeName>
                <Initials>HJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siebler</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stauber</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Steckstor</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schmiegel</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stremmel</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Strey</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tomasiewicz</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trautwein</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zachoval</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Angeli</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Beckebaum</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Doberauer</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ende</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Erhardt</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Garrido-Lüneburg</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gattringer</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Genné</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gschwantler</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gundling</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hartmann</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heyer</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hirschi</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kanzler</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kordecki</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kraus</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kullig</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Magenta</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Terziroli Beretta-Piccoli</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Menges</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mohr</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Muehlenberg</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Niederau</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paulweber</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Petrides</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Piso</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rambach</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reiser</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Riecken</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Roth</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schöfl</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maieron</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schneider</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schuchmann</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schulten-Baumer</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seelhoff</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Semela</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stich</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vollmer</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brückner</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ungemach</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walter</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weber</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Winzer</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abels</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Adler</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Audebert</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baermann</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bästlein</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barth</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barthel</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baumgartl</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Becker</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Benninger</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Beyer</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bodtländer</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Böhm</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bohr</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moll</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Naumann</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Börner</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bruch</LastName>
                <ForeName>H R</ForeName>
                <Initials>HR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Busch</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burkhard</LastName>
                <ForeName>O</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chirca</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dienethal</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dietel</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dreher</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Efken</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ehrle</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Emke</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fischer</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fischer</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Frederking</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Frick</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gantke B</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Geyer</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Glaunsinger</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goebel</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Göbel</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Graf</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Herder</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heuchel</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heuer</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heyne</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Höffl</LastName>
                <ForeName>K H</ForeName>
                <Initials>KH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hofmann</LastName>
                <ForeName>W P</ForeName>
                <Initials>WP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Holst</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hörster</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>John</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jung</LastName>
                <ForeName>M C</ForeName>
                <Initials>MC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kallinowski</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kerzel</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Khaykin</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klarhof</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Knapp</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Knevels</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Körfer</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Köster</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Künzig</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Langenkamp</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuhn</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Littman</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Löhr</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ludwig</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lutz</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maurer</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mayer</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meister</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moritzen</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mroß</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mundlos</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nehls</LastName>
                <ForeName>O</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ningel</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Oelmann</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Olejnik</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pascher</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Philipp</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pichler</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Polzien</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Raddant</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Riedel</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rietzler</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rump</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schmidt</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schmidtler-von Fabris</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schneider</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schober</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schwenzer</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seidel</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seitel</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sick</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Simon</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stähler</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Steffens</LastName>
                <ForeName>H</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Strey</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Svensson</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tacke</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Teubner</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thieringer</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Trappe</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ullrich</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Usadel</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>von Lucadou</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Werheid-Dobers</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zehnter</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zipf</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29146520</ArticleId>
            <ArticleId IdType="pii">S0016-5085(17)36353-9</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2017.11.007</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29091342</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-3231</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>38</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>06</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
                <ISOAbbreviation>Liver Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1010-1021</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.13616</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">We report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) for retreatment of chronic hepatitis C virus (HCV) in individuals who failed to achieve sustained virological response (SVR) with prior SOF-based, non-NS5A inhibitor-containing regimens.</AbstractText>
                <AbstractText Label="METHODS">The RESCUE study enrolled HCV mono-infected adults with genotype (GT) 1 or 4. Non-cirrhotic participants were randomized to 12 weeks of LDV/SOF or LDV/SOF + RBV. Compensated cirrhotic participants were randomized to LDV/SOF + RBV (12 weeks) or LDV/SOF (24 weeks). The AIDS Clinical Trials Group A5348 study randomized genotype 1 adults with HCV/HIV co-infection to LDV/SOF + RBV (12 weeks) or LDV/SOF (24 weeks). Both studies used SVR at 12 weeks post-treatment (SVR12) as the primary endpoint.</AbstractText>
                <AbstractText Label="RESULTS">In the RESCUE study, 82 participants were randomized and treated, and all completed treatment. Overall, SVR12 was 88% (72/82); 81-100% in non-cirrhotic participants treated with LDV/SOF or LDV/SOF + RBV for 12 weeks and 80-92% in cirrhotic participants treated with LDV/SOF + RBV for 12 weeks or LDV/SOF for 24 weeks. Adverse events (AEs), mostly mild-to-moderate in severity, were experienced by 78% of participants, with headache and fatigue most frequently reported. One serious AE, not related to treatment, was observed. No premature discontinuations of study drug, or deaths occurred. In the A5348 study, seven participants were randomized (cirrhotic n = 1; GT1a n = 5) and all attained SVR12, with no serious AEs or premature discontinuations.</AbstractText>
                <AbstractText Label="CONCLUSIONS">In this SOF-experienced, NS5A inhibitor-naïve population, which included participants with cirrhosis or HCV/HIV co-infection, high SVR12 rates were achieved.</AbstractText>
                <CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tam</LastName>
                    <ForeName>Edward</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>LAIR Centre, Vancouver, BC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luetkemeyer</LastName>
                    <ForeName>Anne F</ForeName>
                    <Initials>AF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of California, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mantry</LastName>
                    <ForeName>Parvez S</ForeName>
                    <Initials>PS</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Liver Institute, Methodist Dallas Medical Center, Dallas, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Satapathy</LastName>
                    <ForeName>Sanjaya K</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, Memphis, TN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghali</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Minhee</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haubrich</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Xianlin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ni</LastName>
                    <ForeName>Liyun</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Camus</LastName>
                    <ForeName>Gregory</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Copans</LastName>
                    <ForeName>Amanda</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rossaro</LastName>
                    <ForeName>Lorenzo</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guyer</LastName>
                    <ForeName>Bill</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                    <Suffix>Jr</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York City, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>RESCUE and ACTG A5348 study investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02600351</AccessionNumber>
                        <AccessionNumber>NCT02605304</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>UM1 AI068634</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UM1 AI068636</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UM1 AI069496</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UM1 AI106701</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Liver Int</MedlineTA>
            <NlmUniqueID>101160857</NlmUniqueID>
            <ISSNLinking>1478-3223</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000595958">ledipasvir, sofosbuvir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">HCV</Keyword>
            <Keyword MajorTopicYN="Y">HIV</Keyword>
            <Keyword MajorTopicYN="Y">ledipasvir</Keyword>
            <Keyword MajorTopicYN="Y">sofosbuvir</Keyword>
            <Keyword MajorTopicYN="Y">treatment-experienced</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29091342</ArticleId>
            <ArticleId IdType="doi">10.1111/liv.13616</ArticleId>
            <ArticleId IdType="pmc">PMC5930158</ArticleId>
            <ArticleId IdType="mid">NIHMS918022</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2017 Jun 1;376(22):2134-2146</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28564569</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2016 Jun;16(6):685-697</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26907736</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Med Sci. 2006;3(2):47-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16614742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2015 Apr;15(4):397-404</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25773757</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 Dec;64(6):1893-1899</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27533287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1999 May 15;85(10):2132-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10326690</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2014 Nov 4;161(9):634-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25364884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Gastroenterol. 2009 May;104(5):1147-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19352340</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jun;61(6):1793-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25846014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Aug 20;373(8):705-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26196665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Infect Dis Ther. 2015 Jun;4(2):159-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25896480</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Dec;151(6):1131-1140.e5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27565882</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ther Clin Risk Manag. 2016 Jun 03;12:861-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27350749</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 Aug;64(2):405-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27115523</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1879-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24720702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2016 Jan;43(1):96-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26503414</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2015 Sep;149(3):649-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25985734</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterol Hepatol (N Y). 2014 Jun;10(6 Suppl 2):1-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26180519</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Oct;62(4):1004-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26096332</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">29084747</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>62</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>01</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle><i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">e01620-17</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01620-17</ELocationID>
            <Abstract>
                <AbstractText>Glecaprevir (formerly ABT-493) is a novel hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) with pangenotypic activity. It inhibited the enzymatic activity of purified NS3/4A proteases from HCV genotypes 1 to 6 <i>in vitro</i> (half-maximal [50%] inhibitory concentration = 3.5 to 11.3 nM) and the replication of stable HCV subgenomic replicons containing proteases from genotypes 1 to 6 (50% effective concentration [EC<sub>50</sub>] = 0.21 to 4.6 nM). Glecaprevir had a median EC<sub>50</sub> of 0.30 nM (range, 0.05 to 3.8 nM) for HCV replicons containing proteases from 40 samples from patients infected with HCV genotypes 1 to 5. Importantly, glecaprevir was active against the protease from genotype 3, the most-difficult-to-treat HCV genotype, in both enzymatic and replicon assays demonstrating comparable activity against the other HCV genotypes. In drug-resistant colony selection studies, glecaprevir generally selected substitutions at NS3 amino acid position A156 in replicons containing proteases from genotypes 1a, 1b, 2a, 2b, 3a, and 4a and substitutions at position D/Q168 in replicons containing proteases from genotypes 3a, 5a, and 6a. Although the substitutions A156T and A156V in NS3 of genotype 1 reduced susceptibility to glecaprevir, replicons with these substitutions demonstrated a low replication efficiency <i>in vitro</i> Glecaprevir is active against HCV with most of the common NS3 amino acid substitutions that are associated with reduced susceptibility to other currently approved HCV PIs, including those at positions 155 and 168. Combination of glecaprevir with HCV inhibitors with other mechanisms of action resulted in additive or synergistic antiviral activity. In summary, glecaprevir is a next-generation HCV PI with potent pangenotypic activity and a high barrier to the development of resistance.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Ng et al.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Teresa I</ForeName>
                    <Initials>TI</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA teresa.ng@abbvie.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tripathi</LastName>
                    <ForeName>Rakesh</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reisch</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Liangjun</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Middleton</LastName>
                    <ForeName>Timothy</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hopkins</LastName>
                    <ForeName>Todd A</ForeName>
                    <Initials>TA</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pithawalla</LastName>
                    <ForeName>Ron</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Irvin</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dekhtyar</LastName>
                    <ForeName>Tatyana</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krishnan</LastName>
                    <ForeName>Preethi</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schnell</LastName>
                    <ForeName>Gretja</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beyer</LastName>
                    <ForeName>Jill</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McDaniel</LastName>
                    <ForeName>Keith F</ForeName>
                    <Initials>KF</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Guoqiang</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Li-Juan</ForeName>
                    <Initials>LJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Or</LastName>
                    <ForeName>Yat Sun</ForeName>
                    <Initials>YS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kempf</LastName>
                    <ForeName>Dale</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pilot-Matias</LastName>
                    <ForeName>Tami</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">ABT-493</Keyword>
            <Keyword MajorTopicYN="Y">HCV</Keyword>
            <Keyword MajorTopicYN="Y">NS3/4A protease inhibitor</Keyword>
            <Keyword MajorTopicYN="Y">antiviral activity</Keyword>
            <Keyword MajorTopicYN="Y">glecaprevir</Keyword>
            <Keyword MajorTopicYN="Y">resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29084747</ArticleId>
            <ArticleId IdType="pii">AAC.01620-17</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.01620-17</ArticleId>
            <ArticleId IdType="pmc">PMC5740381</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Dec;59(12 ):7426-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26392503</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2016 Feb 04;6:20310</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26842909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2017 Jan;66(1):153-194</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27667367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2017 Apr 24;61(5):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28193664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2013 Jul;19(7):879-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23836238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 1998 Oct;178(4):1193-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9806059</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2013 May;57(1):13-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jan;59(1):318-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24115039</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Jul;151(1):70-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27080301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2014;58(2):698-705</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24217701</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2015 Mar;53(3):967-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25520447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26303801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1994 Aug;68(8):5045-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8035505</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2016 Jan;36 Suppl 1:47-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26725897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Nov;59(11):6807-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26282418</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2015 Apr;65:50-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25766988</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Gastroenterol Hepatol. 2017 Sep 22;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28951228</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Nov;62(5):1623-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2011 Sep;141(3):1067-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21699793</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2012;8(7):e1002832</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22910833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26926625</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anal Biochem. 2007 Sep 15;368(2):156-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17644059</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2017 Oct;17 (10 ):1062-1068</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28818546</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2017 May 2;166(9):637-648</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28319996</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Sep;58(3):902-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23504694</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):988-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25451053</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ACS Med Chem Lett. 2014 Mar 13;5(3):214-220</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24672647</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 1996 Jan;1(1):9-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11322261</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22615282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Dec 28;60(3):1546-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26711747</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2016 Sep 29;11(9):e0163197</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27685471</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2017 Aug;66(2):389-397</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28128852</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2013 Jul;99(1):12-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23648709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 1993 Mar;37(3):540-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Aug;59(2):375-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23567084</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28984067</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2893</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>02</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of viral hepatitis</Title>
                <ISOAbbreviation>J. Viral Hepat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.</ArticleTitle>
            <Pagination>
                <MedlinePgn>134-143</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jvh.12795</ELocationID>
            <Abstract>
                <AbstractText>HCV genotype 4 (GT4) has often been overlooked in drug development, even though it infects ~20 million people worldwide. Ledipasvir/sofosbuvir and sofosbuvir/velpatasvir were highly efficacious in GT4 HCV-infected patients from GS-US-337-1119 and GS-US-342-1138. Here, we characterize the resistance profile of ledipasvir (LDV) and velpatasvir (VEL) in patients with GT4 HCV infection. NS5A deep-sequencing was performed for 454 patients infected with HCV GT4 at baseline, including 44 patients enrolled in GS-US-337-1119 and 116 patients enrolled in GS-US-342-1138, and at relapse for patients with virologic failure. LDV and VEL susceptibilities of 56 patient isolates were determined. In GS-US-337-1119, SVR12 rates were 100% for all subtypes except 4b and 4r. Phenotypic assessment of 56 HCV NS5A patient isolates from various GT4 subtypes indicated that LDV had high potency for the common subtypes 4a/d, and subtypes 4c/f/k/l/m/n/o/p/r/t despite the presence of resistance-associated substitutions (RASs). For the rare GT4b, LDV median EC<sub>50</sub> was higher, but with a broad range of individual values. Importantly, all GT4b isolates tested had 2-4 NS5A RASs, some including Y93H. Similarly, the 2 GT4r infected patients who had virologic relapse had rare triple RASs. Reversion of these substitutions to the consensus residue significantly increased LDV susceptibility. In GS-US-342-1138, all patients achieved SVR12, regardless of their subtype or presence of RASs. In vitro data confirmed that VEL is potent against all GT4 isolates tested. LDV and VEL are potent antiviral drugs, estimated to be effective against &gt;95% and &gt;99%, respectively, of GT4 HCV isolates.</AbstractText>
                <CopyrightInformation>© 2017 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Camus</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <Identifier Source="ORCID">0000-0002-0018-6234</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asselah</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Université Paris-Diderot and INSERM UMR1149, Clichy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsieh</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parhy</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>M D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>D M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kersey</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abergel</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>UMR CNRS 6284, Department of Hepatology and Gastroenterology, Centre Hospitalier Universitaire Estaing, Université d'Auvergne, Clermont-Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Viral Hepat</MedlineTA>
            <NlmUniqueID>9435672</NlmUniqueID>
            <ISSNLinking>1352-0504</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000595958">ledipasvir, sofosbuvir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>KCU0C7RS7Z</RegistryNumber>
                <NameOfSubstance UI="C000604171">velpatasvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024921" MajorTopicYN="N">Drug Resistance, Multiple, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">direct-acting antiviral</Keyword>
            <Keyword MajorTopicYN="Y">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="Y">ledipasvir</Keyword>
            <Keyword MajorTopicYN="Y">resistance</Keyword>
            <Keyword MajorTopicYN="Y">sofosbuvir</Keyword>
            <Keyword MajorTopicYN="Y">velpatasvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28984067</ArticleId>
            <ArticleId IdType="doi">10.1111/jvh.12795</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28941023</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-3231</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>38</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>05</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
                <ISOAbbreviation>Liver Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.</ArticleTitle>
            <Pagination>
                <MedlinePgn>821-833</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.13596</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long-term efficacy and safety of daclatasvir-based regimens administered during clinical studies.</AbstractText>
                <AbstractText Label="METHODS">Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow-up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non-responders or responders who relapsed, and characterization of liver disease progression.</AbstractText>
                <AbstractText Label="RESULTS">Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir-based regimens (follow-up cut-off, 13 October 2015); 60% were male, 18% aged ≥65 years, 87% had genotype-1a (42%) or -1b (45%) infection, and 18% had cirrhosis. Median follow-up from parent study follow-up Week 12 was 111 (range, 11-246) weeks. 1329/1489 evaluable patients were SVR12 responders; 1316/1329 maintained SVR until their latest visit. Twelve responders relapsed by (n = 9) or after (n = 3) parent study follow-up Week 24; one was reinfected. Relapse occurred in 3/842 (0.4%) and 9/487 (2%) responders treated with interferon-free or interferon-containing regimens, respectively. Hepatic disease progression and new hepatocellular carcinoma were diagnosed in 15 and 23 patients, respectively. Among non-responders, emergent non-structural protein-5A (NS5A) and -3 (NS3) substitutions were replaced by wild-type sequences in 27/157 (17%) and 35/47 (74%) patients, respectively.</AbstractText>
                <AbstractText Label="CONCLUSIONS">SVR12 was durable in 99% of recipients of daclatasvir-based regimens. Hepatic disease progression and new hepatocellular carcinoma were infrequent. Emergent NS5A substitutions persisted longer than NS3 substitutions among non-responders.</AbstractText>
                <CopyrightInformation>© 2017 The Authors. Liver International Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>K Rajender</ForeName>
                    <Initials>KR</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, University of Pennsylvania, Philadelphia, PN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0001-9772-9591</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Cochin, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thuluvath</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mercy Medical Center, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumada</LastName>
                    <ForeName>Hiromitsu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Toranomon Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toyota</LastName>
                    <ForeName>Joji</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sapporo-Kosei General Hospital, Sapporo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chayama</LastName>
                    <ForeName>Kazuaki</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hiroshima University, Hiroshima, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levin</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dean Foundation, Madison, WI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gadano</LastName>
                    <ForeName>Adrian</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghesquiere</LastName>
                    <ForeName>Wayne</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vancouver Island Health Authority, University of British Columbia, Victoria, BC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gerken</LastName>
                    <ForeName>Guido</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Duisburg-Essen, Essen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brunetto</LastName>
                    <ForeName>Maurizia R</ForeName>
                    <Initials>MR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Cheng-Yuan</ForeName>
                    <Initials>CY</Initials>
                    <Identifier Source="ORCID">0000-0001-9030-6086</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, China Medical University, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Marcelo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Universitario Austral, Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strasser</LastName>
                    <ForeName>Simone I</ForeName>
                    <Initials>SI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Royal Prince Alfred Hospital, Sydney, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heo</LastName>
                    <ForeName>Jeong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Medicine, Medical Research Institute, Pusan National University Hospital, Pusan National University, Busan, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zhaohui</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Hopewell, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Linaberry</LastName>
                    <ForeName>Misti</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noviello</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01492504</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Liver Int</MedlineTA>
            <NlmUniqueID>101160857</NlmUniqueID>
            <ISSNLinking>1478-3223</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">chronic hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="Y">daclatasvir</Keyword>
            <Keyword MajorTopicYN="Y">hepatocellular carcinoma</Keyword>
            <Keyword MajorTopicYN="Y">long-term follow-up</Keyword>
            <Keyword MajorTopicYN="Y">sustained virologic response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28941023</ArticleId>
            <ArticleId IdType="doi">10.1111/liv.13596</ArticleId>
            <ArticleId IdType="pmc">PMC5947593</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA. 2012 Dec 26;308(24):2584-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23268517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Jun;64(6):1217-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27059129</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Investig Drugs. 2013 Oct;22(10):1337-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23931586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2018;23 (1):53-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28594332</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Jun;64(6):1224-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26829205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol Hepatol. 2016 Nov;31(11):1860-1867</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27003037</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2009 Mar;49(3):729-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19072828</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2015 May 5;313(17):1728-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25942723</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Jan 16;370(3):211-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24428467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Jul;63(1):199-236</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25911336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Jul;63(1):30-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25703086</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Oct;65(4):734-740</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27288051</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2015 Aug 27;21(3):195-205</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26313445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 Feb;146(2):420-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24184132</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2015 Jan;113:71-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25446895</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Virol. 2017 Mar;89(3):476-483</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27531586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Nov 1;384(9954):1597-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25078304</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Oct;65(4):663-665</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27417216</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Oct;65(4):719-726</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27084592</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2009 Jun;50(6):1142-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19395111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gut Liver. 2013 Jul;7(4):458-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23898387</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Apr;58(4):655-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23183526</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2016 Feb;36(2):189-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26473667</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2015 Feb;148(2):355-366.e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25311593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 19;366(3):216-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22256805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 Jul;64(1):130-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26946190</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2012 Sep;12 (9):671-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22714001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2015 Aug;42(3):258-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26014906</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gut. 2015 Jun;64(6):948-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25080450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 May;63(5):1493-505</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26754432</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23460056</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2083-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24604476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Oct 20;28(30):4587-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20855826</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2013 Jul;38(2):118-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23710895</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Aug 20;373(8):714-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26196502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gut. 2016 Nov;65(11):1861-1870</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27605539</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 Nov;64(5):1818-1819</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27136189</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2009 May;50(5):923-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19303163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Apr;61(4):1127-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25614962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 May;63(5):1430-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26822022</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Oct;65(4):741-747</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27388925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Dec;65(6):1272-1273</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27524465</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2011 Apr 1;52(7):889-900</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21427396</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2015 May 5;313(17):1736-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25942724</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2016 Mar 28;22(12 ):3418-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27022224</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Oct;65(4):727-733</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27349488</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Hepatol. 2016 Nov-Dec 2016;15(6):834-845</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27740516</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">28789880</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-0641</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>67</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>12</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hepatology</Title>
                <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1348-1350</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0168-8278(17)32195-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2017.06.035</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>da Silva Filipe</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sreenu</LastName>
                    <ForeName>Vattipally</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aranday-Cortes</LastName>
                    <ForeName>Elihu</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Irving</LastName>
                    <ForeName>William L</ForeName>
                    <Initials>WL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastrointestinal and Liver Disorders Theme, NIHR Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Foster</LastName>
                    <ForeName>Graham R</ForeName>
                    <Initials>GR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Blizard Institute, Queen Mary University of London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agarwal</LastName>
                    <ForeName>Kosh</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Liver Studies, King's College Hospital Foundation Trust, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenberg</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Liver and Digestive Health, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Macdonald</LastName>
                    <ForeName>Douglas</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Liver and Digestive Health, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richardson</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Royal Liverpool University NHS Trust, Liverpool, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aldersley</LastName>
                    <ForeName>Mark A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, St James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wiselka</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Unit, University Hospitals Leicester NHS Trust, Leicester, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ustianowski</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, North Manchester General Hospital, Manchester, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLauchlan</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. Electronic address: john.mclauchlan@glasgow.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomson</LastName>
                    <ForeName>Emma C</ForeName>
                    <Initials>EC</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MC_UU_12014/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0801822</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/N005953/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/K01532X/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_EX_UU_G1000717</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016422">Letter</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D016420">Comment</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Hepatol</MedlineTA>
            <NlmUniqueID>8503886</NlmUniqueID>
            <ISSNLinking>0168-8278</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>J Hepatol. 2017 May;66(5):910-918</RefSource>
                <PMID Version="1">28108232</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Hepatol. 2017 Dec;67(6):1350-1352</RefSource>
                <PMID Version="1">28789882</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28789880</ArticleId>
            <ArticleId IdType="pii">S0168-8278(17)32195-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.06.035</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28783119</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1999-4915</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>08</Month>
                        <Day>07</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Viruses</Title>
                <ISOAbbreviation>Viruses</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E212</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/v9080212</ELocationID>
            <Abstract>
                <AbstractText>Hepatitis C virus (HCV) genotype (GT)3 is associated with increased risk of steatosis, development of cirrhosis and hepatocellular carcinoma. Limited data are available regarding genetic variability and use of direct-acting antiviral agents in these patients. non-structural protein 5A (NS5A) and non-structural protein 5B (NS5B) sequencing was performed on 45 HCV GT3-infected Italian patients subsequently treated with sofosbuvir ± daclatasvir (SOF ± DCV). Novel GT3a polymorphisms were observed by Sanger sequencing in three NS5A (T79S, T107K, and T107S) and three NS5B (G166R, Q180K, and C274W) baseline sequences in patients who achieved sustained virological response (SVR). Baseline NS5A resistance-associated substitutions A30K and Y93H were detected in 9.5% of patients; one patient with A30K did not achieve SVR. Phylogenetic analyses of sequences showed no distinct clustering. Genetic heterogeneity of NS5A and NS5B was evaluated using ultra-deep pyrosequencing (UDPS) in samples longitudinally collected in patients not achieving SVR. Some novel NS5A and NS5B polymorphisms detected at baseline may not impact treatment outcome, as they were not enriched in post-failure samples. In contrast, the novel L31F NS5A variant emerged in one treatment failure, and I184T, G188D and N310S, located on the same NS5B haplotype, became predominant after failure. These findings suggest a potential impact of these novel substitutions on the treatment outcome; however, their significance requires further investigation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bartolini</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. barbara.bartolini@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giombini</LastName>
                    <ForeName>Emanuela</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. emanuela.giombini@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taibi</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. chiara.taibi@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lionetti</LastName>
                    <ForeName>Raffaella</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. Raffaella.lionetti@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montalbano</LastName>
                    <ForeName>Marzia</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. Marzia.montalbano@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Visco-Comandini</LastName>
                    <ForeName>Ubaldo</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. Ubaldo.viscocomandini@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D'Offizi</LastName>
                    <ForeName>Gianpiero</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. Gianpiero.doffizi@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Capobianchi</LastName>
                    <ForeName>Maria Rosaria</ForeName>
                    <Initials>MR</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. maria.capobianchi@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research and Development, Wallingford, CT 06492, USA. Fiona.Mcphee@bms.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garbuglia</LastName>
                    <ForeName>Anna Rosa</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. annarosa.garbuglia@inmi.it.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Virology, National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, Via Portuense 292, 00149 Rome, Italy. annarosa.garbuglia@inmi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Viruses</MedlineTA>
            <NlmUniqueID>101509722</NlmUniqueID>
            <ISSNLinking>1999-4915</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Genotype3</Keyword>
            <Keyword MajorTopicYN="Y">HCV</Keyword>
            <Keyword MajorTopicYN="Y">NS5A</Keyword>
            <Keyword MajorTopicYN="Y">NS5B</Keyword>
            <Keyword MajorTopicYN="Y">genetic variability</Keyword>
            <Keyword MajorTopicYN="Y">polymorphism</Keyword>
            <Keyword MajorTopicYN="Y">resistance-associated substitutions</Keyword>
            <Keyword MajorTopicYN="Y">ultra-deep pyrosequencing</Keyword>
        </KeywordList>
        <CoiStatement>B. Bartolini, E. Giombini, C. Taibi, R. Lionetti, M. Montalbano, U. Visco-Comandini, G. D’Offizi, M.R. Capobianchi, and A.R. Garbuglia declare no conflict of interest. F. McPhee is an employee of Bristol Myers Squibb.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28783119</ArticleId>
            <ArticleId IdType="pii">v9080212</ArticleId>
            <ArticleId IdType="doi">10.3390/v9080212</ArticleId>
            <ArticleId IdType="pmc">PMC5580469</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Rep. 2016 Feb 04;6:20310</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26842909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2017 Jan;66(1):153-194</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27667367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Apr;62(1 Suppl):S87-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25920094</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Jan;57(1):611-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23089758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2012 Dec 1;28(23):3150-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23060610</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2013 May;57(1):13-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Jan 16;370(3):211-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24428467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jan;59(1):318-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24115039</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Infect Dis (Lond). 2015 Aug;47(8):555-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25851241</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Jul;151(1):70-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27080301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2005 May 15;21(10):2531-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15713735</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2015 Jan;53(1):219-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25378574</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Biol Evol. 2013 Dec;30(12):2725-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24132122</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2015 Jan;22 Suppl 1:6-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25560839</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Virol. 2006 Oct;78(10):1296-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16927280</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2004 Mar 19;32(5):1792-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15034147</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virus Res. 2013 Nov 6;177(2):205-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23954579</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2013 Mar;94(Pt 3):543-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23152370</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2017;22(3):237-246</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28008868</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2014 Mar 1;209(5):668-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24154738</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Apr;61(4):1127-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25614962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 May;63(5):1430-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26822022</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24936600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2005 Feb 1;21(3):379-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15377502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2016 Dec;71(12 ):3495-3505</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27605597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2011;6(7):e22245</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21799802</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2009;14 (4):577-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19578243</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2014 Mar 21;20(11):2902-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24659881</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2009 Mar 1;199(5):693-701</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19210162</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jul;60(1):98-105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24615981</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28595606</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>03</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1743-422X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>06</Month>
                        <Day>08</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Virology journal</Title>
                <ISOAbbreviation>Virol. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure.</ArticleTitle>
            <Pagination>
                <MedlinePgn>106</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-017-0779-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">The major resistance-associated substitution for sofosbuvir (S282T) in HCV NS5B causes severe viral fitness costs and rapidly reverts back to prototype in the absence of selection pressure. Accordingly, resistance against sofosbuvir is rarely detected even in patients after treatment failure.</AbstractText>
                <AbstractText Label="CASE PRESENTATION">We report a case of a GT3a infected patient with viral breakthrough under SOF/DCV therapy. At the time of breakthrough the RAS S282T was predominant in NS5B and then rapidly disappeared during follow-up by week 12 after treatment. Interestingly, despite only serine was encoded in position 282 during follow-up, two distinct genetic pathways for reversion were detectable. In 31% of the quasispecies the original codon for serine was present whereas in the majority of the quasispecies an alternative codon was selected. This alternative codon usage was unique for all GT3a isolates from the HCV database and remained detectable as a genetic footprint for prior resistance selection at the RNA level for at least 6 months.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Comparative analyses of viral sequences at the codon level before and after DAA treatment may help to elucidate the patient's history of resistance selection, which is particularly valuable for highly unfit substitutions that are detectable only for a short period of time. If such codon changes increase the risk of re-selection of resistance upon a second exposure to SOF remains to be addressed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Walker</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Virology, Heinrich-Heine-University, University Hospital, Universitätsstr. 1, 40225, Düsseldorf, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Filke</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lübke</LastName>
                    <ForeName>Nadine</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Virology, Heinrich-Heine-University, University Hospital, Universitätsstr. 1, 40225, Düsseldorf, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Obermeier</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Center for Infectious Diseases (MIB), Berlin, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaiser</LastName>
                    <ForeName>Rolf</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Virology, University of Cologne, Cologne, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Häussinger</LastName>
                    <ForeName>Dieter</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Timm</LastName>
                    <ForeName>Jörg</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Virology, Heinrich-Heine-University, University Hospital, Universitätsstr. 1, 40225, Düsseldorf, Germany. joerg.timm@med.uni-duesseldorf.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bock</LastName>
                    <ForeName>Hans H</ForeName>
                    <Initials>HH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Virol J</MedlineTA>
            <NlmUniqueID>101231645</NlmUniqueID>
            <ISSNLinking>1743-422X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013489" MajorTopicYN="N">Suppression, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="Y">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Breakthrough</Keyword>
            <Keyword MajorTopicYN="Y">Daclatasvir</Keyword>
            <Keyword MajorTopicYN="Y">Genotype 3a</Keyword>
            <Keyword MajorTopicYN="Y">MEDCOAT</Keyword>
            <Keyword MajorTopicYN="Y">Resistance</Keyword>
            <Keyword MajorTopicYN="Y">S282T</Keyword>
            <Keyword MajorTopicYN="Y">Sofosbuvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28595606</ArticleId>
            <ArticleId IdType="doi">10.1186/s12985-017-0779-4</ArticleId>
            <ArticleId IdType="pii">10.1186/s12985-017-0779-4</ArticleId>
            <ArticleId IdType="pmc">PMC5465446</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Hepatol. 2017 Jan;66(1):153-194</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27667367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2013 May;57(1):13-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 Dec;64(6):1893-1899</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27533287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Jul;151(1):70-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27080301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2014 Dec 15;59(12):1666-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25266287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2015 Sep;70:43-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26305818</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2016 May 19;11(5):e0155869</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27196673</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):56-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25123381</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Sep;58(3):902-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23504694</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2015 Nov;22(11):871-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25784085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Apr;61(4):1127-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25614962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Feb;64(2):486-504</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26409317</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Gastroenterol Hepatol. 2015 May;12(5):284-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25895822</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28576451</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2468-1253</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>08</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The lancet. Gastroenterology &amp; hepatology</Title>
                <ISOAbbreviation>Lancet Gastroenterol Hepatol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>585-594</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S2468-1253(17)30116-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-1253(17)30116-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">In the C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5 chronic kidney disease resulted in a high rate of virological cure compared with placebo. Here, we report sustained virological response (SVR), safety data, health-related quality-of-life (HRQOL), and virological resistance analyses in patients in C-SURFER who received immediate antiviral therapy or who received placebo before therapy.</AbstractText>
                <AbstractText Label="METHODS">In this phase 3, multicentre, randomised, placebo-controlled study, we randomly assigned adults with HCV genotype 1 infection and stage 4-5 chronic kidney disease enrolled at 68 centres worldwide to either elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (immediate treatment group) or placebo for 12 weeks followed by elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks beginning at week 16 (deferred treatment group). The primary safety and efficacy endpoints for the immediate treatment group and placebo phase of the deferred treatment group have been reported previously. Here, we report safety and efficacy data for the treatment phase of the deferred treatment group, as well as HRQOL assessed using the 36-Item Short Form Health Survey for all groups, and baseline and treatment-emergent resistance-associated substitutions (RASs). SVR at 12 weeks (SVR12) was assessed in the modified full analysis set (FAS), defined as all patients excluding those who did not receive at least one dose of study drug, who died, or who discontinued the study before the end of treatment for reasons determined to be unrelated to HCV treatment. This trial is registered with ClinicalTrials.gov, Number NCT02092350.</AbstractText>
                <AbstractText Label="FINDINGS">Between March 30 and Nov 28, 2014, 235 patients were enrolled and received at least one dose of study drug. The modified FAS included 116 patients assigned to immediate treatment and 99 assigned to deferred treatment. 115 (99·1%; 95% CI 95·3-100·0) of 116 assigned to immediate treatment achieved SVR12 compared with 97 (98·0%; 92·9-99·7) of 99 assigned to deferred treatment. In patients with genotype 1a infections, SVR12 was achieved by 11 (84·6%) of 13 patients with detectable baseline NS5A RASs and in 98 (100%) of 98 without. HRQOL did not differ at week 12 between immediate treatment and the placebo phase of deferred treatment. Safety was generally similar between patients receiving immediate treatment and those receiving placebo in the deferred treatment group. One serious adverse event during deferred treatment (interstitial nephritis) and one during the placebo phase of deferred treatment (raised lipase concentration) were deemed related to study drug. Four patients died, one who received immediate treatment (cardiac arrest) and three who received deferred treatment (aortic aneurysm, pneumonia, and unknown cause); all four deaths were considered unrelated to study drugs. Of the three deaths in the deferred treatment group, one occurred during placebo treatment and two occurred before starting active treatment. There were no notable differences in aminotransferase elevations in the deferred treatment group compared with the immediate treatment group, and no patients in the deferred treatment group had total bilirubin elevations.</AbstractText>
                <AbstractText Label="INTERPRETATION">These data add to the growing body of clinical evidence for the fixed-dose combination regimen of elbasvir plus grazoprevir for 12 weeks and support use of this therapy in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.</AbstractText>
                <AbstractText Label="FUNDING">Merck Sharp &amp; Dohme.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bruchfeld</LastName>
                    <ForeName>Annette</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Renal Medicine, Karolinska University Hospital, Stockholm, Sweden. Electronic address: annette.bruchfeld@ki.se.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roth</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hepatology, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unité d'Hépatologie, Hôpital Cochin; Université Paris Descartes; and UMS20, Institut Pasteur; Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Londoño</LastName>
                    <ForeName>Maria-Carlota</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monsour</LastName>
                    <ForeName>Howard</ForeName>
                    <Initials>H</Initials>
                    <Suffix>Jr</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Hepatology and Transplant Medicine, Houston Methodist Hospital, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Marcelo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology and Liver Transplant Units, Hospital Universitario Austral, Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Peggy</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arduino</LastName>
                    <ForeName>Jean-Marie</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Bach-Yen</ForeName>
                    <Initials>BY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greaves</LastName>
                    <ForeName>Wayne</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02092350</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Lancet Gastroenterol Hepatol</MedlineTA>
            <NlmUniqueID>101690683</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Lancet Gastroenterol Hepatol. 2017 Aug;2(8):544-546</RefSource>
                <PMID Version="1">28691680</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D063868" MajorTopicYN="N">Patient Outcome Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28576451</ArticleId>
            <ArticleId IdType="pii">S2468-1253(17)30116-4</ArticleId>
            <ArticleId IdType="doi">10.1016/S2468-1253(17)30116-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28564569</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>06</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>376</Volume>
                    <Issue>22</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>06</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2134-2146</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1613512</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options.</AbstractText>
                <AbstractText Label="METHODS">We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection who had previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks. Patients who were infected with HCV of other genotypes (114 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group. In POLARIS-4, patients with HCV genotype 1, 2, or 3 infection who had previously received a DAA regimen but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (151 patients) for 12 weeks. An additional 19 patients with HCV genotype 4 infection were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.</AbstractText>
                <AbstractText Label="RESULTS">In the three active-treatment groups, 46% of the patients had compensated cirrhosis. In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir-velpatasvir-voxilaprevir, as compared with 0% with placebo. In POLARIS-4, the rate of response was 98% with sofosbuvir-velpatasvir-voxilaprevir and 90% with sofosbuvir-velpatasvir. The most common adverse events were headache, fatigue, diarrhea, and nausea. In the active-treatment groups in both trials, the percentage of patients who discontinued treatment owing to adverse events was 1% or lower.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed. (Funded by Gilead Sciences; POLARIS-1 and POLARIS-4 ClinicalTrials.gov numbers, NCT02607735 and NCT02639247 .).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bourlière</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Stuart C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flamm</LastName>
                    <ForeName>Steven L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>Curtis L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramji</LastName>
                    <ForeName>Alnoor</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tong</LastName>
                    <ForeName>Myron</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ravendhran</LastName>
                    <ForeName>Natarajan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vierling</LastName>
                    <ForeName>John M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tran</LastName>
                    <ForeName>Tram T</ForeName>
                    <Initials>TT</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pianko</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bansal</LastName>
                    <ForeName>Meena B</ForeName>
                    <Initials>MB</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Lédinghen</LastName>
                    <ForeName>Victor</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyland</LastName>
                    <ForeName>Robert H</ForeName>
                    <Initials>RH</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stamm</LastName>
                    <ForeName>Luisa M</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>K C</ForeName>
                    <Initials>KC</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramanian</LastName>
                    <ForeName>G Mani</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verna</LastName>
                    <ForeName>Elizabeth C</ForeName>
                    <Initials>EC</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buggisch</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Landis</LastName>
                    <ForeName>Charles S</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Younes</LastName>
                    <ForeName>Ziad H</ForeName>
                    <Initials>ZH</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curry</LastName>
                    <ForeName>Michael P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strasser</LastName>
                    <ForeName>Simone I</ForeName>
                    <Initials>SI</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schiff</LastName>
                    <ForeName>Eugene R</ForeName>
                    <Initials>ER</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>K Rajender</ForeName>
                    <Initials>KR</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manns</LastName>
                    <ForeName>Michael P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kowdley</LastName>
                    <ForeName>Kris V</ForeName>
                    <Initials>KV</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeuzem</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>POLARIS-1 and POLARIS-4 Investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02607735</AccessionNumber>
                        <AccessionNumber>NCT02639247</AccessionNumber>
                        <AccessionNumber>NCT02607735</AccessionNumber>
                        <AccessionNumber>NCT02639247</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047028">Macrocyclic Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000619503">voxilaprevir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>KCU0C7RS7Z</RegistryNumber>
                <NameOfSubstance UI="C000604171">velpatasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047028" MajorTopicYN="N">Macrocyclic Compounds</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Roberts</LastName>
                <ForeName>Stuart</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dore</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leggett</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thompson</LastName>
                <ForeName>Alexander</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shafran</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Conway</LastName>
                <ForeName>Brian</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Willems</LastName>
                <ForeName>Bernard</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Feld</LastName>
                <ForeName>Jordan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Borgia</LastName>
                <ForeName>Sergio</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Congly</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pol</LastName>
                <ForeName>Stanislas</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Samuel</LastName>
                <ForeName>Didier</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Botta-Fridlund</LastName>
                <ForeName>Danielle</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Riachi</LastName>
                <ForeName>Ghassan</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hezode</LastName>
                <ForeName>Christophe</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zoulim</LastName>
                <ForeName>Fabien</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bronowicki</LastName>
                <ForeName>Jean-Pierre</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Habersetzer</LastName>
                <ForeName>François</ForeName>
                <Initials>FN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathurin</LastName>
                <ForeName>Philippe</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Guyader</LastName>
                <ForeName>Dominique</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grange</LastName>
                <ForeName>Jean-Didier</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loustaud-Ratti</LastName>
                <ForeName>Véronique</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ratziu</LastName>
                <ForeName>Vlad</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Serfaty</LastName>
                <ForeName>Lawrence</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tran</LastName>
                <ForeName>Albert</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Larrey</LastName>
                <ForeName>Dominique</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Alric</LastName>
                <ForeName>Laurent</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Asselah</LastName>
                <ForeName>Tarik</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abergel</LastName>
                <ForeName>Armando</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leroy</LastName>
                <ForeName>Vincent</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Metivier</LastName>
                <ForeName>Sophie</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berg</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goeser</LastName>
                <ForeName>Tobias</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spengler</LastName>
                <ForeName>Ulrich</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gane</LastName>
                <ForeName>Edward</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stedman</LastName>
                <ForeName>Catherine A M</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ortiz-Lasanta</LastName>
                <ForeName>Grissel</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryder</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Foster</LastName>
                <ForeName>Graham</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Ashley</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Agarwal</LastName>
                <ForeName>Kosh</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ustianowski</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aspinall</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Di Bisceglie</LastName>
                <ForeName>Adrian</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shiffman</LastName>
                <ForeName>Mitchell</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruane</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bennett</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Patel</LastName>
                <ForeName>Anna</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lok</LastName>
                <ForeName>Anna</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rojter</LastName>
                <ForeName>Sergio</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Charlton</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nyberg</LastName>
                <ForeName>Lisa</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chung</LastName>
                <ForeName>Raymond</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lacerda</LastName>
                <ForeName>Marco</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Smith</LastName>
                <ForeName>Coleman</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Khalili</LastName>
                <ForeName>Mandana</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rubin</LastName>
                <ForeName>Raymond</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Smith</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Everson</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sulkowski</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Levin</LastName>
                <ForeName>James</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gitlin</LastName>
                <ForeName>Norman</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Workowski</LastName>
                <ForeName>Kimberly</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nahass</LastName>
                <ForeName>Ronald</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryan</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lawitz</LastName>
                <ForeName>Eric</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanyal</LastName>
                <ForeName>Arun</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nguyen</LastName>
                <ForeName>Mindie</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morelli</LastName>
                <ForeName>Giuseppe</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Freilich</LastName>
                <ForeName>Bradley</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kugelmas</LastName>
                <ForeName>Marcelo</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheikh</LastName>
                <ForeName>Aasim</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sepe</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Davis</LastName>
                <ForeName>Mitchell</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pound</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Benson</LastName>
                <ForeName>Constance</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hinestrosa</LastName>
                <ForeName>Federico</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brau</LastName>
                <ForeName>Norbert</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Herring</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morgan</LastName>
                <ForeName>Timothy</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kayali</LastName>
                <ForeName>Zeid</ForeName>
                <Initials>Z</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rabinovitz</LastName>
                <ForeName>Mordechai</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cooper</LastName>
                <ForeName>James</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pearlman</LastName>
                <ForeName>Brian</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shaikh</LastName>
                <ForeName>Obaid</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harlan</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Agarwal</LastName>
                <ForeName>Ritu</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bourliere</LastName>
                <ForeName>Marc</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ratti</LastName>
                <ForeName>Véronique Loustaud</ForeName>
                <Initials>VL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ortiz-Lasanta</LastName>
                <ForeName>Grisell</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Collier</LastName>
                <ForeName>Jane</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Forton</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kumar</LastName>
                <ForeName>Sonal</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>WeisbergI</LastName>
                <ForeName>lan</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bhandari</LastName>
                <ForeName>Bal Raj</ForeName>
                <Initials>BR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Poulos</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kottilil</LastName>
                <ForeName>Shyamasundaran</ForeName>
                <Initials>S</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28564569</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1613512</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28498551</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>10</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1083-1089</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.29256</ELocationID>
            <Abstract>
                <AbstractText>The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear. In this multicenter, open-label, phase 2 study, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct-acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3/4A protease inhibitor voxilaprevir. The primary efficacy endpoint was the proportion of patients achieving sustained virologic response at 12 weeks after the cessation of treatment. In total, 63 of 69 (91%; 95% confidence interval, 82%-97%) patients achieved sustained virologic response at 12 weeks, including 36 of 37 (97%; 95% confidence interval, 86%-100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 95% confidence interval, 66%-100%) patients with genotype 2 infection, and 14 of 18 (78%; 95% confidence interval, 52%-94%) patients with genotype 3 infection. Most adverse events were of mild or moderate severity. The most frequently reported adverse events were fatigue, nausea, headache, insomnia, and rash. One patient (1%) with genotype 1a infection discontinued all study drugs due to an adverse event (irritability).</AbstractText>
                <AbstractText Label="CONCLUSION">Retreatment of patients who previously failed direct-acting antiviral-based therapies with sofosbuvir-velpatasvir plus ribavirin for 24 weeks was well tolerated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection. (Hepatology 2017;66:1083-1089).</AbstractText>
                <CopyrightInformation>© 2017 by the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Auckland Clinical Studies, Auckland, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shiffman</LastName>
                    <ForeName>Mitchell L</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Institute of Virginia, Richmond, VA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Etzkorn</LastName>
                    <ForeName>Kyle</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Borland Groover Clinic, Jacksonville, FL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morelli</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, FL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stedman</LastName>
                    <ForeName>Catherine A M</ForeName>
                    <Initials>CAM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Christchurch Hospital and University of Otago, Christchurch, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davis</LastName>
                    <ForeName>Mitchell N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>South Florida Center of Gastroenterology, Wellington, FL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hinestrosa</LastName>
                    <ForeName>Federico</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Orlando Immunology Center, Orlando, FL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>K C</ForeName>
                    <Initials>KC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osinusi</LastName>
                    <ForeName>Anu</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McNally</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Alex J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>St. Vincent's Hospital, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>GS-US-342-1553 Investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K24 DA034621</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000611331">sofosbuvir-velpatasvir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28498551</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.29256</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28470815</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>06</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2893</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of viral hepatitis</Title>
                <ISOAbbreviation>J. Viral Hepat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>895-899</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jvh.12719</ELocationID>
            <Abstract>
                <AbstractText>Elbasvir (EBR; HCV NS5A inhibitor) and grazoprevir (GZR; HCV NS3/4A protease inhibitor) are approved as a fixed-dose combination to treat patients chronically infected with HCV genotypes 1 and 4. During the development programme and supported by in vitro potency, the efficacy of EBR+GZR was assessed in HCV GT3-infected patients. This study's aim was to determine the efficacy and tolerability of 12 or 18 weeks of EBR+GZR with ribavirin (RBV) in treatment-naïve, noncirrhotic HCV GT3-infected patients. Randomized patients received open-label EBR (50 mg once daily) + GZR (100 mg once daily) + RBV. The primary efficacy objective was to evaluate the sustained virologic response rates 12 weeks after the end of all study therapy (SVR12). SVR12 rates (95% confidence interval) were 45.0% (23.1, 68.5) and 57.1% (34.0, 78.2) after treatment with EBR+GZR+RBV for 12 weeks or 18 weeks, respectively. On-treatment virologic failure was observed in 41% (17 of 41) of patients. At virologic failure, resistance-associated substitutions (RASs) with a &gt;five-fold shift in potency occurred in the NS3 region in six (35%) patients and in the NS5A region in 16 (94%) patients. The most common RAS at virologic failure was Y93H in NS5A which was identified in 13 of 17 (76%) patients. The efficacy of EBR+GZR+RBV was suboptimal in HCV GT3-infected patients due to a high rate of on-treatment virologic failure and treatment-emergent RASs which demonstrates an inadequate barrier to the development of GT3 resistance. However, rapid viral clearance demonstrated the antiviral activity of EBR+GZR+RBV in GT3-infected patients.clinicaltrials.gov: NCT01717326.</AbstractText>
                <CopyrightInformation>© 2017 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Auckland Clinical Studies, Grafton, Auckland, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahass</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>ID Care, Hillsborough, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luketic</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Hunter Holmes McGuire Department of Veterans Affairs Medical Center, Richmond, VA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asante-Appiah</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haber</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01717326</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Viral Hepat</MedlineTA>
            <NlmUniqueID>9435672</NlmUniqueID>
            <ISSNLinking>1352-0504</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">elbasvir</Keyword>
            <Keyword MajorTopicYN="Y">genotype 3</Keyword>
            <Keyword MajorTopicYN="Y">grazoprevir</Keyword>
            <Keyword MajorTopicYN="Y">hepatitis C virus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28470815</ArticleId>
            <ArticleId IdType="doi">10.1111/jvh.12719</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28416549</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>61</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>07</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">e00363-17</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00363-17</ELocationID>
            <Abstract>
                <AbstractText>Although genotype 4 (GT4)-infected patients represent a minor overall percentage of the global hepatitis C virus (HCV)-infected population, the high prevalence of the genotype in specific geographic regions coupled with substantial sequence diversity makes it an important genotype to study for antiviral drug discovery and development. We evaluated two direct-acting antiviral agents-grazoprevir, an HCV NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor-in GT4 replicons prior to clinical studies in this genotype. Following a bioinformatics analysis of available GT4 sequences, a set of replicons bearing representative GT4 clinical isolates was generated. For grazoprevir, the 50% effective concentration (EC<sub>50</sub>) against the replicon bearing the reference GT4a (ED43) NS3 protease and NS4A was 0.7 nM. The median EC<sub>50</sub> for grazoprevir against chimeric replicons encoding NS3/4A sequences from GT4 clinical isolates was 0.2 nM (range, 0.11 to 0.33 nM; <i>n</i> = 5). The difficulty in establishing replicons bearing NS3/4A resistance-associated substitutions was substantially overcome with the identification of a G162R adaptive substitution in NS3. Single NS3 substitutions D168A/V identified from <i>de novo</i> resistance selection studies reduced grazoprevir antiviral activity by 137- and 47-fold, respectively, in the background of the G162R replicon. For elbasvir, the EC<sub>50</sub> against the replicon bearing the reference full-length GT4a (ED43) NS5A gene was 0.0002 nM. The median EC<sub>50</sub> for elbasvir against chimeric replicons bearing clinical isolates from GT4 was 0.0007 nM (range, 0.0002 to 34 nM; <i>n</i> = 14). <i>De novo</i> resistance selection studies in GT4 demonstrated a high propensity to suppress the emergence of amino acid substitutions that confer high-potency reductions to elbasvir. Phenotypic characterization of the NS5A amino acid substitutions identified (L30F, L30S, M31V, and Y93H) indicated that they conferred 15-, 4-, 2.5-, and 7.5-fold potency losses, respectively, to elbasvir. The activity profiles of grazoprevir and elbasvir supported the testing of the direct-acting antivirals in clinical studies.</AbstractText>
                <CopyrightInformation>Copyright © 2017 American Society for Microbiology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Asante-Appiah</LastName>
                    <ForeName>Ernest</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA ernest_asanteappiah@merck.com fred.lahser@merck.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curry</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McMonagle</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingravallo</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chase</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nickle</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Informatics and Analytics, Merck &amp; Co., Inc., Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Translational Molecular Biomarkers, Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lahser</LastName>
                    <ForeName>Frederick C</ForeName>
                    <Initials>FC</Initials>
                    <Identifier Source="ORCID">0000-0003-4902-0435</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA ernest_asanteappiah@merck.com fred.lahser@merck.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="C000614516">NS3-4A serine protease, Hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="D057057">Serine Proteases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057057" MajorTopicYN="N">Serine Proteases</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">HCV</Keyword>
            <Keyword MajorTopicYN="Y">NS3/4A</Keyword>
            <Keyword MajorTopicYN="Y">NS5A</Keyword>
            <Keyword MajorTopicYN="Y">antiviral</Keyword>
            <Keyword MajorTopicYN="Y">antiviral agents</Keyword>
            <Keyword MajorTopicYN="Y">drug resistance mechanisms</Keyword>
            <Keyword MajorTopicYN="Y">elbasvir</Keyword>
            <Keyword MajorTopicYN="Y">genotype 4</Keyword>
            <Keyword MajorTopicYN="Y">grazoprevir</Keyword>
            <Keyword MajorTopicYN="Y">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="Y">resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28416549</ArticleId>
            <ArticleId IdType="pii">AAC.00363-17</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.00363-17</ArticleId>
            <ArticleId IdType="pmc">PMC5487656</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Dec;59(12 ):7426-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26392503</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMJ Open Gastroenterol. 2016 Sep 30;3(1):e000112</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27752338</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5365-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22869572</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ACS Med Chem Lett. 2012 Mar 02;3(4):332-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24900473</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2011 Feb;140(2):667-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21056040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2000 Feb;74(4):2046-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10644379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 Aug;147(2):453-62.e7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24768676</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jan;59(1):318-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24115039</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2008 Mar;77(3):177-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18201776</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet HIV. 2015 Aug;2(8):e319-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26423374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Bioinformatics. 2004 Aug 19;5:113</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15318951</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26303801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ChemMedChem. 2013 Dec;8(12):1930-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24127258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2008 Apr;47(4):1371-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18240152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2016 Nov 1;165(9):625-634</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27537841</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2017 Feb;152(3):586-597</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27773808</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Jul;57(7):3250-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23629699</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26926625</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2016 Dec;23 (12 ):950-954</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27405785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2006 Jun;70(2):28-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16448708</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22615282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2007 May;88(Pt 5):1526-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17412982</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Syst Biol. 2010 May;59(3):307-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20525638</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2017 May;66(5):910-918</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28108232</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2016 Jul 28;22(28):6393-401</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27605875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Apr;57(4):1333-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23172780</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28412293</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-0641</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>67</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>08</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hepatology</Title>
                <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>263-271</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0168-8278(17)30211-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2017.03.039</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable. The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.</AbstractText>
                <AbstractText Label="METHODS">SURVEYOR-I and SURVEYOR-II were phase II, open-label, multicenter, dose-ranging trials including patients with chronic HCV genotype 1-6 infection who were either previously untreated or treated with pegylated interferon plus ribavirin. Patients received once-daily glecaprevir plus pibrentasvir at varying doses with or without ribavirin for 8 or 12weeks. The primary efficacy endpoint was the percentage of patients with a sustained virologic response at post-treatment week 12 (SVR12).</AbstractText>
                <AbstractText Label="RESULTS">Of the 449 patients who received varying doses of glecaprevir plus pibrentasvir, 25%, 29%, 39%, and 8% had HCV genotype 1, 2, 3, and 4-6 infection, respectively. Twelve-week treatment achieved SVR12 in 97-100%, 96-100%, 83-94%, and 100% in genotypes 1, 2, 3, and 4-6, respectively. Eight-week treatment with 300mg glecaprevir plus 120mg pibrentasvir in genotype 1-, 2-, or 3-infected patients yielded 97-98% SVR12 with no virologic failures. Three (0.7%) patients discontinued treatment due to adverse events; most events were mild (grade 1) in severity. No post-nadir alanine aminotransferase elevations were observed.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virologic response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-week treatment durations.</AbstractText>
                <AbstractText Label="LAY SUMMARY">The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection. This article describes results from two phase II trials investigating a range of doses at treatment durations of 8 or 12weeks in 449 patients without cirrhosis. Efficacy of the optimal dose, as determined by rates of sustained virologic response at post-treatment week 12, ranged from 92%-100%; treatment was well tolerated and significant laboratory abnormalities were rare.</AbstractText>
                <AbstractText Label="CLINICAL TRIAL REGISTRATION">clinicaltrials.gov Identifiers: NCT02243280 and NCT02243293. http://www.clinicaltrials.gov/show/NCT02243280, http://www.clinicaltrials.gov/show/NCT01939197.</AbstractText>
                <CopyrightInformation>Copyright © 2017. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kwo</LastName>
                    <ForeName>Paul Y</ForeName>
                    <Initials>PY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Stanford University Division of Gastroenterology and Hepatology, Palo Alto, CA, USA. Electronic address: pkwo@stanford.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poordad</LastName>
                    <ForeName>Fred</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asatryan</LastName>
                    <ForeName>Armen</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Stanley</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wyles</LastName>
                    <ForeName>David L</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Colorado School of Medicine, Denver, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassanein</LastName>
                    <ForeName>Tarek</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Felizarta</LastName>
                    <ForeName>Franco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Private Practice, Bakersfield, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Auckland, Auckland, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maliakkal</LastName>
                    <ForeName>Benedict</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Rochester Medical Center, Rochester, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Overcash</LastName>
                    <ForeName>J Scott</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>eStudySite, San Diego, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Stuart C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Henry Ford Health System, Detroit, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muir</LastName>
                    <ForeName>Andrew J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Duke University School of Medicine, Durham, NC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aguilar</LastName>
                    <ForeName>Humberto</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Louisiana Research Center, Shreveport, LA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agarwal</LastName>
                    <ForeName>Kosh</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dore</LastName>
                    <ForeName>Gregory J</ForeName>
                    <Initials>GJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kirby Institute, UNSW Sydney, and St. Vincent's Hospital, Sydney, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Chih-Wei</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ran</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lovell</LastName>
                    <ForeName>Sandra S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Teresa I</ForeName>
                    <Initials>TI</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kort</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mensa</LastName>
                    <ForeName>Federico J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02243280</AccessionNumber>
                        <AccessionNumber>NCT02243293</AccessionNumber>
                        <AccessionNumber>NCT01939197</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Hepatol</MedlineTA>
            <NlmUniqueID>8503886</NlmUniqueID>
            <ISSNLinking>0168-8278</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000612853">ABT-493</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000612854">ABT-530</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024921" MajorTopicYN="N">Drug Resistance, Multiple, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">ABT-493</Keyword>
            <Keyword MajorTopicYN="Y">ABT-530</Keyword>
            <Keyword MajorTopicYN="Y">D-alanine transaminase</Keyword>
            <Keyword MajorTopicYN="Y">Direct-acting antiviral</Keyword>
            <Keyword MajorTopicYN="Y">Genotype</Keyword>
            <Keyword MajorTopicYN="Y">Hepatitis C, chronic</Keyword>
            <Keyword MajorTopicYN="Y">Interferons</Keyword>
            <Keyword MajorTopicYN="Y">Liver cirrhosis</Keyword>
            <Keyword MajorTopicYN="Y">Pangenotypic</Keyword>
            <Keyword MajorTopicYN="Y">SURVEYOR</Keyword>
            <Keyword MajorTopicYN="Y">Sustained virologic response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28412293</ArticleId>
            <ArticleId IdType="pii">S0168-8278(17)30211-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.03.039</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28369411</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1537-6591</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Jun</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
                <ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1615-1618</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/cix214</ELocationID>
            <Abstract>
                <AbstractText>We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.</AbstractText>
                <CopyrightInformation>© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fourati</LastName>
                    <ForeName>Slim</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chevaliez</LastName>
                    <ForeName>Stéphane</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scoazec</LastName>
                    <ForeName>Giovanna</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soulier</LastName>
                    <ForeName>Alexandre</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varaut</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>François</LastName>
                    <ForeName>Murielle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruiz</LastName>
                    <ForeName>Isaac</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roudot-Thoraval</LastName>
                    <ForeName>Françoise</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mallat</LastName>
                    <ForeName>Ariane</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pawlotsky</LastName>
                    <ForeName>Jean-Michel</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, and.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Infect Dis</MedlineTA>
            <NlmUniqueID>9203213</NlmUniqueID>
            <ISSNLinking>1058-4838</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9WS5RD66HZ</RegistryNumber>
                <NameOfSubstance UI="D000069616">Simeprevir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069616" MajorTopicYN="N">Simeprevir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">chronic hepatitis C</Keyword>
            <Keyword MajorTopicYN="N">resistance</Keyword>
            <Keyword MajorTopicYN="N">resistance-associated substitutions.</Keyword>
            <Keyword MajorTopicYN="N">retreatment</Keyword>
            <Keyword MajorTopicYN="N">sustained virological response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28369411</ArticleId>
            <ArticleId IdType="pii">3065638</ArticleId>
            <ArticleId IdType="doi">10.1093/cid/cix214</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">28332272</PMID>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1386-6346</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>47</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology research : the official journal of the Japan Society of Hepatology</Title>
                <ISOAbbreviation>Hepatol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1308-1316</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/hepr.12898</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study explored treatment outcomes of sofosbuvir (SOF)/ledipasvir (LDV) therapy for chronic hepatitis C patients with and without prior daclatasvir (DCV)/asunaprevir (ASV) therapy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Overall, 530 Japanese patients who were infected with hepatitis C virus genotype 1 received SOF/LDV therapy for 12 weeks, and resistance-associated variants (RAVs) in the hepatitis C virus non-structural protein (NS)5A and NS5B regions were assessed at baseline and virological relapse by direct sequencing.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sustained virological response (SVR) rates did not significantly differ between patients with and without NS5A Y93H/N (94.2% [113/120] vs. 97.7% [345/353]), but the SVR rate was significantly lower in patients with prior DCV/ASV therapy compared to those without (69.2% [18/26] vs. 98.4% [496/504], P &lt; 0.001). Among 26 patients with prior DCV/ASV therapy, the prevalence of NS5A multi-RAVs (≥2) was similar between responders and non-responders (61% [11/18] vs. 75% [5/8]), but all patients without RAVs achieved SVR. Multivariate analysis showed that prior DCV/ASV therapy and history of hepatocellular carcinoma were independently associated with treatment failure (odds ratio, 37.55; 95% confidence interval, 10.78-130.76; P &lt; 0.001 for prior DCV/ASV therapy; odds ratio, 4.42; 95% confidence interval, 1.09-18.04; P = 0.03 for the history of HCC). All SOF/LDV failure patients (n = 8) with prior DCV/ASV treatment had two or more factors of cirrhosis, IL28B unfavorable genotype, and baseline NS5A multi-RAVs. The multiple NS5A RAVs had increased but NS5B substitutions, C316N/A207T/A218S or L159F, had not changed at the time of relapse.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prior DCV/ASV therapy is associated with failure of SOF/LDV therapy due to multiple RAVs.</AbstractText>
                <CopyrightInformation>© 2017 The Japan Society of Hepatology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Iio</LastName>
                    <ForeName>Etsuko</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimada</LastName>
                    <ForeName>Noritomo</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Otakanomori Hospital, Kashiwa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takaguchi</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kagawa Prefectural Central Hospital, Takamatsu, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Senoh</LastName>
                    <ForeName>Tomonori</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kagawa Prefectural Central Hospital, Takamatsu, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eguchi</LastName>
                    <ForeName>Yuichiro</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Saga University Hospital, Saga, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Atsukawa</LastName>
                    <ForeName>Masanori</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nippon Medical School, Chiba Hokusoh Hospital, Chiba, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsubota</LastName>
                    <ForeName>Akihito</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jikei University School of Medicine, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abe</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jikei University School of Medicine, Katsushika Medical Center, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kato</LastName>
                    <ForeName>Keizo</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jikei University School of Medicine, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Shinmatsudo Central General Hospital, Matsudo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kusakabe</LastName>
                    <ForeName>Atsunori</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miyaki</LastName>
                    <ForeName>Tomokatsu</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Toyokawa City Hospital, Toyokawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuura</LastName>
                    <ForeName>Kentaro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsunami</LastName>
                    <ForeName>Kayoko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shinkai</LastName>
                    <ForeName>Noboru</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujiwara</LastName>
                    <ForeName>Kei</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nojiri</LastName>
                    <ForeName>Shunsuke</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Yasuhito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Hepatol Res</MedlineTA>
            <NlmUniqueID>9711801</NlmUniqueID>
            <ISSNLinking>1386-6346</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DCV/ASV failure</Keyword>
            <Keyword MajorTopicYN="N">HCV</Keyword>
            <Keyword MajorTopicYN="N">SOF/LDV</Keyword>
            <Keyword MajorTopicYN="N">direct-acting antivirals</Keyword>
            <Keyword MajorTopicYN="N">resistance-associated variants</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28332272</ArticleId>
            <ArticleId IdType="doi">10.1111/hepr.12898</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28193664</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>61</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>05</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle><i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">e02558-16</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.02558-16</ELocationID>
            <Abstract>
                <AbstractText>Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with 50% effective concentration (EC<sub>50</sub>) values ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6. Pibrentasvir demonstrated similar activity against a panel of chimeric replicons containing HCV NS5A of genotypes 1 to 6 from clinical samples. Resistance selection studies were conducted using HCV replicon cells with NS5A from genotype 1a, 1b, 2a, 2b, 3a, 4a, 5a, or 6a at a concentration of pibrentasvir that was 10- or 100-fold over its EC<sub>50</sub> for the respective replicon. With pibrentasvir at 10-fold over the respective EC<sub>50</sub>, only a small number of colonies (0.00015 to 0.0065% of input cells) with resistance-associated amino acid substitutions were selected in replicons containing genotype 1a, 2a, or 3a NS5A, and no viable colonies were selected in replicons containing NS5A from other genotypes. With pibrentasvir at 100-fold over the respective EC<sub>50</sub>, very few colonies (0.0002% of input cells) were selected by pibrentasvir in genotype 1a replicon cells while no colonies were selected in other replicons. Pibrentasvir is active against common resistance-conferring substitutions in HCV genotypes 1 to 6 that were identified for other NS5A inhibitors, including those at key amino acid positions 28, 30, 31, or 93. The combination of pibrentasvir with HCV inhibitors of other classes produced synergistic inhibition of HCV replication. In summary, pibrentasvir is a next-generation HCV NS5A inhibitor with potent and pan-genotypic activity, and it maintains activity against common amino acid substitutions of HCV genotypes 1 to 6 that are known to confer resistance to currently approved NS5A inhibitors.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Ng et al.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Teresa I</ForeName>
                    <Initials>TI</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA teresa.ng@abbvie.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krishnan</LastName>
                    <ForeName>Preethi</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pilot-Matias</LastName>
                    <ForeName>Tami</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kati</LastName>
                    <ForeName>Warren</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schnell</LastName>
                    <ForeName>Gretja</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beyer</LastName>
                    <ForeName>Jill</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reisch</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Liangjun</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dekhtyar</LastName>
                    <ForeName>Tatyana</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Irvin</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tripathi</LastName>
                    <ForeName>Rakesh</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maring</LastName>
                    <ForeName>Clarence</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Randolph</LastName>
                    <ForeName>John T</ForeName>
                    <Initials>JT</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wagner</LastName>
                    <ForeName>Rolf</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie, Inc., North Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000612854">ABT-530</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000622691">pibrentasvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">ABT-530</Keyword>
            <Keyword MajorTopicYN="Y">HCV</Keyword>
            <Keyword MajorTopicYN="Y">NS5A inhibitor</Keyword>
            <Keyword MajorTopicYN="Y">antiviral activity</Keyword>
            <Keyword MajorTopicYN="Y">pibrentasvir</Keyword>
            <Keyword MajorTopicYN="Y">resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28193664</ArticleId>
            <ArticleId IdType="pii">AAC.02558-16</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.02558-16</ArticleId>
            <ArticleId IdType="pmc">PMC5404558</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA. 2012 Dec 26;308(24):2584-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23268517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25534735</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Oct;151(4):651-659.e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27456384</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 May;57(5):2054-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23403428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2008 Aug;82(16):7964-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18524832</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Jan;57(1):611-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23089758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2013 May;57(1):13-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jan;59(1):318-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24115039</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 May;146(5):1176-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24631495</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26303801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2016 Jan;36 Suppl 1:47-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26725897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Dec;57(12):6333-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23877691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Nov;62(5):1623-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2011 Jul;31 Suppl 2:61-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21651703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22430955</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1956-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21837752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2012 Jul;57(1):24-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22314425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):979-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25451055</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2016 Jan 11;60(3):1847-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26824950</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Sep;58(3):902-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23504694</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ACS Med Chem Lett. 2014 Mar 13;5(3):214-220</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24672647</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2015 Dec;22(12 ):1011-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26183611</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Sep;59(9):5445-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26100711</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 1996 Jan;1(1):9-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11322261</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Dec 28;60(3):1546-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26711747</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2013 Feb;13(2):123-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23344543</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24936600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2016 Dec;71(12 ):3495-3505</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27605597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Sep;85(Pt 9):2485-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15302943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 1993 Mar;37(3):540-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2014 Mar 21;20(11):2902-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24659881</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28193518</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>152</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>05</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1372-1382.e2</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(17)30150-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2017.01.050</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and decompensation. We analyzed the effects of the direct-acting antiviral agents elbasvir and grazoprevir in patients with HCV infection and compensated cirrhosis, combining data from 6 clinical trials.</AbstractText>
                <AbstractText Label="METHODS">We performed an integrated analysis of 402 patients with HCV genotype 1, 4, or 6 infection and Child-Pugh A compensated cirrhosis enrolled in 6 clinical trials. All patients received elbasvir/grazoprevir 50 mg/100 mg once daily, with or without ribavirin, for 12-18 weeks. The primary end point was sustained virologic response 12 weeks after completion of therapy (SVR12), defined as a level of HCV RNA &lt;15 IU/mL.</AbstractText>
                <AbstractText Label="RESULTS">Among treatment-naïve and treatment-experienced patients receiving elbasvir/grazoprevir for 12 weeks, 97.8% (135 of 138) and 88.9% (48 of 54) achieved SVR12, respectively. Among patients receiving elbasvir/grazoprevir for 12 weeks, addition of ribavirin did not increase the proportion of treatment-naïve patients (90.3%, 28 of 31) or treatment-experienced patients who achieved an SVR12 (91.4%, 74 of 81). All (49 of 49) treatment-experienced patients receiving elbasvir/grazoprevir with ribavirin for 16 or 18 weeks, and 93.9% (46 of 49) of patients receiving elbasvir/grazoprevir without ribavirin for 16 or 18 weeks achieved SVR12. Virologic failure was higher among patients with HCV genotype 1a infections compared with patients with genotype 1b or 4 infections, particularly in patients who had not responded to previous interferon therapy. Baseline tests for resistance-associated substitutions (RASs) led to an individualized approach for selecting treatment duration and established a need for ribavirin for patients with HCV genotype 1a infection and RASs, regardless of treatment history. Among patients with HCV genotype 1a infection with and without baseline RASs in HCV nonstructural protein 5A who received elbasvir/grazoprevir for 12 weeks, 73% (8 of 11) and 98% (96 of 98) achieved SVR12, respectively. Both patients with HCV genotype 1a infection with baseline RASs who received 16 or 18 weeks of elbasvir/grazoprevir and ribavirin achieved SVR12. Grade 3 or 4 increases in levels of alanine aminotransferase and aspartate aminotransferase, which did not cause symptoms, were reported in 2.3% (6 of 264) of patients receiving elbasvir/grazoprevir. Serious adverse events were reported in 3% (8 of 264) patients and no patient had a decompensation-related event.</AbstractText>
                <AbstractText Label="CONCLUSIONS">In an analysis of data from 6 clinical trials, rates of SVR12 ranged from 89% to 100% in patients with HCV genotype 1, 4, or 6 infections and compensated cirrhosis treated with elbasvir/grazoprevir, with or without ribavirin. Addition of ribavirin to a 12-week regimen of elbasvir/grazoprevir had little effect on the proportion of treatment-naïve or treatment-experienced patients who achieved an SVR12. However, virologic failure did not occur in any treatment-experienced patients when the duration of elbasvir/grazoprevir and ribavirin therapy was extended to 16 or 18 weeks. Baseline analysis of RASs (or in the absence of this test, a history of nonresponse to interferon) can be used to determine treatment duration and the need for ribavirin in patients with HCV genotype 1a infection. Clinicaltrials.gov ID: NCT02092350, NCT02105662, NCT02105467, NCT02105701, NCT01717326, and NCT02105454.</AbstractText>
                <CopyrightInformation>Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jacobson</LastName>
                    <ForeName>Ira M</ForeName>
                    <Initials>IM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mount Sinai Beth Israel and Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ijacobson@chpnet.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwo</LastName>
                    <ForeName>Paul Y</ForeName>
                    <Initials>PY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Indiana University School of Medicine, Indianapolis, Indiana.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Henri Mondor Hospital, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Cheng-Yuan</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>China Medical University Hospital, Taichung City, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AYM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Peggy</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haber</LastName>
                    <ForeName>Barbara A</ForeName>
                    <Initials>BA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02105662</AccessionNumber>
                        <AccessionNumber>NCT01717326</AccessionNumber>
                        <AccessionNumber>NCT02105701</AccessionNumber>
                        <AccessionNumber>NCT02092350</AccessionNumber>
                        <AccessionNumber>NCT02105467</AccessionNumber>
                        <AccessionNumber>NCT02105454</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">ALT</Keyword>
            <Keyword MajorTopicYN="Y">Fibrosis</Keyword>
            <Keyword MajorTopicYN="Y">NS5A</Keyword>
            <Keyword MajorTopicYN="Y">Virus Mutation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28193518</ArticleId>
            <ArticleId IdType="pii">S0016-5085(17)30150-6</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2017.01.050</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28128852</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>08</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>389-397</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.29081</ELocationID>
            <Abstract>
                <AbstractText>Although direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent treatment. Treatment options for patients who failed previous DAA-containing regimens, particularly those with nonstructural protein 5A inhibitors, are limited and remain an area of unmet medical need. This phase 2, open-label study (MAGELLAN-1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) ± ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy. A total of 50 patients without cirrhosis were randomized to three arms: 200 mg GLE + 80 mg PIB (arm A), 300 mg GLE + 120 mg PIB with 800 mg once-daily RBV (arm B), or 300 mg GLE + 120 mg PIB without RBV (arm C). By intent-to-treat analysis, sustained virologic response at posttreatment week 12 was achieved in 100% (6/6, 95% confidence interval 61-100), 95% (21/22, 95% confidence interval 78-99), and 86% (19/22, 95% confidence interval 67-95) of patients in arms A, B, and C, respectively. Virologic failure occurred in no patients in arm A and in 1 patient each in arms B and C (two patients were lost to follow-up in arm C). The majority of adverse events were mild in severity; no serious adverse events related to study drug and no relevant laboratory abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed.</AbstractText>
                <AbstractText Label="CONCLUSION">The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV coadministration did not improve efficacy. (Hepatology 2017;66:389-397).</AbstractText>
                <CopyrightInformation>© 2017 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Poordad</LastName>
                    <ForeName>Fred</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Felizarta</LastName>
                    <ForeName>Franco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Private Practice, Bakersfield, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asatryan</LastName>
                    <ForeName>Armen</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc, North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reindollar</LastName>
                    <ForeName>Robert W</ForeName>
                    <Initials>RW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Landis</LastName>
                    <ForeName>Charles S</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology, University of Washington, Seattle, WA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Stuart C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Henry Ford Health System, Detroit, MI.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flamm</LastName>
                    <ForeName>Steven L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Northwestern Feinberg School of Medicine, Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fried</LastName>
                    <ForeName>Michael W</ForeName>
                    <Initials>MW</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of North Carolina, Chapel Hill, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernstein</LastName>
                    <ForeName>David E</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>North Shore University Hospital, Manhasset, NY.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Chih-Wei</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc, North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ran</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc, North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lovell</LastName>
                    <ForeName>Sandra S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc, North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Teresa I</ForeName>
                    <Initials>TI</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc, North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kort</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc, North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mensa</LastName>
                    <ForeName>Federico J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc, North Chicago, IL.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>04</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000612853">ABT-493</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000622691">pibrentasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>Hepatology. 2017 Nov;66(5):1708</RefSource>
                <PMID Version="1">29053199</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28128852</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.29081</ArticleId>
            <ArticleId IdType="pmc">PMC5573922</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Hepatology. 2005 Feb;41(2):275-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15660393</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2015 Jun 18;11(6):e1004854</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26087286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1983-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24795200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Oct;151(4):651-659.e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27456384</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2016 Jan 1;62(1):32-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26371152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2017 Apr 24;61(5):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28193664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Dec;58(6):1918-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23907700</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 May;146(5):1176-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24631495</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2016 Jan;36 Suppl 1:47-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26725897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterol Hepatol (N Y). 2016 Jun;12 (6 Suppl 2):1-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28070175</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Viruses. 2015 Dec 18;7(12):6716-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26694454</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1973-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2014 Aug;108:181-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24911972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28105744</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-3231</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>37</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>04</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
                <ISOAbbreviation>Liver Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>514-528</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.13327</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures.</AbstractText>
                <AbstractText Label="METHODS">Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70).</AbstractText>
                <AbstractText Label="RESULTS">The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P&lt;.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure.</AbstractText>
                <AbstractText Label="CONCLUSIONS">In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resistance testing at failure, in all three genes for the best second-line therapeutic tailoring.</AbstractText>
                <CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Di Maio</LastName>
                    <ForeName>Velia C</ForeName>
                    <Initials>VC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cento</LastName>
                    <ForeName>Valeria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lenci</LastName>
                    <ForeName>Ilaria</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aragri</LastName>
                    <ForeName>Marianna</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rossi</LastName>
                    <ForeName>Piera</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barbaliscia</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Melis</LastName>
                    <ForeName>Michela</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Unit, University of Sassari, Sassari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verucchi</LastName>
                    <ForeName>Gabriella</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infection Disease Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Magni</LastName>
                    <ForeName>Carlo F</ForeName>
                    <Initials>CF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Disease, Hospital Sacco of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teti</LastName>
                    <ForeName>Elisabetta</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertoli</LastName>
                    <ForeName>Ada</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Antonucci</LastName>
                    <ForeName>FrancescoPaolo</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bellocchi</LastName>
                    <ForeName>Maria C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Micheli</LastName>
                    <ForeName>Valeria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Microbiology, Hospital Sacco of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masetti</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Landonio</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Disease, Hospital Sacco of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Francioso</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santopaolo</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pellicelli</LastName>
                    <ForeName>Adriano M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Disease Unit, Department of Liver Transplantation, San Camillo Forlanini Hospital, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calvaruso</LastName>
                    <ForeName>Vincenza</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, &quot;P. Giaccone&quot; University Hospital, Palermo, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gianserra</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Sant'Andrea Hospital - Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siciliano</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, Catholic University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Romagnoli</LastName>
                    <ForeName>Dante</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cozzolongo</LastName>
                    <ForeName>Raffaele</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Scientific Institute for Digestive Disease &quot;Saverio de Bellis&quot; Hospital, Castellana Grotte, Bari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grieco</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, Catholic University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vecchiet</LastName>
                    <ForeName>Jacopo</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Disease Clinic, Hospital of Chieti, Chieti, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morisco</LastName>
                    <ForeName>Filomena</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, Department of Clinical Medicine and Surgery, University of Naples &quot;Federico II&quot;, Naples, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merli</LastName>
                    <ForeName>Manuela</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brancaccio</LastName>
                    <ForeName>Giuseppina</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases and Viral Hepatitis Unit, Second University, Naples, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di Biagio</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Unit, Department of Social Health (DISSAL) of the University of Genoa, IRCCS S. Martino-IST, Genoa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loggi</LastName>
                    <ForeName>Elisabetta</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mastroianni</LastName>
                    <ForeName>Claudio M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Public Health and Infectious Diseases, Sapienza University, Polo Pontino, Latina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pace Palitti</LastName>
                    <ForeName>Valeria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, Pescara General Hospital, Pescara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tarquini</LastName>
                    <ForeName>Pierluigi</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Disease, Hospital &quot;G. Mazzini&quot;, Teramo, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puoti</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Hospital Niguarda Ca'Granda, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taliani</LastName>
                    <ForeName>Gloria</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious and Tropical Diseases Unit, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sarmati</LastName>
                    <ForeName>Loredana</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Picciotto</LastName>
                    <ForeName>Antonino</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Gastroenterology Unit, University of Genova, Genoa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vullo</LastName>
                    <ForeName>Vincenzo</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caporaso</LastName>
                    <ForeName>Nicola</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, Department of Clinical Medicine and Surgery, University of Naples &quot;Federico II&quot;, Naples, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paoloni</LastName>
                    <ForeName>Maurizio</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Disease Unit, Avezzano General Hospital, Avezzano, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pasquazzi</LastName>
                    <ForeName>Caterina</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Sant'Andrea Hospital - Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rizzardini</LastName>
                    <ForeName>Giuliano</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Disease, Hospital Sacco of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Clinical Medicine, Faculty of Health Science University of the Witwatersrand, Johannesburg, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parruti</LastName>
                    <ForeName>Giustino</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Disease Unit, Pescara General Hospital, Pescara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Craxì</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology, &quot;P. Giaccone&quot; University Hospital, Palermo, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Babudieri</LastName>
                    <ForeName>Sergio</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Unit, University of Sassari, Sassari, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andreoni</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Angelico</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perno</LastName>
                    <ForeName>Carlo F</ForeName>
                    <Initials>CF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ceccherini-Silberstein</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>HCV Italian Resistance Network Study Group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Liver Int</MedlineTA>
            <NlmUniqueID>101160857</NlmUniqueID>
            <ISSNLinking>1478-3223</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9008-11-1</RegistryNumber>
                <NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Liver Int. 2017 Apr;37(4):506-508</RefSource>
                <PMID Version="1">28371101</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">antiviral therapy</Keyword>
            <Keyword MajorTopicYN="Y">direct-acting antivirals</Keyword>
            <Keyword MajorTopicYN="Y">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="Y">resistance test</Keyword>
            <Keyword MajorTopicYN="Y">resistance-associated substitutions</Keyword>
        </KeywordList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Mariani</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Iapadre</LastName>
                <ForeName>N</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grimaldi</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cozzolongo</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Andreone</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Verucchi</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Menzaghi</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Quirino</LastName>
                <ForeName>T</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pisani</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Torti</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vecchiet</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bruzzone</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Maria</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marenco</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nicolini</LastName>
                <ForeName>L A</ForeName>
                <Initials>LA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Viscoli</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Casinelli</LastName>
                <ForeName>K</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Delle Monache</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lichtner</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aghemo</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boccaccio</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bruno</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cerrone</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Colombo</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>D'Arminio Monforte</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Danieli</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donato</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gubertini</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lleo</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Magni</LastName>
                <ForeName>C F</ForeName>
                <Initials>CF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mancon</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Monico</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Niero</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Russo</LastName>
                <ForeName>M L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gnocchi</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Orro</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Milanesi</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baldelli</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bertolotti</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Borghi</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mussini</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brancaccio</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gaeta</LastName>
                <ForeName>G B</ForeName>
                <Initials>GB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lembo</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sangiovanni</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Di Marco</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mazzola</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Petta</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>D'Amico</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cacciatore</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Consorte</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pieri</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Polilli</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sozio</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Antenucci</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aragri</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baiocchi</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barbaliscia</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Biliotti</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Biolato</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carioti</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ceccherini-Silberstein</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cerasari</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cerva</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ciotti</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>D'Ambrosio</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>D'Ettorre</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Leonardis</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Sanctis</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Di Maio</LastName>
                <ForeName>V C</ForeName>
                <Initials>VC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Di Paolo</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Furlan</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gallo</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gasbarrini</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Giannelli</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grieco</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lambiase</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lattanzi</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lenci</LastName>
                <ForeName>I</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lula</LastName>
                <ForeName>R</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Malagnino</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manuelli</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miglioresi</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Milana</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moretti</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nosotti</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Palazzo</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pellicelli</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Romano</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sarrecchia</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sforza</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sorbo</LastName>
                <ForeName>M C</ForeName>
                <Initials>MC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spaziante</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Svicher</LastName>
                <ForeName>V</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tisone</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vespasiani-Gentilucci</LastName>
                <ForeName>U</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>D'Adamo</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mangia</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maida</LastName>
                <ForeName>I</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mura</LastName>
                <ForeName>M S</ForeName>
                <Initials>MS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Falconi</LastName>
                <ForeName>L</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Di Giammartino</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28105744</ArticleId>
            <ArticleId IdType="doi">10.1111/liv.13327</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28078469</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1435-5922</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gastroenterology</Title>
                <ISOAbbreviation>J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>855-867</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00535-016-1303-0</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Daclatasvir (DCV) and asunaprevir (ASV) combination therapy has been primarily used in patients without NS5A L31 or Y93 resistance-associated substitutions (RASs) before treatment. We examined the characteristics of patients without these baseline RASs who did not achieve hepatitis C virus eradication with DCV and ASV combination therapy and identified new baseline NS5A RASs that are closely associated with failure of combination therapy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Three hundred thirty-five patients with hepatitis C virus genotype 1 infection with no NS5A L31, NS5A Y93, and NS3 D168 RASs before DCV and ASV combination therapy and no history of protease inhibitor therapy were enrolled. All RASs were evaluated by direct sequencing.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sustained virologic response at 12 weeks (SVR12) was achieved in 297 patients (89%). Patients with NS5A Q24, L28, and/or R30 RASs or concomitant NS5A F37 and Q54 RASs had a significantly lower SVR12 rate than patients without these RASs (70% vs 92%, p &lt; 0.001 and 79% vs 92%, p = 0.002 respectively). Multivariate analysis showed that NS5A Q24, L28, and/or R30 RASs and concomitant NS5A F37 and Q54 RASs were significantly associated with virologic failure. The SVR12 rate in patients without NS5A Q24, L28, and/or R30 RASs and concomitant NS5A F37 and Q54 RASs was 96.2% (202/210).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients without NS5A L31 or Y93 RASs, the presence of NS5A Q24, L28, and/or R30 RASs and concomitant NS5A F37 and Q54 RASs at the baseline was associated with failure of DCV and ASV combination therapy. The coexistence of baseline RASs other than NS5A L31 and Y93 may affect the therapeutic effectiveness of DCV and ASV combination therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mawatari</LastName>
                    <ForeName>Seiichi</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3847-1065</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan. mawatari@m2.kufm.kagoshima-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oda</LastName>
                    <ForeName>Kohei</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tabu</LastName>
                    <ForeName>Kazuaki</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ijuin</LastName>
                    <ForeName>Sho</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumagai</LastName>
                    <ForeName>Kotaro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inada</LastName>
                    <ForeName>Yukiko</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Digestive and Liver Diseases, Miyazaki Medical Center Hospital, 2-16 Takamatsu-cho, Miyazaki, 880-0003, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uto</LastName>
                    <ForeName>Hirofumi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Digestive and Liver Diseases, Miyazaki Medical Center Hospital, 2-16 Takamatsu-cho, Miyazaki, 880-0003, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hiramine</LastName>
                    <ForeName>Yasunari</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Kagoshima Kouseiren Hospital, 22-25 Tenpozan-cho, Kagoshima, 890-0061, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kure</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Kagoshima Kouseiren Hospital, 22-25 Tenpozan-cho, Kagoshima, 890-0061, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujisaki</LastName>
                    <ForeName>Kunio</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Kirishima Medical Center, 3320 Hayato-cho, Kirishima, Kagoshima, 899-5112, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hashiguchi</LastName>
                    <ForeName>Masafumi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Kirishima Medical Center, 3320 Hayato-cho, Kirishima, Kagoshima, 899-5112, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hori</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Kagoshima City Hospital, 37-1 Uearata-cho, Kagoshima, 890-8760, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oshige</LastName>
                    <ForeName>Akihiko</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Kagoshima City Hospital, 37-1 Uearata-cho, Kagoshima, 890-8760, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imanaka</LastName>
                    <ForeName>Dai</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenteroloby, Ikeda Hospital, 1830 Shimoharaigawa-cho, Kanoya, Kagoshima, 893-0024, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saishoji</LastName>
                    <ForeName>Akiko</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Kagoshima Teishin Hospital, 1-12-1 Shimoishiki, Kagoshima, 890-8798, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taniyama</LastName>
                    <ForeName>Oki</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakae</LastName>
                    <ForeName>Haruka</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamai</LastName>
                    <ForeName>Tsutomu</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moriuchi</LastName>
                    <ForeName>Akihiro</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ido</LastName>
                    <ForeName>Akio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Gastroenterol</MedlineTA>
            <NlmUniqueID>9430794</NlmUniqueID>
            <ISSNLinking>0944-1174</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S9X0KRJ00S</RegistryNumber>
                <NameOfSubstance UI="C571889">asunaprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Asunaprevir</Keyword>
            <Keyword MajorTopicYN="N">Daclatasvir</Keyword>
            <Keyword MajorTopicYN="N">Hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="N">NS5A resistance-associated substitutions</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28078469</ArticleId>
            <ArticleId IdType="doi">10.1007/s00535-016-1303-0</ArticleId>
            <ArticleId IdType="pii">10.1007/s00535-016-1303-0</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Gastroenterol. 2014 May;49(5):941-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24626851</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatol Res. 2014 Dec;44(14):E360-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24612030</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1996 Jan 11;334(2):77-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8531962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol. 2017 Jan;52(1):94-103</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27236547</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol. 2013 Jan;48(1):1-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23188091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2009 Oct;41(10):1100-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19749758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2015 Jun;15(6):645-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25863559</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Nov;56(5):1611-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22577043</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2008 Jul;48(1):38-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18537193</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Nov 1;384(9954):1597-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25078304</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Ther. 2016 Jul;33(7):1169-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27287851</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Sep;62(3):715-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26033798</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2003 Jun;37(6):1335-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12774012</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Aug;61(2):219-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24727123</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2009 Oct;41(10):1105-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19749757</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2012 Aug;54(4):352-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22658798</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol. 2015 Feb;50(2):238-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25115901</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2011 Mar;54(3):439-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21129805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Gastroenterol Hepatol. 2011 Jul;9(7):602-8.e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21397726</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jun;61(6):1798-808</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25627448</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2012 Feb;19(2):e134-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22239511</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2016 May;63(5):1493-505</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26754432</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Intervirology. 2010;53(1):39-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2083-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24604476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Virol. 2016 Mar;88(3):506-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26292191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Virol. 2006 Jan;78(1):83-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16299715</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2016 Sep;151(3):501-512.e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27296509</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2010 Oct;30(9):1259-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20633102</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015 Jun 17;10(6):e0130022</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26083687</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2014 Nov 14;9(11):e112647</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25397971</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatol Res. 2015 May;45(5):501-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24961662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2001 Nov;39(11):3858-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11682498</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2010 Feb;138(2):447-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20006612</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2012 Jan;56(1):78-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21827730</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Gastroenterol Hepatol. 2011 Jan;9(1):e1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20621199</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatol Res. 2015 Oct;45(10):E115-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25564756</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2007 Nov;81(21):11658-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17699568</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatol Res. 2016 Nov;46(12 ):1234-1246</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26878268</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27923693</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>03</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-0641</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>66</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>04</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hepatology</Title>
                <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>703-710</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0168-8278(16)30699-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2016.11.022</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Ledipasvir/sofosbuvir combination treatment in phase III clinical trials resulted in sustained viral suppression in 94-99% of patients. This study characterized drug resistance in treatment failures, which may help to inform retreatment options.</AbstractText>
                <AbstractText Label="METHODS">We performed NS5A and NS5B deep sequencing of hepatitis C virus (HCV) from patients infected with genotype (GT) 1 who participated in ledipasvir/sofosbuvir phase II and III clinical trials.</AbstractText>
                <AbstractText Label="RESULTS">Fifty-one of 2144 (2.4%) (42 GT1a and 9 GT1b) treated patients met the criteria for resistance analysis due to virologic failure following the end of treatment. The majority of patients with virologic failure (38 of 51; 74.5%) had detectable ledipasvir-specific resistance-associated substitutions (RASs) at the time of virologic failure (1% deep sequencing cut-off). The percent of patients with NS5A RASs at virologic failure were 37.5%, 66.7%, 94.7% and 100% in patients treated for 6, 8, 12 and 24weeks, respectively. The common substitutions detected at failure were Q30R/H, and/or Y93H/N in GT1a and Y93H in GT1b. At failure, 35.3% (18/51) of virologic failure patients' viruses had two or more NS5A RASs and the majority of patients harbored NS5A RASs conferring a 100-1000-fold (n=10) or &gt;1000-fold (n=23) reduced susceptibility to ledipasvir. One patient in a phase II study with a known ledipasvir RAS at baseline (L31M) developed the S282T sofosbuvir (NS5B) RAS at failure.</AbstractText>
                <AbstractText Label="CONCLUSIONS">In GT1 HCV-infected patients treated with ledipasvir/sofosbuvir±ribavirin, virologic failure was rare. Ledipasvir resistance in NS5A was selected or enhanced in most patients with virologic failure, one of whom also developed resistance to sofosbuvir.</AbstractText>
                <AbstractText Label="LAY SUMMARY">Clinical studies have shown that combination treatment with ledipasvir/sofosbuvir efficiently cures most patients with genotype 1 hepatitis C infection. For the few patients failing treatment, we show that resistance to ledipasvir was observed in most patients, whereas resistance to sofosbuvir was less common. This has important implications for the selection of optimal retreatment strategies for these patients.</AbstractText>
                <CopyrightInformation>Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wyles</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California San Diego, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA. Electronic address: Hadas.dvory-sobol@gilead.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia S</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doehle</LastName>
                    <ForeName>Brian P</ForeName>
                    <Initials>BP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Ross</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Afdhal</LastName>
                    <ForeName>Nezam H</ForeName>
                    <Initials>NH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beth Israel Deaconess Medical Center, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kowdley</LastName>
                    <ForeName>Kris V</ForeName>
                    <Initials>KV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Swedish Medical Center, Seattle, WA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Hepatol</MedlineTA>
            <NlmUniqueID>8503886</NlmUniqueID>
            <ISSNLinking>0168-8278</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000595958">ledipasvir, sofosbuvir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005814" MajorTopicYN="N">Genes, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">DAA</Keyword>
            <Keyword MajorTopicYN="Y">Drug resistance</Keyword>
            <Keyword MajorTopicYN="Y">Hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="Y">Ledipasvir</Keyword>
            <Keyword MajorTopicYN="Y">NS5A</Keyword>
            <Keyword MajorTopicYN="Y">NS5B</Keyword>
            <Keyword MajorTopicYN="Y">Ribavirin</Keyword>
            <Keyword MajorTopicYN="Y">Sofosbuvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27923693</ArticleId>
            <ArticleId IdType="pii">S0168-8278(16)30699-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2016.11.022</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27873094</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1435-5922</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gastroenterology</Title>
                <ISOAbbreviation>J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>520-533</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00535-016-1285-y</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials primarily conducted in the USA and Europe. We investigated the safety and efficacy of EBR in combination with GZR in Japanese patients with chronic HCV infection, with or without cirrhosis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The study was conducted in two parts. In part 1, noncirrhotic patients were randomized 1:1 to receive EBR (50 mg) in combination with GZR (50 or 100 mg) once daily for 12 weeks. In part 2, noncirrhotic patients were randomized 3:1 to receive immediate or deferred treatment with EBR (50 mg) and GZR (100 mg, determined in part 1) for 12 weeks; cirrhotic patients received open-label immediate treatment. The primary efficacy end point was the rate of sustained virologic response 12 weeks after completion of the study treatment.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In part 1, 63 patients were randomized to receive EBR in combination with GZR at a dose of 50 mg (n = 31) or 100 mg (n = 32). The SVR12 rates were 100% with GZR at a dose of 50 mg and 96.8% with GZR at a dose of 100 mg. Tolerability was similar in both arms. In part 2, 301 noncirrhotic patients were randomized to receive immediate treatment (n = 227) or deferred treatment (n = 74), and 35 cirrhotic patients were enrolled. The SVR12 rates were 96.5% and 97.1% after immediate treatment in noncirrhotic and cirrhotic patients respectively. Safety was generally similar between immediate and deferred treatment.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with EBR in combination with GZR for 12 weeks is effective and well tolerated in Japanese patients with chronic HCV infection. CLINICALTRIALS.</AbstractText>
                <AbstractText Label="GOV IDENTIFIER" NlmCategory="UNASSIGNED">NCT02203149.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kumada</LastName>
                    <ForeName>Hiromitsu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Toranomon Hospital, 1-3-1 Kajigaya, Takatsu-ku, Kawasaki, Kanagawa, 213-8587, Japan. kumahiro@toranomon.gr.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Yoshiyuki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Toranomon Hospital, 1-3-1 Kajigaya, Takatsu-ku, Kawasaki, Kanagawa, 213-8587, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karino</LastName>
                    <ForeName>Yoshiyasu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Sapporo Kosei General Hospital, North-3 East-8, Chuou-ku, Sapporo, Hokkaido, 060-0033, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chayama</LastName>
                    <ForeName>Kazuaki</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Metabolism, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawada</LastName>
                    <ForeName>Norifumi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okanoue</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, Suita-Shi, Osaka, 564-0013, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itoh</LastName>
                    <ForeName>Yoshito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mochida</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toyoda</LastName>
                    <ForeName>Hidenori</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, 503-8502, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshiji</LastName>
                    <ForeName>Hitoshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takaki</LastName>
                    <ForeName>Shintaro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology/Liver Center, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, 1-9-6, Senda-machi, Naka-ku, Hiroshima, 730-8619, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yatsuzuka</LastName>
                    <ForeName>Naoyoshi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yodoya</LastName>
                    <ForeName>Etsuo</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iwasa</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujimoto</LastName>
                    <ForeName>Go</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Stuart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caro</LastName>
                    <ForeName>Luzelena</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co.Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02203149</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Gastroenterol</MedlineTA>
            <NlmUniqueID>9430794</NlmUniqueID>
            <ISSNLinking>0944-1174</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Clinical trial</Keyword>
            <Keyword MajorTopicYN="N">Efficacy</Keyword>
            <Keyword MajorTopicYN="N">Genotype</Keyword>
            <Keyword MajorTopicYN="N">Sustained virologic response</Keyword>
            <Keyword MajorTopicYN="N">Therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27873094</ArticleId>
            <ArticleId IdType="doi">10.1007/s00535-016-1285-y</ArticleId>
            <ArticleId IdType="pii">10.1007/s00535-016-1285-y</ArticleId>
            <ArticleId IdType="pmc">PMC5357479</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Infect Dis. 2016 Jan 1;62(1):32-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26371152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet HIV. 2015 Aug;2(8):e319-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26423374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatol Res. 2016 Feb;46(2):129-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26876581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2015 Jun;15(6):645-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25863559</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ChemMedChem. 2013 Dec;8(12):1930-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24127258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol. 2016 Jan;51(1):63-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25904097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1087-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Intervirology. 2010;53(1):39-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2083-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24604476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Sep;63(3):564-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25895428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 Aug;147(2):366-76.e6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24727022</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Microbiol Infect. 2011 Feb;17(2):107-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21091831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22615282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1075-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467591</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology. 2002;62 Suppl 1:8-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11868791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Oct;62(4):1037-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26147154</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Oct 17;386(10003):1537-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26456905</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27537841</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1539-3704</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>165</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Nov</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of internal medicine</Title>
                <ISOAbbreviation>Ann. Intern. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>625-634</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.7326/M16-0816</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID).</AbstractText>
                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To evaluate elbasvir-grazoprevir in treating HCV infection in PWID.</AbstractText>
                <AbstractText Label="Design" NlmCategory="UNASSIGNED">Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688).</AbstractText>
                <AbstractText Label="Setting" NlmCategory="UNASSIGNED">Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan, the United Kingdom, and the United States.</AbstractText>
                <AbstractText Label="Patients" NlmCategory="UNASSIGNED">301 treatment-naive patients with chronic HCV genotype 1, 4, or 6 infection who were at least 80% adherent to visits for opioid agonist therapy (OAT).</AbstractText>
                <AbstractText Label="Intervention" NlmCategory="UNASSIGNED">The immediate-treatment group (ITG) received elbasvir-grazoprevir for 12 weeks; the deferred-treatment group (DTG) received placebo for 12 weeks, no treatment for 4 weeks, then open-label elbasvir-grazoprevir for 12 weeks.</AbstractText>
                <AbstractText Label="Measurements" NlmCategory="UNASSIGNED">The primary outcome was sustained virologic response at 12 weeks (SVR12), evaluated separately in the ITG and DTG. Other outcomes included SVR24, viral recurrence or reinfection, and adverse events.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The SVR12 was 91.5% (95% CI, 86.8% to 95.0%) in the ITG and 89.5% (95% CI, 81.5% to 94.8%) in the active phase of the DTG. Drug use at baseline and during treatment did not affect SVR12 or adherence to HCV therapy. Among 18 patients with posttreatment viral recurrence through 24-week follow-up, 6 had probable reinfection. If the probable reinfections were assumed to be responses, SVR12 was 94.0% (CI, 89.8% to 96.9%) in the ITG. One patient in the ITG (1 of 201) and 1 in the placebo-phase DTG (1 of 100) discontinued treatment because of an adverse event.</AbstractText>
                <AbstractText Label="Limitation" NlmCategory="UNASSIGNED">These findings may not be generalizable to PWID who are not receiving OAT, nor do they apply to persons with genotype 3 infection, a common strain in PWID.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Patients with HCV infection who were receiving OAT and treated with elbasvir-grazoprevir had high rates of SVR12, regardless of ongoing drug use. These results support the removal of drug use as a barrier to interferon-free HCV treatment for patients receiving OAT.</AbstractText>
                <AbstractText Label="Primary Funding Source" NlmCategory="UNASSIGNED">Merck &amp; Co.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dore</LastName>
                    <ForeName>Gregory J</ForeName>
                    <Initials>GJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Altice</LastName>
                    <ForeName>Frederick</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Litwin</LastName>
                    <ForeName>Alain H</ForeName>
                    <Initials>AH</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dalgard</LastName>
                    <ForeName>Olav</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibolet</LastName>
                    <ForeName>Oren</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luetkemeyer</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahass</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Cheng-Yuan</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conway</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grebely</LastName>
                    <ForeName>Jason</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gendrano</LastName>
                    <ForeName>Isaias N</ForeName>
                    <Initials>IN</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Erluo</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Hsueh-Cheng</ForeName>
                    <Initials>HC</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dutko</LastName>
                    <ForeName>Frank J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nickle</LastName>
                    <ForeName>David C</ForeName>
                    <Initials>DC</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Bach-Yen</ForeName>
                    <Initials>BY</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Platt</LastName>
                    <ForeName>Heather L</ForeName>
                    <Initials>HL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From The Kirby Institute, UNSW Australia, Sydney, Australia; Yale School of Medicine, New Haven, Connecticut; Montefiore Medical Center, Bronx, New York; Akershus University Hospital, Lorenskog, Norway; Auckland Clinical Studies, Auckland, New Zealand; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of California, San Francisco, San Francisco, California; ID Care, Hillsborough, New Jersey; China Medical University, Taichung, Taiwan; Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; and Merck &amp; Co., Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>C-EDGE CO-STAR Study Group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02105688</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Intern Med</MedlineTA>
            <NlmUniqueID>0372351</NlmUniqueID>
            <ISSNLinking>0003-4819</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000069479">Buprenorphine, Naloxone Drug Combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000611265">elbasvir-grazoprevir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>40D3SCR4GZ</RegistryNumber>
                <NameOfSubstance UI="D002047">Buprenorphine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UC6VBE7V1Z</RegistryNumber>
                <NameOfSubstance UI="D008691">Methadone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>BMJ. 2016 Aug 08;354:i4346</RefSource>
                <PMID Version="1">27506612</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002047" MajorTopicYN="N">Buprenorphine</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069479" MajorTopicYN="N">Buprenorphine, Naloxone Drug Combination</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008691" MajorTopicYN="N">Methadone</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058850" MajorTopicYN="Y">Opiate Substitution Treatment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009293" MajorTopicYN="N">Opioid-Related Disorders</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015819" MajorTopicYN="N">Substance Abuse, Intravenous</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27537841</ArticleId>
            <ArticleId IdType="pii">2542526</ArticleId>
            <ArticleId IdType="doi">10.7326/M16-0816</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27773808</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>06</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>152</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>02</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>586-597</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(16)35241-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2016.10.017</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A protease inhibitor) are direct-acting antiviral agents recently approved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infections, as a fixed-dose combination. Trials of elbasvir and grazoprevir, with or without ribavirin, demonstrated high rates of sustained virologic response 12 weeks after treatment ended (SVR12). However, 12 weeks of treatment with elbasvir and grazoprevir failed in a small proportion of patients with HCV genotype 1 infection. We summarize findings from independent US Food and Drug Administration analyses of drug resistance data from trials of elbasvir and grazoprevir, with and without ribavirin.</AbstractText>
                <AbstractText Label="METHODS">We independently analyzed HCV drug resistance and HCV RNA measurement results that were submitted to the US Food and Drug Administration to support the regulatory approval of elbasvir and grazoprevir. These data were reported from selected phase 2 and 3 clinical trials of elbasvir and grazoprevir, with and without ribavirin. Genotypic resistance analyses were conducted using Sanger population nucleotide sequencing data derived from blood samples from study patients.</AbstractText>
                <AbstractText Label="RESULTS">In 56 of 506 (11%) patients with HCV genotype 1a infection who received elbasvir and grazoprevir for 12 weeks, baseline HCV genetic variants encoding amino acid polymorphisms in NS5A (M28, Q30, L31, or Y93) reduced treatment efficacy; rates of SVR12 were 70% and 98% for patients with or without NS5A polymorphisms, respectively (P &lt; .0001). Most patients with treatment failure acquired resistance-associated substitutions in NS3 and/or NS5A. Based on data from a small number of patients (n = 6), an intensified 16-week regimen of elbasvir and grazoprevir plus ribavirin could increase efficacy in patients with HCV genotype 1a infection with NS5A polymorphisms. Among patients with HCV genotype 4a or 4d infections with NS5A polymorphisms, all 26 who received the elbasvir and grazoprevir regimens recommended in prescribing information achieved an SVR12.</AbstractText>
                <AbstractText Label="CONCLUSIONS">The combination of elbasvir and grazoprevir, with or without ribavirin is safe and effective for patients with HCV genotype 1 or 4 infections. In patients with HCV genotype 1a infection, polymorphisms in NS5A at baseline (before treatment) can affect the efficacy of this direct-acting antiviral regimen, and pretreatment resistance analyses can optimize treatment selection.</AbstractText>
                <CopyrightInformation>Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Komatsu</LastName>
                    <ForeName>Takashi E</ForeName>
                    <Initials>TE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland. Electronic address: takashi.komatsu@fda.hhs.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boyd</LastName>
                    <ForeName>Sarita</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sherwat</LastName>
                    <ForeName>Adam</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tracy</LastName>
                    <ForeName>LaRee</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naeger</LastName>
                    <ForeName>Lisa K</ForeName>
                    <Initials>LK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Rear</LastName>
                    <ForeName>Julian J</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harrington</LastName>
                    <ForeName>Patrick R</ForeName>
                    <Initials>PR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland. Electronic address: patrick.harrington@fda.hhs.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000611265">elbasvir-grazoprevir drug combination</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">DAA</Keyword>
            <Keyword MajorTopicYN="Y">FDA</Keyword>
            <Keyword MajorTopicYN="Y">Post-Hoc Analysis</Keyword>
            <Keyword MajorTopicYN="Y">Replication</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27773808</ArticleId>
            <ArticleId IdType="pii">S0016-5085(16)35241-6</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.10.017</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27720838</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>152</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>01</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>164-175.e4</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(16)35170-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2016.09.045</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Patients infected with hepatitis C virus (HCV) genotype 1, 4, or 6, with or without cirrhosis, previously treated with peg-interferon and ribavirin, are a challenge to treat. We performed a phase 3 randomized controlled open-label trial to assess the effects of 12 or 16 weeks of treatment with once-daily elbasvir (an HCV NS5A inhibitor, 50 mg) and grazoprevir (an HCV NS3/4A protease inhibitor, 100 mg), in a fixed-dose combination tablet, with or without twice-daily ribavirin, in this patient population.</AbstractText>
                <AbstractText Label="METHODS">We analyzed data from 420 patients (35% with cirrhosis, 64% with a null or partial response to peg-interferon and ribavirin) who were randomly assigned (1:1:1:1) to groups given elbasvir and grazoprevir once daily, with or without twice-daily ribavirin, for 12 or 16 weeks, at 65 study centers in 15 countries in Europe, Asia, and Central and North America. Randomization was stratified by cirrhosis status and type of peg-interferon and ribavirin treatment failure. HCV RNA was measured using COBAS TaqMan v2.0. The primary end point was HCV RNA &lt;15 IU/mL, 12 weeks after completion of treatment (SVR12). We aimed to determine whether the proportion of patients achieving an SVR12 in any group was greater than the reference rate (58%).</AbstractText>
                <AbstractText Label="RESULTS">With 12 weeks of treatment, an SVR12 was achieved by 92.4% of patients given elbasvir and grazoprevir and 94.2% of patients given elbasvir and grazoprevir with ribavirin. With 16 weeks of treatment, an SVR12 was achieved by 92.4% of patients given elbasvir and grazoprevir and 98.1% of patients given elbasvir and grazoprevir with ribavirin. Among patients treated for 12 weeks without ribavirin, virologic failure occurred in 6.8%, 0%, and 12.5% of patients with HCV genotype 1a, 1b, or 4 infection, respectively. Among patients given elbasvir and grazoprevir for 12 weeks, virologic failure occurred in 0% of patients infected with HCV genotypes 1 and 4 who relapsed after completing peg-interferon and ribavirin, and 7.5% infected with HCV genotypes 1 and 4, respectively, with a null or partial response to peg-interferon and ribavirin. Among patients treated for 16 weeks who received ribavirin, there were no incidences of virologic failure. Common adverse events were fatigue (23.1%), headache (19.8%), and nausea (11.0%).</AbstractText>
                <AbstractText Label="CONCLUSIONS">The combination tablet of elbasvir and grazoprevir, with or without ribavirin, was highly efficacious in inducing an SVR12 in patients with HCV genotype 1, 4, or 6 infection failed by previous treatment with peg-interferon and ribavirin, including patients with cirrhosis and/or a prior null response. The treatment was generally well tolerated. ClinicalTrials.gov Number: NCT02105701.</AbstractText>
                <CopyrightInformation>Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kwo</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Indiana University, Indianapolis, Indiana. Electronic address: pkwo@stanford.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Auckland Clinical Studies, Grafton, Auckland, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Cheng-Yuan</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, China Medical University, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pearlman</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Hepatitis C, Atlanta Medical Center, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vierling</LastName>
                    <ForeName>John M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor College of Medicine, Baylor-St. Luke's Medical Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serfaty</LastName>
                    <ForeName>Lawrence</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'Hépatologie, Hôpital Saint-Antoine, APHP, UPMC Paris 6, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buti</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Universitari Vall d'Hebron, and Ciberehd del Instituto Carlos III, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shafran</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Alberta, Edmonton, Alberta, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stryszak</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gress</LastName>
                    <ForeName>Jacqueline</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Stuart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dutko</LastName>
                    <ForeName>Frank J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lupinacci</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haber</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02105701</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">C-EDGE Treatment-Experienced</Keyword>
            <Keyword MajorTopicYN="Y">Hepatitis C</Keyword>
            <Keyword MajorTopicYN="Y">Randomized</Keyword>
            <Keyword MajorTopicYN="Y">Therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>05</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27720838</ArticleId>
            <ArticleId IdType="pii">S0016-5085(16)35170-8</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.09.045</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27605597</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2091</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>71</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>12</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of antimicrobial chemotherapy</Title>
                <ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3495-3505</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE">Daclatasvir (DCV) is a pan-genotypic non-structural protein 5A (NS5A) inhibitor that is approved for treatment of hepatitis C virus (HCV) genotype (GT)1 and GT3 in the USA and GT1, GT3 and GT4 in Europe. We set out to examine the impact of daclatasvir-based regimens on the sustained virologic response (SVR) in patients with GT2 infection with respect to GT2 subtype and NS5A polymorphisms at amino acid positions associated with daclatasvir resistance.</AbstractText>
                <AbstractText Label="METHODS">Analyses were performed on 283 GT2 NS5A sequences from five daclatasvir regimen-based clinical trials (ClinicalTrials.gov: NCT-01257204, NCT-01359644, NCT-02032875, NCT-02032888 and NCT-01616524) and 143 NS5A sequences from the Los Alamos HCV database. Susceptibility analyses of substitutions at amino acid positions associated with daclatasvir resistance and patient-derived NS5A sequences were performed using an in vitro HCV replication assay.</AbstractText>
                <AbstractText Label="RESULTS">Of 13 GT2 subtypes identified from 426 NS5A sequences, the most prevalent were GT2a (32%), GT2b (48%) and GT2c (10%). The most prevalent NS5A polymorphism was L31M (GT2a = 88%; GT2b = 59%; GT2c = 10%). Substitutions identified in 96% of GT2 NS5A sequences exhibited daclatasvir EC<sub>50</sub> values ranging from 0.005 to 20 nM when tested in vitro. A similar range in daclatasvir EC<sub>50</sub> values was observed for 16 diverse GT2 patient-derived NS5A sequences (EC<sub>50</sub> = 0.005-60 nM). Depending on the daclatasvir-based regimen studied (daclatasvir/interferon-based or daclatasvir/sofosbuvir-based), SVR rates ranged from 90% to 100% in GT2 patients with the most prevalent baseline NS5A-L31M polymorphism, compared with from 96% to 100% without this polymorphism.</AbstractText>
                <AbstractText Label="CONCLUSIONS">High SVR rates were achieved in patients infected with GT2 treated with daclatasvir-based regimens irrespective of GT2 subtype or baseline NS5A polymorphisms.</AbstractText>
                <CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Nannan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Zhou</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hartman-Neumann</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeGray</LastName>
                    <ForeName>Brenda</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueland</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vellucci</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernandez</LastName>
                    <ForeName>Dennis</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb R&amp;D, Wallingford, CT 06492, USA fiona.mcphee@bms.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Antimicrob Chemother</MedlineTA>
            <NlmUniqueID>7513617</NlmUniqueID>
            <ISSNLinking>0305-7453</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27605597</ArticleId>
            <ArticleId IdType="pii">dkw336</ArticleId>
            <ArticleId IdType="doi">10.1093/jac/dkw336</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27597318</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>07</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1440-1746</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>32</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gastroenterology and hepatology</Title>
                <ISOAbbreviation>J. Gastroenterol. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>45-52</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jgh.13587</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Daclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activity in patients with hepatitis C virus (HCV) genotype 1b infection. A definite conclusion about efficacy and safety of DCV + ASV in patients with HCV genotype 1b is not available. A meta-analysis was conducted to evaluate outcomes of all-oral treatment with DCV + ASV in terms of sustained virological response at 12 (SVR<sub>12</sub> ) and 24 (SVR<sub>24</sub> ) weeks and adverse effects after the end of treatment.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">PUBMED, MEDLINE, and EMBASE databases were searched in May 2016. The data were analyzed with Review Manager 5.3.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine trials (n = 1690) met entry criteria. SVR<sub>12</sub> was achieved by 89.9% of treatment-naïve patients, 84.7% of interferon-ineligible/intolerant patients, and 81.9% of nonresponder patients. Moreover, 89.0% of interferon-ineligible/intolerant patients and 83.1% of nonresponder patients achieved SVR<sub>24</sub> . Baseline characteristics, including gender, race, advanced age, non-CC IL28B genotype, and cirrhosis, did not appear to impact SVR rates. However, the rate of SVR<sub>12</sub> in all patients with viral load &lt; 8 × 10<sup>5</sup> was higher than that of all those with viral load ≥ 8 × 10<sup>5</sup> (151/162 vs 625/753). Moreover, pre-existing nonstructural protein 5A resistance-associated variants (RAVs) were associated with virological failure during DCV + ASV therapy, resulting in the emergence of multiple RAVs. Treatment with DCV + ASV was well tolerated, with low incidences of serious adverse effects, discontinuations, and grade 3 or 4 laboratory abnormalities in all patients.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Daclatasvir plus asunaprevir provides a highly effective and well-tolerated treatment option for patients with HCV genotype 1b. However, patients with nonstructural protein 5A RAVs at baseline should be assessed to optimize more potent direct antiviral agent therapies.</AbstractText>
                <CopyrightInformation>© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Hui-Lian</ForeName>
                    <Initials>HL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics and Molecular Biology, Xi'an Jiaotong University School of Medicine, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Xi</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Mechanical Engineering, Xi'an Jiaotong University, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xudong</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics and Molecular Biology, Xi'an Jiaotong University School of Medicine, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Nan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>2nd Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
                <PublicationType UI="D000078182">Systematic Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>J Gastroenterol Hepatol</MedlineTA>
            <NlmUniqueID>8607909</NlmUniqueID>
            <ISSNLinking>0815-9319</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S9X0KRJ00S</RegistryNumber>
                <NameOfSubstance UI="C571889">asunaprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016206" MajorTopicYN="N">Databases, Bibliographic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">asunaprevir</Keyword>
            <Keyword MajorTopicYN="N">daclatasvir</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C virus genotype 1</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C virus genotype 1b</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27597318</ArticleId>
            <ArticleId IdType="doi">10.1111/jgh.13587</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27453546</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>05</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-0012</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>151</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>11</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroenterology</Title>
                <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>973-985.e2</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(16)34809-0</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2016.07.013</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Direct-acting antivirals (DAAs) effectively eradicate chronic hepatitis C virus (HCV) infection, although HCV genotype 3a is less responsive to these drugs. We aimed to develop genotype 3a infectious cultures and study the effects of inhibitors of NS5A and NS5B and resistance to sofosbuvir-the only nucleotide analog approved for treatment of chronic HCV infection.</AbstractText>
                <AbstractText Label="METHODS">The developed HCV genotype 3a full-length genome (DBN3a), with a strain-DBN coding sequence, modified NS5B consensus sequence, pS52 untranslated regions, and coding mutations from a culture-efficient JFH1-based core-NS5A (DBN) recombinant, was transfected into Huh7.5 cells. The efficacy of selected DAAs was determined in dose-response assays, in which the number of HCV-infected cells was measured after incubation with different concentrations of the specific DAA. Long-term culture of infected Huh7.5 cells with increasing concentrations of sofosbuvir was used to promote selection of HCV-resistant variants.</AbstractText>
                <AbstractText Label="RESULTS">We engineered a DBN3a variant with 17 substitutions (DBN3a<sub>cc</sub>) that had replication and propagation kinetics in Huh7.5 cells comparable with prototype J6/JFH1. The adaptive mutations also produced culture-efficient DBN-based recombinants with NS5B from HCV genotype 3a strains S52 and DH11. Compared with genotype 1a, genotype 3a was less sensitive to daclatasvir, ledipasvir, and elbasvir, but equally sensitive to ombitasvir, velpatasvir, beclabuvir, dasabuvir, MK-3682, and sofosbuvir. Exposure of Huh7.5 cells infected with DBN3a to sofosbuvir led to identification of an escape variant with substitutions in NS5B, including the resistance-associated substitution S282T. This variant showed increased infectivity of Huh7.5 cells, compared with DBN3a, and was genetically stable in cell cultures without sofosbuvir. Sofosbuvir, MK-3682, dasabuvir, or combinations of sofosbuvir and ledipasvir or sofosbuvir and velpatasvir had decreased efficacy against infection with the DBN3a sofosbuvir escape variant.</AbstractText>
                <AbstractText Label="CONCLUSIONS">We developed a system for highly efficient culture of HCV genotype 3a. Genotype 1a has a high genetic barrier to resistance for sofosbuvir, whereas resistance to this DAA can be induced in genotype 3a. We therefore isolated HCV genotype 3a variants with reduced sensitivity to sofosbuvir, with increased fitness and with cross-resistance to other NS5B inhibitors. These findings indicate that sofosbuvir escape variants could compromise the effectiveness of nucleotide analogs against HCV. GenBank accession numbers: KX280712-KX280716.</AbstractText>
                <CopyrightInformation>Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ramirez</LastName>
                    <ForeName>Santseharay</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mikkelsen</LastName>
                    <ForeName>Lotte S</ForeName>
                    <Initials>LS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gottwein</LastName>
                    <ForeName>Judith M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bukh</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: jbukh@sund.ku.dk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gastroenterology</MedlineTA>
            <NlmUniqueID>0374630</NlmUniqueID>
            <ISSNLinking>0016-5085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Drug Evasion</Keyword>
            <Keyword MajorTopicYN="Y">In Vitro</Keyword>
            <Keyword MajorTopicYN="Y">Liver Disease</Keyword>
            <Keyword MajorTopicYN="Y">NUC</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27453546</ArticleId>
            <ArticleId IdType="pii">S0016-5085(16)34809-0</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.07.013</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27353271</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>60</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>09</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5368-78</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00763-16</ELocationID>
            <Abstract>
                <AbstractText>Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. In a phase 1b 3-day monotherapy study, patients treated with a 150-mg dose of GS-5816 had a mean maximal HCV RNA decline of ≥3.3 log10 IU/ml in GT1a, -1b, -2, -3, and -4. This report characterizes virologic resistance to VEL in these patients. NS5A resistance-associated substitutions (RASs) were detected by deep sequencing (1% cutoff) pretreatment in 22/70 patients, i.e., 10/35 (29%) patients with GT1a, 1/8 (13%) with GT1b, 4/8 (50.0%) with GT2, 5/17 (29.4%) with GT3, and 2/2 (100.0%) with GT4. In GT1a and GT3 patients, pretreatment RASs were associated with a slightly reduced HCV RNA response compared to that of patients without pretreatment RASs; among patients with GT1b, GT2, and GT4, no significant difference in response was observed in those with or without pretreatment RASs. Following treatment, the pattern of emergent RASs was more complex for GT1a than for the other genotypes. In GT1a, substitutions emerged at positions M28, Q30, L31, P32, H58, E92, and Y93, with the most prevalent substitutions at positions Y93, M28, and L31. RASs were observed at two positions in GT1b and GT2 (Y93 and L31), three positions in GT3 (Y93, L31, and E92), and four positions in GT4 (L28, M31, P32L, and Y93). RASs that were present pretreatment persisted through the 48-week follow-up period; however, RASs emerging during treatment were more likely to decline both in prevalence and in frequency within the viral population during follow-up. (This study has been registered at ClinicalTrials.gov under registration no. NCT01740791.).</AbstractText>
                <CopyrightInformation>Copyright © 2016, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA Hadas.Dvory-Sobol@Gilead.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doehle</LastName>
                    <ForeName>Brian P</ForeName>
                    <Initials>BP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Worth</LastName>
                    <ForeName>Angela S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McNally</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Link</LastName>
                    <ForeName>John O</ForeName>
                    <Initials>JO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01740791</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>KCU0C7RS7Z</RegistryNumber>
                <NameOfSubstance UI="C000604171">velpatasvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27353271</ArticleId>
            <ArticleId IdType="pii">AAC.00763-16</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.00763-16</ArticleId>
            <ArticleId IdType="pmc">PMC4997818</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2011 May;55(5):2197-205</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21357305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jan;59(1):318-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24115039</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2014 Nov;58(11):6599-606</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25155588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2014;19(5):479-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24448487</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Dec 31;373(27):2599-607</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26571066</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2013 Nov;100(2):439-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24013001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Dec;57(12):6333-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23877691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1867-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5289-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22869562</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Nov;62(5):1623-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Virol. 2006 Apr;78(4):452-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16482560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mol Diagn. 2010 Jul;12 (4):425-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20431034</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2011 Jul;31 Suppl 2:61-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21651703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Dec 31;373(27):2618-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26569658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4431-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24867983</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 24;370(17):1594-603</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24720703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2012 Jul;57(1):24-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22314425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1560-1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24738674</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2013 Jan;144(1):59-61.e6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000598</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2008 Feb;82(3):1073-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18032500</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):979-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25451055</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Dec 31;373(27):2608-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26575258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Aug;54(8):3099-106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20516274</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2012 Jun;56(6):1247-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22326470</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2015 Nov;22(11):871-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25784085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2015 Dec;22(12 ):1011-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26183611</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1879-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24720702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Microbiol Infect. 2011 Feb;17(2):107-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21091831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2016 Mar 25;60(4):2402-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26856832</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2016 Feb;64(2):486-504</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26409317</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2011 Sep;55(9):4196-203</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21746939</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27351341</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>07</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1049-56</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.28706</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon-alpha (Peg-IFN-α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4. In this phase 2, open-label study, 44 patients (22 treatment naïve and 22 treatment experienced) received a fixed-dose combination tablet of 90 mg of ledipasvir and 400 mg of sofosbuvir orally once-daily for 12 weeks. The primary endpoint was the percentage of patients with HCV RNA &lt;15 IU/mL 12 weeks after stopping therapy (SVR12). Among study participants, HCV genotype 4 subtypes were well represented (4a, n = 25; 4d, n = 10; other subtypes, n = 9). Ten patients (23%) had compensated cirrhosis. Of the 22 treatment-experienced patients, 21 (95%) had a non-CC IL-28B genotype. All 44 patients completed the full 12 weeks of dosing. The SVR12 rate was 93% (41 of 44; 95% confidence interval, 81-99). SVR12 rates were similar between treatment-naïve (95%; 21 of 22) and treatment-experienced (91%; 20 of 22) patients. All 3 patients who did not achieve SVR12 had virological relapse within 4 weeks of the end of treatment; all 3 had baseline HCV RNA ≥800,000 IU/mL, a non-CC IL-28B genotype, and pretreatment NS5A resistance-associated variants. None of the patients who relapsed had cirrhosis. The most common adverse events were asthenia, headache, and fatigue. No patients experienced a serious adverse event.</AbstractText>
                <AbstractText Label="CONCLUSION">The all-oral regimen of ledipasvir and sofosbuvir is an effective and safe treatment for a wide range of HCV 4 subtypes in both treatment-naïve and -experienced patients, including those with compensated cirrhosis. (EudraCT number: 2013-003978-27; Clinicaltrials.gov NCT02081079) (Hepatology 2016;64:1049-1056).</AbstractText>
                <CopyrightInformation>© 2016 by the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Abergel</LastName>
                    <ForeName>Armand</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and Gastroenterology, Centre Hospitalier Universitaire Estaing, Université d'Auvergne, UMR CNRS 6284, Clermont-Ferrand, France. aabergel@chu-clermontferrand.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Metivier</LastName>
                    <ForeName>Sophie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and Gastroenterology, Centre Hospitalier Universitaire Purpan, Toulouse, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samuel</LastName>
                    <ForeName>Didier</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre Hépato-Biliaire, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris, UMR-S 1193, Université Paris-Sud, INSERM U785, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Deyuan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kersey</LastName>
                    <ForeName>Kathryn</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pang</LastName>
                    <ForeName>Phillip S</ForeName>
                    <Initials>PS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knox</LastName>
                    <ForeName>Steven J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc, Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loustaud-Ratti</LastName>
                    <ForeName>Veronique</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and Gastroenterology, Centre Hospitalier Universitaire Limoges, U850 INSERM, Université de Limoges, Limoges, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asselah</LastName>
                    <ForeName>Tarik</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Université Paris-Diderot and INSERM UMR1149, Clichy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02081079</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
                <DataBank>
                    <DataBankName>EudraCT</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>2013-003978-27</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>013TE6E4WV</RegistryNumber>
                <NameOfSubstance UI="C586541">ledipasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27351341</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.28706</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27236547</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1435-5922</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gastroenterology</Title>
                <ISOAbbreviation>J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>94-103</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00535-016-1225-x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present study explored the treatment outcome of daclatasvir (DCV) and asunaprevir (ASV) therapy combining oral direct-acting antiviral agents (DAAs) for chronic hepatitis C (HCV) including liver cirrhosis according to resistance-associated variants (RAVs) in NS3/NS5A region.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Overall, 641 patients enrolled in Japan with HCV-1b received DCV and ASV for 24 weeks. Baseline drug-resistant mutations L31F/I/M/V, Q54H, P58S, A92K, and Y93H in the HCV NS5A region and V36A, T54A/S, Q80K/L/R, R155K/T/Q, A156S/V/T, and D168A/E/H/T/V in the HCV NS3/4A region were assessed by direct sequencing.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 86.9 % (543/625) of patients had SVR12, which was significantly higher in NS5A 93Y (wild) (88.3 %) compared with NS5A 93H at baseline (48.0 %), indicating the SVR12 rate was significantly lower in patients with 93H mutations. Additionally, 66.7 % (18/27) of patients with prior triple therapy including simeprevir (SMV) failure had virological failure. The virological failure rate of DCV/ASV therapy after SMV failure was significantly higher in those with preexisting NS3/4A 168 substitutions compared with without substitutions at baseline [84.2 % (16/19) vs. 28.6 % (2/7), p = 0.014]. The number of patients with multiple RAVs or deletions in NS5A increased from 0 to 85 % in failed patients. Alanine aminotransferase elevation was a frequent adverse event causing discontinuation of DCV/ASV therapy, although 87.5 % (14/16) patients achieved SVR12, subsequently.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">History of SMV therapy and pre-existing NS5A Y93H were associated with virological failure of DCV/ASV therapy, resulting in the emergence of multiple RAVs. Patients with RAVs at baseline should be assessed to optimize future DAA therapies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Iio</LastName>
                    <ForeName>Etsuko</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Aichi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimada</LastName>
                    <ForeName>Noritomo</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ootakanomori Hospital, Kashiwa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abe</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jikei University School of Medicine Katsushika Medical Center, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Atsukawa</LastName>
                    <ForeName>Masanori</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshizawa</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Machida Municipal Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takaguchi</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kagawa Prefectural Central Hospital, Takamatsu, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eguchi</LastName>
                    <ForeName>Yuichiro</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Saga University Hospital, Saga, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nomura</LastName>
                    <ForeName>Hideyuki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shin-Kokura Hospital, Kitakyushu, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuramitsu</LastName>
                    <ForeName>Tomoyuki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kuramitsu Clinic, Akita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Jong-Hon</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Teine Keijinkai Hospital, Sapporo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsui</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Teine Keijinkai Hospital, Sapporo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirashima</LastName>
                    <ForeName>Noboru</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Hospital Organization Nagoya Medical Center, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsubota</LastName>
                    <ForeName>Akihito</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jikei University School of Medicine, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kusakabe</LastName>
                    <ForeName>Atsunori</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya Red Cross Hospital, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasegawa</LastName>
                    <ForeName>Izumi</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Japan Community Health Care Organization, Chukyo Hospital, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miyaki</LastName>
                    <ForeName>Tomokatsu</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Toyokawa City Hospital, Toyokawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shinkai</LastName>
                    <ForeName>Noboru</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Aichi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujiwara</LastName>
                    <ForeName>Kei</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Aichi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nojiri</LastName>
                    <ForeName>Shunsuke</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Aichi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Yasuhito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Aichi, Japan. ytanaka@med.nagoya-cu.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>05</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Gastroenterol</MedlineTA>
            <NlmUniqueID>9430794</NlmUniqueID>
            <ISSNLinking>0944-1174</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9WS5RD66HZ</RegistryNumber>
                <NameOfSubstance UI="D000069616">Simeprevir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S9X0KRJ00S</RegistryNumber>
                <NameOfSubstance UI="C571889">asunaprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007564" MajorTopicYN="N">Japan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069616" MajorTopicYN="N">Simeprevir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DCV/ASV</Keyword>
            <Keyword MajorTopicYN="N">Direct acting antivirals</Keyword>
            <Keyword MajorTopicYN="N">HCV</Keyword>
            <Keyword MajorTopicYN="N">Resistance-associated variants</Keyword>
            <Keyword MajorTopicYN="N">Simeprevir failure</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>05</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>5</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>5</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27236547</ArticleId>
            <ArticleId IdType="doi">10.1007/s00535-016-1225-x</ArticleId>
            <ArticleId IdType="pii">10.1007/s00535-016-1225-x</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Adv Ther. 2015 Jul;32(7):637-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26155891</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 May;57(5):2054-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23403428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2015 Dec;22(12 ):992-1001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26075320</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Apr;58(4):646-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23178977</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Aug 2;384(9941):403-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24907225</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2014;19(5):479-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24448487</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 1999 Nov;117(5):1164-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10535880</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Nov;56(5):1611-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22577043</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 1999 Apr;29(4):1124-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10094956</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol Hepatol. 2016 Jan;31(1):14-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26252875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015 Sep 14;10(9):e0138060</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26368554</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):400-1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25308083</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2010 Aug;52(2):518-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20683951</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Transl Hepatol. 2014 Mar;2(1):1-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26356295</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Jul;56(7):3670-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22508297</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 May;54(5):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20176898</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2012 Nov;143(5):1176-8.e1-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22885330</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Dec 07;60(2):1106-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26643326</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2016;21(4):307-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26562322</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2009 Jan;29 Suppl 1:74-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19207969</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2083-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24604476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Virol. 2016 Mar;88(3):506-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26292191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gastroenterol. 2015 Nov;50(11):1145-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26208695</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2011 Jun 23;364(25):2405-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21696307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Sep;58(3):902-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23504694</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1879-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24720702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Aug;59(2):375-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23567084</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27025835</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>10</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6591</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>62</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>06</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
                <ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1489-96</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciw163</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Highly effective hepatitis C virus (HCV) direct-acting antiviral therapies that do not require modification of human immunodeficiency virus (HIV) antiretroviral regimens are needed. We evaluated the efficacy and safety of daclatasvir + sofosbuvir (DCV + SOF) for 12 weeks by antiretroviral (ARV) regimen in HIV-HCV-coinfected patients.</AbstractText>
                <AbstractText Label="METHODS">In the randomized, open-label ALLY-2 study, HIV-HCV-coinfected patients received 8 or 12 weeks of once-daily DCV 60 mg (dose-adjusted as-necessary for concomitant ARVs) + SOF 400 mg. Results were stratified by ARV class for the 151 patients who received 12 weeks of DCV + SOF.</AbstractText>
                <AbstractText Label="RESULTS">Fifty-one patients were HCV treatment experienced, 100 were treatment naive, 89% male and 33% black. HCV genotypes were: genotype 1a (GT1a; 69%), GT1b (15%), GT2 (8%), GT3 (6%), and GT4 (2%). Sustained virologic response 12 weeks post-treatment (SVR12) was 97% and was similar across ARV regimens (P = .774): protease inhibitor-based, 97% (95% confidence interval [CI], 90%-99.7%); nonnucleoside reverse transcriptase inhibitor-based, 100% (95% CI, 91%-100%); and integrase inhibitor based, 95% (95% CI, 83%-99.4%). SVR12 among patients receiving either tenofovir disoproxil fumarate or abacavir as part of their antiretroviral therapy regimen was 98% (95% CI, 93%-99.5%) and 100% (95% CI, 85%-100%), respectively. Age, gender, race, cirrhosis, HCV treatment history, GT , and baseline HCV RNA did not affect SVR12. No discontinuations were attributed to treatment-related adverse events.</AbstractText>
                <AbstractText Label="CONCLUSIONS">DCV + SOF x12 weeks is a highly efficacious, all-oral, pan-GT HCV treatment for HIV-HCV coinfected patients across a broad range of ARV regimens.</AbstractText>
                <AbstractText Label="CLINICAL TRIALS REGISTRATION">NCT02032888.</AbstractText>
                <CopyrightInformation>© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Luetkemeyer</LastName>
                    <ForeName>Anne F</ForeName>
                    <Initials>AF</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California, San Francisco.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McDonald</LastName>
                    <ForeName>Cheryl</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tarrant County Infectious Disease Associates, Fort Worth, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramgopal</LastName>
                    <ForeName>Moti</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Midway Immunology and Research Center, Fort Pierce, Florida.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noviello</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Lawrenceville.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhore</LastName>
                    <ForeName>Rafia</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Hopewell, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ackerman</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02032888</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Infect Dis</MedlineTA>
            <NlmUniqueID>9203213</NlmUniqueID>
            <ISSNLinking>1058-4838</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="Y">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="Y">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">HIV-HCV</Keyword>
            <Keyword MajorTopicYN="Y">antiretroviral therapy</Keyword>
            <Keyword MajorTopicYN="Y">coinfection</Keyword>
            <Keyword MajorTopicYN="Y">daclatasvir</Keyword>
            <Keyword MajorTopicYN="Y">sofosbuvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27025835</ArticleId>
            <ArticleId IdType="pii">ciw163</ArticleId>
            <ArticleId IdType="doi">10.1093/cid/ciw163</ArticleId>
            <ArticleId IdType="pmc">PMC4885650</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Viral Hepat. 2007 Jun;14(6):371-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17501757</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>AIDS Patient Care STDS. 2015 Jul;29(7):379-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26066094</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Jan 16;370(3):211-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24428467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Jul;63(1):199-236</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25911336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2001 Feb 1;32(3):492-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11170959</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2004 Jul 29;351(5):438-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15282351</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Aug 20;373(8):705-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26196665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am Health Drug Benefits. 2015 Mar;8(Spec Feature):142-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26629280</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2013;18(7):931-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23963204</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2015 Mar 24-31;313(12):1223-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25706092</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Aug 20;373(8):714-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26196502</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27009831</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>10</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-3231</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>36</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
                <ISOAbbreviation>Liver Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1433-41</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.13128</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">Daclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activity in patients with hepatitis C virus (HCV) genotype 1b (GT-1b) infection in the HALLMARK DUAL trial. This post hoc analysis was conducted to determine the efficacy and safety of this treatment in Asian patients.</AbstractText>
                <AbstractText Label="METHODS">Treatment-naive patients were randomly assigned (2:1; double-blinded) to receive DCV (60 mg once daily) plus ASV (100 mg twice daily) or placebo for 12 weeks. Subsequently, placebo patients entered another study, and the remaining patients continued treatment for an additional 12 weeks. Non-responders to peginterferon/ribavirin and ineligible/intolerant patients received dual therapy for 24 weeks. Sustained virological response at post-treatment Week 12 [sustained virological response (SVR)12] and safety outcomes were evaluated.</AbstractText>
                <AbstractText Label="RESULTS">This post hoc analysis included 186 Asian patients (Korean, 78; Taiwanese, 85; others, 23), of whom 32.3% were cirrhotic. SVR12 was observed in 92.3, 78.6 and 80.0% of treatment-naive, ineligible/intolerant and non-responder patients, respectively, and was comparable with non-Asian patients. SVR12 by baseline factors including age, viral load, interleukin-28B genotype and cirrhosis status was similar between the Asian sub-cohorts. Among 18 Asian patients with NS5A-Y93H or NS5A-L31M/V resistance-associated variants (RAVs), seven patients achieved SVR12. Multivariate regression analysis showed a significant influence of NS5A RAVs in both Asian and non-Asian cohorts. The incidence of serious adverse events in Asian patients was low (7.2%). Two Taiwanese patients had elevated alanine aminotransferase (≥5.1 × ULN); both achieved SVR12.</AbstractText>
                <AbstractText Label="CONCLUSIONS">All-oral dual therapy with DCV + ASV resulted in high SVR rates and was well tolerated in Asian patients with HCV GT-1b infection.</AbstractText>
                <CopyrightInformation>© 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kao</LastName>
                    <ForeName>Jia-Horng</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. kaojh@ntu.edu.tw.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Youn-Jae</ForeName>
                    <Initials>YJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Inje University Busan-Paik Hospital, Busan, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heo</LastName>
                    <ForeName>Jeong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Pusan National University, Busan, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Sang-Hoon</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Young-Suk</ForeName>
                    <Initials>YS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Cheng-Yuan</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>China Medical University, School of Medicine, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Ting-Tsung</ForeName>
                    <Initials>TT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torbeyns</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Global Biometric Sciences, Bristol-Myers Squibb, Braine-l'Alleud, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhore</LastName>
                    <ForeName>Rafia</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noviello</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01581203</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Liver Int</MedlineTA>
            <NlmUniqueID>101160857</NlmUniqueID>
            <ISSNLinking>1478-3223</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.2</RegistryNumber>
                <NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S9X0KRJ00S</RegistryNumber>
                <NameOfSubstance UI="C571889">asunaprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000410" MajorTopicYN="N">Alanine Transaminase</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Asia</Keyword>
            <Keyword MajorTopicYN="Y">asunaprevir</Keyword>
            <Keyword MajorTopicYN="Y">daclatasvir</Keyword>
            <Keyword MajorTopicYN="Y">genotype 1b</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27009831</ArticleId>
            <ArticleId IdType="doi">10.1111/liv.13128</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27003037</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>06</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1440-1746</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>31</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of gastroenterology and hepatology</Title>
                <ISOAbbreviation>J. Gastroenterol. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1860-1867</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jgh.13379</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in interferon (±ribavirin)-ineligible or -intolerant Asian patients with genotype 1b infection from mainland China, Korea, and Taiwan.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Interferon (±ribavirin)-ineligible and -intolerant patients with genotype 1b infection received daclatasvir 60 mg tablets once daily plus asunaprevir 100 mg soft capsules twice daily for 24 weeks. The primary endpoint was sustained virologic response at post-treatment week 24 (SVR24).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 159 patients treated, 89.3% were Chinese, 65.4% were female, and 73.6% were interferon-intolerant. Cirrhosis was present in 32.7% of patients, and 40.3% had IL28B non-CC genotypes. SVR24 was achieved by 145/159 (91.2%) patients (100% concordance with SVR12) and was similarly high in cirrhotic patients (47/52, 90.4%). SVR24 was higher in patients without baseline NS5A (L31M or Y93H) resistance-associated variants (RAVs) (137/139, 98.6%), including those with cirrhosis (43/44, 97.7%). Prevalence of baseline NS5A RAVs was low (19/159, 11.9%), particularly in mainland China (10/127, 7.9%). One death (0.6%), five serious adverse events (3.1%), and three grade 4 laboratory abnormalities (1.9%) occurred on treatment; none were considered related to study drugs. Two patients (1.3%) discontinued because of adverse events. Treatment was generally well tolerated regardless of cirrhosis status.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Daclatasvir plus asunaprevir achieved a SVR24 rate of 91.2%, rising to 98.6% in patients without baseline NS5A RAVs, and was generally well tolerated in interferon (±ribavirin)-ineligible or -intolerant patients with genotype 1b infection from mainland China, Korea, and Taiwan.</AbstractText>
                <CopyrightInformation>© 2016 The Authors Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Lai</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peking University People's Hospital and Peking University Hepatology Institute, Beijing.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Mingxiang</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Sixth People's Hospital of Shenyang, Shenyang.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Guangzhou No.8 People's Hospital, Guangzhou.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chuang</LastName>
                    <ForeName>Wan-Long</ForeName>
                    <Initials>WL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tianjin Second People's Hospital, Tianjin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Zhansheng</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tangdu Hospital, Xi'an.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Guozhong</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Xiangya Hospital of Central South University, Changsha.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yueqi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>302 Military Hospital of China, Beijing.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>Si Hyun</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul St. Mary Hospital, The Catholic University of Korea, Seoul.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Yong-Feng</ForeName>
                    <Initials>YF</Initials>
                    <AffiliationInfo>
                        <Affiliation>The 2nd Hospital of Nanjing, Affiliated to Medical School of South East University, Nanjing.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Ruijin Hospital, Jiaotong University School of Medicine, Guangzhou.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Shumei</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xinyue</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Youan Hospital, Capital Medical University, Beijing.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niu</LastName>
                    <ForeName>Junqi</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Hospital of Jilin University, Changchun.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Jidong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Friendship Hospital, Capital Medical University, Beijing.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garimella</LastName>
                    <ForeName>Tushar</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torbeyns</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Braine-l'Alleud.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Treitel</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Philip D</ForeName>
                    <Initials>PD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Shanghai.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>J Gastroenterol Hepatol</MedlineTA>
            <NlmUniqueID>8607909</NlmUniqueID>
            <ISSNLinking>0815-9319</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S9X0KRJ00S</RegistryNumber>
                <NameOfSubstance UI="C571889">asunaprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>J Gastroenterol Hepatol. 2017 Mar;32(3):727</RefSource>
                <PMID Version="1">28320061</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">asunaprevir</Keyword>
            <Keyword MajorTopicYN="N">daclatasvir</Keyword>
            <Keyword MajorTopicYN="N">efficacy</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C</Keyword>
            <Keyword MajorTopicYN="N">safety</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27003037</ArticleId>
            <ArticleId IdType="doi">10.1111/jgh.13379</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26926625</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>60</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>05</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2954-64</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00051-16</ELocationID>
            <Abstract>
                <AbstractText>The selection of resistance-associated variants (RAVs) against single agents administered to patients chronically infected with hepatitis C virus (HCV) necessitates that direct-acting antiviral agents (DAAs) targeting multiple viral proteins be developed to overcome failure resulting from emergence of resistance. The combination of grazoprevir (formerly MK-5172), an NS3/4A protease inhibitor, and elbasvir (formerly MK-8742), an NS5A inhibitor, was therefore studied in genotype 1a (GT1a) replicon cells. Both compounds were independently highly potent in GT1a wild-type replicon cells, with 90% effective concentration (EC90) values of 0.9 nM and 0.006 nM for grazoprevir and elbasvir, respectively. No cross-resistance was observed when clinically relevant NS5A and NS3 RAVs were profiled against grazoprevir and elbasvir, respectively. Kinetic analyses of HCV RNA reduction over 14 days showed that grazoprevir and elbasvir inhibited prototypic NS5A Y93H and NS3 R155K RAVs, respectively, with kinetics comparable to those for the wild-type GT1a replicon. In combination, grazoprevir and elbasvir interacted additively in GT1a replicon cells. Colony formation assays with a 10-fold multiple of the EC90 values of the grazoprevir-elbasvir inhibitor combination suppressed emergence of resistant colonies, compared to a 100-fold multiple for the independent agents. The selected resistant colonies with the combination harbored RAVs that required two or more nucleotide changes in the codons. Mutations in the cognate gene caused greater potency losses for elbasvir than for grazoprevir. Replicons bearing RAVs identified from resistant colonies showed reduced fitness for several cell lines and may contribute to the activity of the combination. These studies demonstrate that the combination of grazoprevir and elbasvir exerts a potent effect on HCV RNA replication and presents a high genetic barrier to resistance. The combination of grazoprevir and elbasvir is currently approved for chronic HCV infection.</AbstractText>
                <CopyrightInformation>Copyright © 2016, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lahser</LastName>
                    <ForeName>Frederick C</ForeName>
                    <Initials>FC</Initials>
                    <Identifier Source="ORCID">0000-0003-4902-0435</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA fred.lahser@merck.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bystol</LastName>
                    <ForeName>Karin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curry</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McMonagle</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xia</LastName>
                    <ForeName>Ellen</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of In Vitro Pharmacology, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingravallo</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chase</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Todd</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hazuda</LastName>
                    <ForeName>Daria</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA Vaccine Research, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asante-Appiah</LastName>
                    <ForeName>Ernest</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26926625</ArticleId>
            <ArticleId IdType="pii">AAC.00051-16</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.00051-16</ArticleId>
            <ArticleId IdType="pmc">PMC4862497</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2005 May 19;435(7040):374-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15902263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5365-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22869572</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ACS Med Chem Lett. 2012 Mar 02;3(4):332-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24900473</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2011 Feb;140(2):667-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21056040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2000 Feb;74(4):2046-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10644379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 Aug;147(2):453-62.e7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24768676</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2008 Mar;77(3):177-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18201776</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2011 Aug;66(8):1673-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21652618</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2004 Aug;78(15):7904-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15254163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ChemMedChem. 2013 Dec;8(12):1930-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24127258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 1990 Oct-Nov;14(4-5):181-205</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2088205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Investig Drugs. 2013 Apr;22(4):527-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23448131</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5230-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22850513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin HIV AIDS. 2015 Sep;10(5):381-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26248125</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 May;83(9):4395-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19244328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2015 Apr;96(Pt 4):727-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25481754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jun;61(6):1798-808</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25627448</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Jul;57(7):3250-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23629699</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2003 Dec;125(6):1808-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14724833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2000 Dec 8;290(5498):1972-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11110665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Med Chem. 2015 Feb 09;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25666806</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2006 Jun;70(2):28-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16448708</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22615282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drugs. 2015 Jun;75(9):1027-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26059288</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Biosyst. 2015 Sep;11(9):2568-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26219385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Sep;85(Pt 9):2485-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15302943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 1993 Mar;37(3):540-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2002 Mar;76(6):2997-3006</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11861865</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Apr;57(4):1333-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23172780</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">26878268</PMID>
        <DateRevised>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1386-6346</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>46</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology research : the official journal of the Japan Society of Hepatology</Title>
                <ISOAbbreviation>Hepatol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1234-1246</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/hepr.12673</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The virologic characteristics of resistance-associated variants (RAVs) developing in patients receiving dual oral therapy with daclatasvir/asunaprevir, including those with previous triple therapy with simeprevir, were evaluated.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 206 patients with genotype-1b HCV infection, including 5 patients with previous simeprevir therapy, were treated with daclatasvir/asunaprevir for 24 weeks. Resistance-associated variants in the NS5A regions at baseline and during/after therapy were evaluated using cycling-probe real-time polymerase chain reaction combined with direct sequencing. The dynamics of rare RAVs were also assessed using ultra-deep sequencing.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A sustained virologic response (SVR12) was achieved in 180 patients (87%); the rates were 95% in patients without baseline NS5A-RAVs and 83%, 59%, and 77% in those with hepatitis C virus (HCV) strains carrying NS5A-L31M, NS5A-Y93H/C, and NS5A-R30Q/H/L mutations, respectively. A multivariate analysis revealed baseline NS5A-R30Q/H/L mutation and NS5A-Y93H mutations as significant factors associated with SVR12. Virologic failure developed in all 5 patients with previous simeprevir treatment, and rare RAVs (HCV strains with NS5A-R30H, NS5A-A92K, NS5A-P29del, and NS5A-P32del) developed at virologic failure. Ultra-deep sequencing revealed that HCV strains with NS5A-P29del or NS5A-P32del were absent at baseline and emerged within 4 weeks of dual oral therapy among the strains appearing after simeprevir administration.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NS5A-R30Q/H/L and NS5A-Y93H mutations at baseline determined the therapeutic efficacy of dual oral therapy with daclatasvir/asunaprevir, but rare NS5A-RAVs developed frequently in patients with previous simeprevir treatment. Such RAVs may develop in a two-hit manner, with simeprevir altering the quasispecies of HCV strains in the NS5A regions, leading to the emergence of HCV strains with NS5A-P29del and NS5A-P32del during exposure to daclatasvir/asunaprevir.</AbstractText>
                <CopyrightInformation>© 2016 The Japan Society of Hepatology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Uchida</LastName>
                    <ForeName>Yoshihito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kouyama</LastName>
                    <ForeName>Jun-Ichi</ForeName>
                    <Initials>JI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naiki</LastName>
                    <ForeName>Kayoko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugawara</LastName>
                    <ForeName>Kayoko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inao</LastName>
                    <ForeName>Mie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imai</LastName>
                    <ForeName>Yukinori</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakayama</LastName>
                    <ForeName>Nobuaki</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mochida</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Hepatol Res</MedlineTA>
            <NlmUniqueID>9711801</NlmUniqueID>
            <ISSNLinking>1386-6346</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HCV</Keyword>
            <Keyword MajorTopicYN="N">NS3/4A protease inhibitor</Keyword>
            <Keyword MajorTopicYN="N">NS5A inhibitor</Keyword>
            <Keyword MajorTopicYN="N">resistance-associated variants</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26878268</ArticleId>
            <ArticleId IdType="doi">10.1111/hepr.12673</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26822022</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>63</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).</ArticleTitle>
            <Pagination>
                <MedlinePgn>1430-41</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.28473</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination of daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SOF; nucleotide nonstructural protein 5B inhibitor) for 12 weeks previously showed high efficacy (96%) in noncirrhotic genotype 3 infection. The phase III ALLY-3+ study (N = 50) evaluated DCV-SOF with ribavirin (RBV) in treatment-naïve (n = 13) or treatment-experienced (n = 37) genotype 3-infected patients with advanced fibrosis (n = 14) or compensated cirrhosis (n = 36). Patients were randomized 1:1 to receive open-label DCV-SOF (60 + 400 mg daily) with weight-based RBV for 12 or 16 weeks. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12). SVR12 (intention-to-treat) was 90% overall (45 of 50): 88% (21 of 24) in the 12-week (91% observed) and 92% (24 of 26) in the 16-week group. All patients with advanced fibrosis achieved SVR12. SVR12 in patients with cirrhosis was 86% overall (31 of 36): 83% (15 of 18) in the 12-week (88% observed) and 89% (16 of 18) in the 16-week group; for treatment-experienced patients with cirrhosis, these values were 87% (26 of 30), 88% (14 of 16; 93% observed), and 86% (12 of 14), respectively. One patient (12-week group) did not enter post-treatment follow-up (death unrelated to treatment). There were 4 relapses (2 per group) and no virological breakthroughs. The most common adverse events (AEs) were insomnia, fatigue, and headache. There were no discontinuations for AEs and no treatment-related serious AEs.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The all-oral regimen of DCV-SOF-RBV was well tolerated and resulted in high and similar SVR12 after 12 or 16 weeks of treatment among genotype 3-infected patients with advanced liver disease, irrespective of past HCV treatment experience.</AbstractText>
                <CopyrightInformation>© 2016 The Authors. HEPATOLOGY published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Leroy</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinique Universitaire d'Hepato-Gastroentérologie, Pôle Digidune, CHU de Grenoble and Unité INSERM/Université Grenoble Alpes U823, IAPC Institut Albert Bonniot, Grenoble, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Angus</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Austin Hospital, Heidelberg, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bronowicki</LastName>
                    <ForeName>Jean-Pierre</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U954, CHU de Nancy, Université de Lorraine, Nancy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dore</LastName>
                    <ForeName>Gregory J</ForeName>
                    <Initials>GJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>St. Vincent's Hospital and Kirby Institute, UNSW Australia, Sydney, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hezode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>CHU Henri Mondor, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pianko</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Monash Medical Centre, Clayton, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Cochin, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stuart</LastName>
                    <ForeName>Katherine</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gallipoli Medical Research Foundation, Greenslopes, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tse</LastName>
                    <ForeName>Edmund</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>South Australia Health, Adelaide, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research &amp; Development, Wallingford, CT.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhore</LastName>
                    <ForeName>Rafia</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research &amp; Development, Princeton, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jimenez-Exposito</LastName>
                    <ForeName>Maria Jesus</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research &amp; Development, Princeton, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Alexander J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>St Vincent's Hospital and the University of Melbourne, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26822022</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.28473</ArticleId>
            <ArticleId IdType="pmc">PMC5069621</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25534735</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2011 Oct;18(10):e516-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21914071</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Jul;63(1):199-236</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25911336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18549461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2004 Jun;40(6):993-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15158341</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22869577</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>AIDS Rev. 2007 Jan-Mar;9(1):16-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17474310</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1867-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2015 Nov;149(6):1462-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26248087</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2009 Oct;51(4):655-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19665246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Mar;61(3):769-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25322962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):212-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21386812</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2005 Sep;5(9):558-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16122679</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2000 Jul;33(1):106-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10905593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1993-2001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24795201</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2015 Dec 31;373(27):2608-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26575258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2013 Feb;37(4):473-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23289640</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2001 Jun;33(6):1358-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11391523</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dig Liver Dis. 2015 Feb;47(2):151-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25483909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Mar;58(3):445-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23142061</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2012 Jun;56(6):1247-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22326470</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Infect Dis. 2008 May 23;8:69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18498666</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 1997 Sep;4(5):351-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9310934</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Lab. 2012;58(1-2):173-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22372362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2010 Oct 14;53(19):7202-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20845908</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Apr;61(4):1127-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25614962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2008 Jun;42(2):156-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18353714</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neth J Med. 2006 Apr;64(4):109-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16609157</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2011 Aug;49(8):3040-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21613437</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2002 Jan;9(1):62-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11851904</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2008 Feb 28;14(8):1237-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18300350</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26778412</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-3231</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>36</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>08</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
                <ISOAbbreviation>Liver Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1125-32</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.13067</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS">ABT-530 is a next-generation hepatitis C virus (HCV) NS5A inhibitor with potent pangenotypic antiviral activity in vitro. Paritaprevir is an NS3/4A protease inhibitor codosed with ritonavir that displays in vitro activity against HCV genotypes 1-4 and 6.</AbstractText>
                <AbstractText Label="METHODS">Efficacy, pharmacokinetics and safety of ABT-530 with paritaprevir/ritonavir and ribavirin were evaluated in this phase 2, open-label, multicentre study in treatment-naïve non-cirrhotic patients with genotype 3 infection. Ten patients, all genotype 3a, received 120 mg ABT-530 and 150/100 mg paritaprevir/ritonavir once daily with ribavirin for 12 weeks.</AbstractText>
                <AbstractText Label="RESULTS">Nine (90%) patients achieved a sustained virological response at post-treatment weeks 12 and 24. One patient experienced virological failure at treatment week 6. Sequence analyses for HCV variants in samples from this patient identified A166S in NS3 at baseline and after breakthrough, as well as A30K at baseline and linked S24F+M28K+A30K variants in NS5A after breakthrough. Neither genotype 3 NS3 A166S nor NS5A A30K variant confers any resistance to paritaprevir or ABT-530 respectively. However, genotype 3 NS5A S24F+M28K+A30K-linked variant confers a &gt;5000-fold increase in ABT-530 EC50 relative to that of the wild-type replicon. This patient's ABT-530 exposure was comparable to the cohort, while paritaprevir and ritonavir exposures were the lowest of all patients. No serious or severe adverse events and adverse events leading to early discontinuation were reported.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Results from this study show that ABT-530 holds promise as part of a direct-acting antiviral treatment regimen for HCV genotype 3 infection.</AbstractText>
                <CopyrightInformation>© 2016 AbbVie Inc. Liver International Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Poordad</LastName>
                    <ForeName>Fred</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Landis</LastName>
                    <ForeName>Charles S</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology, University of Washington, Seattle, WA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asatryan</LastName>
                    <ForeName>Armen</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jackson</LastName>
                    <ForeName>Daniel F</ForeName>
                    <Initials>DF</Initials>
                    <Suffix>3rd</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Digestive Health Specialists of the Southeast, Dothan, AL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Teresa I</ForeName>
                    <Initials>TI</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Chih-Wei</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yao</LastName>
                    <ForeName>Betty</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kort</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02068222</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Liver Int</MedlineTA>
            <NlmUniqueID>101160857</NlmUniqueID>
            <ISSNLinking>1478-3223</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C585405">ABT-450</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000612854">ABT-530</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047028">Macrocyclic Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>O3J8G9O825</RegistryNumber>
                <NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047028" MajorTopicYN="N">Macrocyclic Compounds</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">direct-acting antiviral</Keyword>
            <Keyword MajorTopicYN="Y">next generation</Keyword>
            <Keyword MajorTopicYN="Y">pharmacokinetics</Keyword>
            <Keyword MajorTopicYN="Y">resistant variant</Keyword>
            <Keyword MajorTopicYN="Y">sustained virological response</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26778412</ArticleId>
            <ArticleId IdType="doi">10.1111/liv.13067</ArticleId>
            <ArticleId IdType="pmc">PMC5067610</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Infect. 2015 Feb;70(2):197-205</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25246359</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2011 Oct;18(10):e516-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21914071</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2008 Jan 15;197(2):283-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18177246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2014 Aug 13;312(6):631-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25117132</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Jan 16;370(3):211-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24428467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18549461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2013 Oct;20(10):669-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24010641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2011 Jul;55(1):192-206</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21284949</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drugs. 2015 Apr;75(6):675-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25837989</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2012 Aug;19(8):525-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22762136</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Nov;59(11):6807-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26282418</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2007 Nov;45(11):3595-600</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17898157</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am Health Drug Benefits. 2015 Mar;8(Spec Feature):142-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26629280</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterol Hepatol (N Y). 2015 Jun;11(6 Suppl 3):1-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26504459</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Infect Genet Evol. 2005 Mar;5(2):131-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15639745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):979-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25451055</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Lett Drugs Ther. 2015 Feb 2;57(1461):15-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25629810</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):988-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25451053</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aliment Pharmacol Ther. 2014 Apr;39(7):686-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24612116</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Apr;61(4):1127-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25614962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Dec 28;60(3):1546-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26711747</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2403-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24155107</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2014 Mar 21;20(11):2902-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24659881</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Apr;57(4):1333-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23172780</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26603202</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>08</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6613</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>213</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Apr</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1240-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiv564</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B substitution or phenotypic resistance detected in phase 3 registration studies.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Here, emergence of the NS5B variants L159F and V321A and possible association with resistance was evaluated in 8 studies of SOF (NEUTRINO, FISSION, POSITRON, FUSION, VALENCE, PHOTON-1, PHOTON-2, and P7977-2025) and 5 studies of combination ledipasvir (LDV) and SOF (LDV/SOF; LONESTAR, ELECTRON [LDV/SOF arms], ION1, ION2, and ION3), using deep sequencing.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Deep sequencing detected L159F in 15% (53 of 353) and V321A in 5% (17 of 353) of patients with virologic failure in the SOF studies. Intensification of SOF treatment with LDV reduced the emergence of L159F or V321A to 2% (1 of 50 each) at virologic failure. L159F and V321A did not influence the outcome of retreatment with SOF, ribavirin, and pegylated interferon. At baseline, L159F was detected only in genotype 1-infected patients (1%) and was only associated with increased virologic failure in patients treated for short durations with SOF and ribavirin.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Deep-sequencing analysis confirmed that NS5B variants L159F and V321A emerged in a subset of patients treated with SOF at virologic failure. These variants had no impact on retreatment outcome with SOF, ribavirin, and pegylated interferon. Baseline L159F in genotype 1 did not affect the treatment outcome with LDV/SOF.</AbstractText>
                <CopyrightInformation>© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia S</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Auckland, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Ross</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doehle</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hedskog</LastName>
                    <ForeName>Charlotte</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobson</LastName>
                    <ForeName>Ira M</ForeName>
                    <Initials>IM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Weill Cornell Medical College, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017720" MajorTopicYN="N">Molecular Epidemiology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HCV NS5B sofosbuvir resistance–associated variants</Keyword>
            <Keyword MajorTopicYN="N">L159F</Keyword>
            <Keyword MajorTopicYN="N">V321A</Keyword>
            <Keyword MajorTopicYN="N">direct-acting antivirals</Keyword>
            <Keyword MajorTopicYN="N">resistance</Keyword>
            <Keyword MajorTopicYN="N">sofosbuvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26603202</ArticleId>
            <ArticleId IdType="pii">jiv564</ArticleId>
            <ArticleId IdType="doi">10.1093/infdis/jiv564</ArticleId>
            <ArticleId IdType="pmc">PMC6281391</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Aug;54(8):3187-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20516278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2014 Dec 15;59(12):1666-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25266287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2013 May;13(5):401-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23499158</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Feb 8;383(9916):515-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24209977</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1867-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2015 Jan;35(1):79-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24814388</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2013 Jun 15;381(9883):2100-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23499440</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22430955</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1993-2001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24795201</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):56-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25123381</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Apr;58(4):663-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23183528</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2014 Mar 1;209(5):668-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24154738</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2010 Oct 14;53(19):7202-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20845908</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 Jan 3;368(1):34-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23281974</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26575258</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>373</Volume>
                    <Issue>27</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Dec</Month>
                        <Day>31</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2608-17</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1512612</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis. In one trial, patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus weight-based ribavirin (132 patients) for 12 weeks. In a second trial, patients with HCV genotype 3 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir for 12 weeks (277 patients) or sofosbuvir-ribavirin for 24 weeks (275 patients). The primary end point for the two trials was a sustained virologic response at 12 weeks after the end of therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among patients with HCV genotype 2, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir-ribavirin group (P=0.02). Among patients with HCV genotype 3, the rate of sustained virologic response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir-ribavirin group (P&lt;0.001). The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir-ribavirin. (Funded by Gilead Sciences; ASTRAL-2 ClinicalTrials.gov number, NCT02220998; and ASTRAL-3, NCT02201953.).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Foster</LastName>
                    <ForeName>Graham R</ForeName>
                    <Initials>GR</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Queen Mary University of London (G.R.F.), University College London (W.R.), King's College Hospital (W.R.), and Institute of Liver Studies (K.A.) - all in London; Beth Israel Deaconess Medical Center, Boston (N.A.); Alfred Health and Monash University (S.K.R.) and St. Vincent's Hospital (A.T.), Melbourne, VIC, and Monash Health and Monash University, Clayton, VIC (S.P.) - all in Australia; James J. Peters Veterans Affairs Medical Center, Bronx (N.B.), and Icahn School of Medicine at Mount Sinai, New York (N.B.) - both in New York; Auckland Clinical Studies, Auckland (E.J.G.), and Christchurch Clinical Studies Trust and University of Otago, Christchurch (C.A.M.S.) - both in New Zealand; Texas Liver Institute, University of Texas Health Science Center, San Antonio (E.L.); Liver Institute of Virginia, Richmond (M.L.S.); University of Ottawa, Ottawa (C.C.), and Vancouver Infectious Diseases Centre, Vancouver, BC (B.C.) - both in Canada; Kaiser Permanente (W.J.T.), Ruane Medical (P.R.), and Cedars-Sinai Medical Center (T.T.T.), Los Angeles, and Gilead Sciences, Foster City (H.M., H.D.-S., L.H., J.W., J.M., A.O., D.M.B., J.G.M.) - all in California; Hôpital Saint Joseph, Marseilles (M.B.), and Service d'Hépatologie, Hôpital Beaujon, INSERM UMR 1149, Université Paris Diderot, Clichy (T.A.) - both in France; University Hospital Leipzig, Leipzig (T.B.), and Johann Wolfgang Goethe University, Frankfurt (S.Z.) - both in Germany; Santa Maria Annunziata Hospital, Florence (F.M.), and Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (A.M.) - both in Italy; Henry Ford Health System, Detroit (S.C.G.); Duke University School of Medicine, Durham, NC (K.P.); Rush University Medical Center, Chicago (N.R.); and Johns Hopkins University, Baltimore (M.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Afdhal</LastName>
                    <ForeName>Nezam</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roberts</LastName>
                    <ForeName>Stuart K</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bräu</LastName>
                    <ForeName>Norbert</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pianko</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Alex</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shiffman</LastName>
                    <ForeName>Mitchell L</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>Curtis</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Towner</LastName>
                    <ForeName>William J</ForeName>
                    <Initials>WJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conway</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruane</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourlière</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asselah</LastName>
                    <ForeName>Tarik</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berg</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeuzem</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenberg</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agarwal</LastName>
                    <ForeName>Kosh</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stedman</LastName>
                    <ForeName>Catherine A M</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Lingling</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McNally</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osinusi</LastName>
                    <ForeName>Anu</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mazzotta</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tran</LastName>
                    <ForeName>Tram T</ForeName>
                    <Initials>TT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Stuart C</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Keyur</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reau</LastName>
                    <ForeName>Nancy</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mangia</LastName>
                    <ForeName>Alessandra</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>ASTRAL-2  Investigators</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>ASTRAL-3 Investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02201953</AccessionNumber>
                        <AccessionNumber>NCT02220998</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>KCU0C7RS7Z</RegistryNumber>
                <NameOfSubstance UI="C000604171">velpatasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2015 Dec 31;373(27):2678-80</RefSource>
                <PMID Version="1">26575359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2016 Apr 28;374(17):1687</RefSource>
                <PMID Version="1">27119243</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2016 Apr 28;374(17):1687-8</RefSource>
                <PMID Version="1">27119242</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Afdhal</LastName>
                <ForeName>Nezam</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Agarwal</LastName>
                <ForeName>Ritu</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Al-Assi</LastName>
                <ForeName>M  Tarek</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bennett</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bernstein</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bhandari</LastName>
                <ForeName>Raj</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bräu</LastName>
                <ForeName>Norbert</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cohen</LastName>
                <ForeName>Stuart</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Davis</LastName>
                <ForeName>Mitchell</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Di Bisceglie</LastName>
                <ForeName>Adrian</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Etzkorn</LastName>
                <ForeName>Kyle</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Everson</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fessel</LastName>
                <ForeName>Jeffrey</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Flamm</LastName>
                <ForeName>Steven</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ghalib</LastName>
                <ForeName>Reem</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gitlin</LastName>
                <ForeName>Norm</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Godofsky</LastName>
                <ForeName>Elliot</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>Stuart</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harlan</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hawkins</LastName>
                <ForeName>Trevor</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Herring</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hinestrosa</LastName>
                <ForeName>Federico</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jacobson</LastName>
                <ForeName>Ira</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lawitz</LastName>
                <ForeName>Eric</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Luetkemeyer</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morelli</LastName>
                <ForeName>Giuseppe</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morgan</LastName>
                <ForeName>Timothy</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nyberg</LastName>
                <ForeName>Anders</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pimstone</LastName>
                <ForeName>Neville</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pound</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reau</LastName>
                <ForeName>Nancy</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reddy</LastName>
                <ForeName>Rajender</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rodriguez-Torres</LastName>
                <ForeName>Maribel</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rotjer</LastName>
                <ForeName>Sergio</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruane</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rustgi</LastName>
                <ForeName>Vinod</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryan</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanyal</LastName>
                <ForeName>Arun</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schiff</LastName>
                <ForeName>Eugene</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sepe</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shaikh</LastName>
                <ForeName>Obaid</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheikh</LastName>
                <ForeName>Aasim</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shiffman</LastName>
                <ForeName>Mitchell</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sulkowski</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thuluvath</LastName>
                <ForeName>Paul</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tong</LastName>
                <ForeName>Myron</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Towner</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tran</LastName>
                <ForeName>Tram</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Workowski</LastName>
                <ForeName>Kimberly</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wyles</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Younes</LastName>
                <ForeName>Ziad</ForeName>
                <Initials>Z</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cheng</LastName>
                <ForeName>Wendy</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dore</LastName>
                <ForeName>Greg</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leggett</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mollison</LastName>
                <ForeName>Lindsay</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pianko</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Roberts</LastName>
                <ForeName>Stuart</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Strasser</LastName>
                <ForeName>Simone</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thompson</LastName>
                <ForeName>Alexander</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Conway</LastName>
                <ForeName>Brian</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cooper</LastName>
                <ForeName>Curtis</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Feld</LastName>
                <ForeName>Jordan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shafran</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Swain</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Willems</LastName>
                <ForeName>Bernard</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yoshida</LastName>
                <ForeName>Eric</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abergel</LastName>
                <ForeName>Armand</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Alric</LastName>
                <ForeName>Laurent</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Asselah</LastName>
                <ForeName>Tarik</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bourlière</LastName>
                <ForeName>Marc</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Ledinghen</LastName>
                <ForeName>Victor</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hézode</LastName>
                <ForeName>Christophe</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loustaud-Ratti</LastName>
                <ForeName>Véronique</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathurin</LastName>
                <ForeName>Philippe</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pol</LastName>
                <ForeName>Stanislas</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Samuel</LastName>
                <ForeName>Didier</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zoulim</LastName>
                <ForeName>Fabien</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Arastéh</LastName>
                <ForeName>Keikawus</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berg</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gerken</LastName>
                <ForeName>Guido</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goeser</LastName>
                <ForeName>Tobias</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gruener</LastName>
                <ForeName>Norbert</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manns</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mauss</LastName>
                <ForeName>Stefan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Petersen</LastName>
                <ForeName>Jorg</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zeuzem</LastName>
                <ForeName>Stefan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mangia</LastName>
                <ForeName>Alessandra</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mazzotta</LastName>
                <ForeName>Francesco</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gane</LastName>
                <ForeName>Edward</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stedman</LastName>
                <ForeName>Catherine</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Agarwal</LastName>
                <ForeName>Kosh</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aspinall</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Ashley</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Collier</LastName>
                <ForeName>Jane</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cramp</LastName>
                <ForeName>Matthew</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Forton</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Foster</LastName>
                <ForeName>Graham</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fox</LastName>
                <ForeName>Ray</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosenberg</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryder</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ustianowski</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Afdhal</LastName>
                <ForeName>Nezam</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bennett</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bräu</LastName>
                <ForeName>Norbert</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cohen</LastName>
                <ForeName>Stuart</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Davis</LastName>
                <ForeName>Mitchell</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Etzkorn</LastName>
                <ForeName>Kyle</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Everson</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Flamm</LastName>
                <ForeName>Steven</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>Stuart</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hinestrosa</LastName>
                <ForeName>Federico</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jacobson</LastName>
                <ForeName>Ira</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lawitz</LastName>
                <ForeName>Eric</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morelli</LastName>
                <ForeName>Giuseppe</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Patel</LastName>
                <ForeName>Keyur</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pound</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reddy</LastName>
                <ForeName>K  Rajender</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rodriguez-Torres</LastName>
                <ForeName>Maribel</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryan</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schiff</LastName>
                <ForeName>Eugene</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shaikh</LastName>
                <ForeName>Obaid</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheikh</LastName>
                <ForeName>Aasim</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shiffman</LastName>
                <ForeName>Mitchell</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sulkowski</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Towner</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tran</LastName>
                <ForeName>Tram</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Younes</LastName>
                <ForeName>Ziad</ForeName>
                <Initials>Z</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26575258</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1512612</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26569658</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>03</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>373</Volume>
                    <Issue>27</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Dec</Month>
                        <Day>31</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2618-28</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1512614</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a phase 3, open-label study involving both previously treated and previously untreated patients infected with HCV genotypes 1 through 6 who had decompensated cirrhosis (classified as Child-Pugh-Turcotte class B). Patients were randomly assigned in a 1:1:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin for 12 weeks, or sofosbuvir-velpatasvir for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 267 patients who received treatment, 78% had HCV genotype 1, 4% genotype 2, 15% genotype 3, 3% genotype 4, and less than 1% genotype 6; no patients had genotype 5. Overall rates of sustained virologic response were 83% (95% confidence interval [CI], 74 to 90) among patients who received 12 weeks of sofosbuvir-velpatasvir, 94% (95% CI, 87 to 98) among those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 86% (95% CI, 77 to 92) among those who received 24 weeks of sofosbuvir-velpatasvir. Post hoc analysis did not detect any significant differences in rates of sustained virologic response among the three study groups. Serious adverse events occurred in 19% of patients who received 12 weeks of sofosbuvir-velpatasvir, 16% of those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 18% of those who received 24 weeks of sofosbuvir-velpatasvir. The most common adverse events were fatigue (29%), nausea (23%), and headache (22%) in all patients and anemia (31%) in the patients receiving ribavirin.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis. (Funded by Gilead Sciences; ASTRAL-4 ClinicalTrials.gov number, NCT02201901.).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Curry</LastName>
                    <ForeName>Michael P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Beth Israel Deaconess Medical Center, Boston (M.P.C.); Baylor University Medical Center, Dallas (J.G.O.), and Texas Liver Institute, University of Texas Health Science Center, San Antonio (E.L.) - both in Texas; Ochsner Medical Center, New Orleans (N.B.); Duke University, Durham (A.J.M.), and School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (M.F.) - both in North Carolina; Washington University School of Medicine, St. Louis (K.M.K.); Thomas Jefferson University (J.M.F.) and University of Pennsylvania School of Medicine (K.R.R.) - both in Philadelphia; Northwestern University, Chicago (S.L.F.); Mount Sinai Hospital (T.S.), New York University School of Medicine (L.T.), and Weill Cornell Medical College (R.S.B.) - all in New York; University of Michigan, Ann Arbor (R.F.); University of Miami, Miami (E.S.); Gilead Sciences, Foster City, CA (B.D., D.A., J.M., A.O., D.M.B., J.G.M.); and Intermountain Medical Center, Salt Lake City (M.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Leary</LastName>
                    <ForeName>Jacqueline G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bzowej</LastName>
                    <ForeName>Natalie</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muir</LastName>
                    <ForeName>Andrew J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Korenblat</LastName>
                    <ForeName>Kevin M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fenkel</LastName>
                    <ForeName>Jonathan M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>K Rajender</ForeName>
                    <Initials>KR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flamm</LastName>
                    <ForeName>Steven L</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schiano</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teperman</LastName>
                    <ForeName>Lewis</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fontana</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schiff</LastName>
                    <ForeName>Eugene</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fried</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doehle</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>An</LastName>
                    <ForeName>Di</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McNally</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osinusi</LastName>
                    <ForeName>Anu</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Charlton</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>ASTRAL-4 Investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02201901</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>KCU0C7RS7Z</RegistryNumber>
                <NameOfSubstance UI="C000604171">velpatasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2015 Dec 31;373(27):2678-80</RefSource>
                <PMID Version="1">26575359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Ann Transl Med. 2016 Oct;4(Suppl 1):S8</RefSource>
                <PMID Version="1">27867976</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2016 Apr 28;374(17):1688</RefSource>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2016 Apr 28;374(17):1687</RefSource>
                <PMID Version="1">27119243</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2016 Apr 28;374(17 ):1688</RefSource>
                <PMID Version="1">27135094</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Al-Assi</LastName>
                <ForeName>Tarek M</ForeName>
                <Initials>TM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Alsina</LastName>
                <ForeName>Angel</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bhandari</LastName>
                <ForeName>Bal Raj</ForeName>
                <Initials>BR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Borg</LastName>
                <ForeName>Brian B</ForeName>
                <Initials>BB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Kimberly A</ForeName>
                <Initials>KA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Robert S</ForeName>
                <Initials>RS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bzowej</LastName>
                <ForeName>Natalie</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Charlton</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Curry</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Etzkorn</LastName>
                <ForeName>Kyle P</ForeName>
                <Initials>KP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Everson</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fenkel</LastName>
                <ForeName>Jonathan M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Firpi-Morell</LastName>
                <ForeName>Roberto J</ForeName>
                <Initials>RJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Flamm</LastName>
                <ForeName>Steve</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fontana</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Frenette</LastName>
                <ForeName>Catherine T</ForeName>
                <Initials>CT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fried</LastName>
                <ForeName>Michael Warren</ForeName>
                <Initials>MW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gallant</LastName>
                <ForeName>Joel E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gilroy</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Herring</LastName>
                <ForeName>Robert W</ForeName>
                <Initials>RW</Initials>
                <Suffix>Jr</Suffix>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Humar</LastName>
                <ForeName>Abhinav</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Korenblat</LastName>
                <ForeName>Kevin</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kumar</LastName>
                <ForeName>Princy N</ForeName>
                <Initials>PN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kwo</LastName>
                <ForeName>Paul Y</ForeName>
                <Initials>PY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Landis</LastName>
                <ForeName>Charles</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lawitz</LastName>
                <ForeName>Eric J</ForeName>
                <Initials>EJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Muir</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Leary</LastName>
                <ForeName>Jacqueline</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pound</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reddy</LastName>
                <ForeName>K  Rajender</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rodriguez-Torres</LastName>
                <ForeName>Maribel</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Romero-Marrero</LastName>
                <ForeName>Carlos Javier</ForeName>
                <Initials>CJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruane</LastName>
                <ForeName>Peter J</ForeName>
                <Initials>PJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryan</LastName>
                <ForeName>Michael J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schiano</LastName>
                <ForeName>Thomas D</ForeName>
                <Initials>TD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schiff</LastName>
                <ForeName>Eugene</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sepe</LastName>
                <ForeName>Thomas E</ForeName>
                <Initials>TE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shaikh</LastName>
                <ForeName>Obaid Shakil</ForeName>
                <Initials>OS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheikh</LastName>
                <ForeName>Aasim M</ForeName>
                <Initials>AM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shiffman</LastName>
                <ForeName>Mitchell</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sulkowski</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Teperman</LastName>
                <ForeName>Lewis</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Terrault</LastName>
                <ForeName>Norah</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tong</LastName>
                <ForeName>Myron J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tran</LastName>
                <ForeName>Tram</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vargas</LastName>
                <ForeName>Hugo E</ForeName>
                <Initials>HE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Venkat</LastName>
                <ForeName>Deepak</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Watt</LastName>
                <ForeName>Kymberly</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Younes</LastName>
                <ForeName>Ziad</ForeName>
                <Initials>Z</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zamor</LastName>
                <ForeName>Philippe Jude</ForeName>
                <Initials>PJ</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26569658</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1512614</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26521268</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>10</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6591</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>62</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Feb</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
                <ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.</ArticleTitle>
            <Pagination>
                <MedlinePgn>280-288</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/civ874</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal retreatment strategy for chronic hepatitis C virus (HCV) patients who fail directly-acting antiviral agent (DAA)-based treatment is unknown. In this study, we assessed the efficacy and safety of ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks in HCV genotype-1 (GT-1) patients who failed LDV/SOF-containing therapy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In this single-center, open-label, phase 2a trial, 34 participants with HCV (GT-1) and early-stage liver fibrosis who previously failed 4-6 weeks of LDV/SOF with GS-9669 and/or GS-9451 received LDV/SOF for 12 weeks. The primary endpoint was HCV viral load below the lower limit of quantification 12 weeks after completion of therapy (sustained virological response [SVR]12). Deep sequencing of the NS3, NS5A, and NS5B regions were performed at baseline, at initial relapse, prior to retreatment, and at second relapse with Illumina next-generation sequencing technology.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-two of 34 enrolled participants completed therapy. Two patients withdrew after day 0. Participants were predominantly male and black, with median baseline HCV viral load of 1.3 × 10(6) IU/mL and Metavir fibrosis stage 1 and genotype-1a. Median time from relapse to retreatment was 22 weeks. Prior to retreatment, 29 patients (85%) had NS5A-resistant variants. The SVR12 rate was 91% (31/34; intention to treat, ITT) after retreatment. One patient relapsed.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients who previously failed short-course combination DAA therapy, we demonstrate a high SVR rate in response to 12 weeks of LDV/SOF, even for patients with NS5A resistance-associated variants.</AbstractText>
                <AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT01805882.</AbstractText>
                <CopyrightInformation>Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>Eleanor M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Critical Care Medicine Department, Clinical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kattakuzhy</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sidharthan</LastName>
                    <ForeName>Sreetha</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Critical Care Medicine Department, Clinical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sims</LastName>
                    <ForeName>Zayani</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Lydia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLaughlin</LastName>
                    <ForeName>Mary</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Price</LastName>
                    <ForeName>Angie</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silk</LastName>
                    <ForeName>Rachel</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gross</LastName>
                    <ForeName>Chloe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akoth</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences Inc., Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramanian</LastName>
                    <ForeName>G Mani</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences Inc., Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pang</LastName>
                    <ForeName>Phillip S</ForeName>
                    <Initials>PS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences Inc., Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences Inc., Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osinusi</LastName>
                    <ForeName>Anu</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences Inc., Foster City, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masur</LastName>
                    <ForeName>Henry</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Critical Care Medicine Department, Clinical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kohli</LastName>
                    <ForeName>Anita</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Critical Care Medicine Department, Clinical Center.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, St. Joseph's Hospital and Medical Center, Creighton University, Phoenix, Arizona.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kottilil</LastName>
                    <ForeName>Shyam</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01805882</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Infect Dis</MedlineTA>
            <NlmUniqueID>9203213</NlmUniqueID>
            <ISSNLinking>1058-4838</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>013TE6E4WV</RegistryNumber>
                <NameOfSubstance UI="C586541">ledipasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">direct-acting antiviral agents</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C</Keyword>
            <Keyword MajorTopicYN="N">ledipasvir</Keyword>
            <Keyword MajorTopicYN="N">retreatment</Keyword>
            <Keyword MajorTopicYN="N">sofosbuvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26521268</ArticleId>
            <ArticleId IdType="pii">civ874</ArticleId>
            <ArticleId IdType="doi">10.1093/cid/civ874</ArticleId>
            <ArticleId IdType="pmc">PMC4706633</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1983-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24795200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2015 Apr;15(4):397-404</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25773757</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2013 Aug 28;310(8):804-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23982366</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2014 Dec 15;59(12):1666-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25266287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2014 Nov 4;161(9):634-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25364884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Dec;57(12):6333-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23877691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jul;62(1):25-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25963890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterol Hepatol (N Y). 2015 Jun;11(6 Suppl 3):1-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26504459</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Nov;62(5):1623-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1973-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Gastroenterol. 2010;10:40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20412588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1879-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24720702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1107-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25591505</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2016 Feb 15;62(4):440-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26503379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015;10(4):e0122844</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25856426</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 Jan 3;368(1):34-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23281974</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Mar;53(3):726-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21319189</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26453968</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>07</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-0641</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hepatology</Title>
                <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>292-300</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0168-8278(15)00672-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2015.09.024</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">We evaluated the combination of daclatasvir (pan-genotypic NS5A inhibitor) and simeprevir (NS3/4A protease inhibitor), with or without ribavirin, in hepatitis C virus genotype 1-infected patients.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This phase II, open-label study enrolled treatment-naive patients or prior null responders with genotype 1b (n=147) or 1a (n=21) infection. Genotype 1b-infected patients were randomized 1:1 to receive daclatasvir 30mg plus simeprevir 150mg once daily with or without ribavirin; those who completed the initial 12-week treatment were re-randomized 1:1 to stop treatment or continue treatment through to week 24. Genotype 1a-infected patients received daclatasvir plus simeprevir with ribavirin for 24weeks. The primary endpoint was the proportion of patients with sustained virologic response at posttreatment week 12 (SVR12).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">For genotype 1b, 84.9% (45/53) and 74.5% (38/51) of treatment-naive patients and 69.6% (16/23) and 95.0% (19/20) of prior null responders to peginterferon and ribavirin achieved SVR12 with daclatasvir plus simeprevir alone and with ribavirin, respectively. Treatment duration did not have a well-defined impact on response. For genotype 1a, daclatasvir plus simeprevir with ribavirin provided a 66.7% (8/12) response rate in treatment-naive patients and was not effective in prior null responders. Data suggest that baseline resistance polymorphisms influenced SVR12 rates. Daclatasvir plus simeprevir was well tolerated with or without ribavirin with low incidences of serious adverse events and adverse events leading to discontinuation.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Daclatasvir plus simeprevir, with or without ribavirin, was effective with a 12- or 24-week duration in genotype 1b-infected patients and was well tolerated. ClinicalTrials.gov identifier: NCT01628692.</AbstractText>
                <CopyrightInformation>Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zeuzem</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Klinikum der Goethe Universität, Frankfurt, Germany. Electronic address: zeuzem@em.uni-frankfurt.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Henri Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bronowicki</LastName>
                    <ForeName>Jean-Pierre</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U954, Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre les Nancy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loustaud-Ratti</LastName>
                    <ForeName>Veronique</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>U850 INSERM, Univ. Limoges, CHU Limoges, F-87000 Limoges, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gea</LastName>
                    <ForeName>Francisco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Universitario La Paz, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buti</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Vall Hebron, Barcelona and CIBEREHD del Instituto Carlos III, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olveira</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Universitario La Paz, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Banyai</LastName>
                    <ForeName>Tivadar</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pándy Kálmán Hospital, Gyula, Hungary.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Al-Assi</LastName>
                    <ForeName>M Tarek</ForeName>
                    <Initials>MT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Digestive Disease Consultants, Arlington, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petersen</LastName>
                    <ForeName>Joerg</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>IFI Institut für Interdisziplinäre Medizin, Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thabut</LastName>
                    <ForeName>Dominique</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Pitié-Salpêtrière, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gadano</LastName>
                    <ForeName>Adrian</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pruitt</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nashville Medical Research Institute, Nashville, TN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Makara</LastName>
                    <ForeName>Mihály</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Saint Laszlo Hospital, Budapest, Hungary.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourlière</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Saint Joseph, Marseilles, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université Paris Descartes, AP-HP, Unité d'Hépatologie, Hôpital Cochin, INSERM UMS-20, Institut Pasteur, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beumont-Mauviel</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Janssen Infectious Disease BVBA, Beerse, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ouwerkerk-Mahadevan</LastName>
                    <ForeName>Sivi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Janssen Research and Development, Beerse, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Picchio</LastName>
                    <ForeName>Gaston</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bifano</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research and Development, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boparai</LastName>
                    <ForeName>Navdeep</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research and Development, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheung</LastName>
                    <ForeName>Kin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Eric A</ForeName>
                    <Initials>EA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research and Development, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noviello</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb Research and Development, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>LEAGUE-1 Study Team</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01628692</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Hepatol</MedlineTA>
            <NlmUniqueID>8503886</NlmUniqueID>
            <ISSNLinking>0168-8278</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9WS5RD66HZ</RegistryNumber>
                <NameOfSubstance UI="D000069616">Simeprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="Y">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="Y">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="Y">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="Y">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069616" MajorTopicYN="Y">Simeprevir</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">All-oral therapy</Keyword>
            <Keyword MajorTopicYN="N">Daclatasvir</Keyword>
            <Keyword MajorTopicYN="N">Direct-acting antiviral</Keyword>
            <Keyword MajorTopicYN="N">Genotype 1</Keyword>
            <Keyword MajorTopicYN="N">Hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="N">NS3 protease inhibitor</Keyword>
            <Keyword MajorTopicYN="N">NS5A inhibitor</Keyword>
            <Keyword MajorTopicYN="N">Simeprevir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>05</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>09</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>09</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26453968</ArticleId>
            <ArticleId IdType="pii">S0168-8278(15)00672-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2015.09.024</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26423374</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>07</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2352-3018</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The lancet. HIV</Title>
                <ISOAbbreviation>Lancet HIV</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e319-27</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S2352-3018(15)00114-9</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S2352-3018(15)00114-9</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in patients with HIV-1. The C-EDGE CO-INFECTION study assessed the efficacy, safety, and tolerability of grazoprevir (MK-5172) plus elbasvir (MK-8742) in patients with HCV and HIV co-infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In this uncontrolled, non-randomised, phase 3, open-label, single-arm study, treatment-naive patients with chronic HCV genotype 1, 4, or 6 infection and HIV co-infection, with or without cirrhosis, were enrolled from 37 centres in nine countries across Europe, the USA, and Australia. Patients were either naive to treatment with any antiretroviral therapy (ART) or stable on ART for at least 8 weeks. All patients received grazoprevir 100 mg plus elbasvir 50 mg in a fixed-dose combination tablet once daily for 12 weeks. The primary endpoint was sustained virological response (HCV RNA &lt;15 IU/mL) 12 weeks after the end of therapy (SVR12). The primary population for efficacy analyses was all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, number NCT02105662.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between June 11, 2014, and Aug 29, 2014, 218 patients were enrolled and received grazoprevir plus elbasvir for 12 weeks, all of whom completed follow-up at week 12. SVR12 was achieved by 210 (96%) of 218 patients (95% CI 92·9-98·4). One patient did not achieve SVR12 because of a non-virological reason, and seven patients without cirrhosis relapsed (two subsequently confirmed as reinfections). All 35 patients with cirrhosis achieved SVR12. The most common adverse events were fatigue (29; 13%), headache (27; 12%), and nausea (20; 9%). No patient discontinued treatment because of an adverse event. Two patients receiving ART had transient HIV viraemia.</AbstractText>
                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">This HCV treatment regimen seems to be effective and well tolerated for patients co-infected with HIV with or without cirrhosis. These data are consistent with previous trials of this regimen in the monoinfected population. This regimen continues to be studied in phase 3 trials.</AbstractText>
                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Merck Sharp &amp; Dohme Corp.</AbstractText>
                <CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rockstroh</LastName>
                    <ForeName>Jürgen K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bonn University Hospital, Bonn, Germany. Electronic address: juergen.rockstroh@ukb.uni-bonn.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Chelsea and Westminster Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katlama</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sorbonne Universities, UPMC University of Paris 06, INSERM UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, Paris, France; APHP Pitié-Salpêtrière Hospital, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lalezari</LastName>
                    <ForeName>Jay</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Quest Clinical Research, San Francisco, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mallolas</LastName>
                    <ForeName>Josep</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Clinic-University of Barcelona, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bloch</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Holdsworth House Medical Practice, Darlinghurst, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matthews</LastName>
                    <ForeName>Gail V</ForeName>
                    <Initials>GV</Initials>
                    <AffiliationInfo>
                        <Affiliation>St Vincent's Hospital, Sydney, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saag</LastName>
                    <ForeName>Michael S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zamor</LastName>
                    <ForeName>Philippe J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hepatology, Carolinas Medical Center, Charlotte, NC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Orkin</LastName>
                    <ForeName>Chloe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Royal London Hospital, Bart's Health NHS Trust, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gress</LastName>
                    <ForeName>Jacqueline</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klopfer</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaughnessy</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Bach-Yen T</ForeName>
                    <Initials>BY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Platt</LastName>
                    <ForeName>Heather L</ForeName>
                    <Initials>HL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02105662</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Lancet HIV</MedlineTA>
            <NlmUniqueID>101645355</NlmUniqueID>
            <ISSNLinking>2352-3018</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CitationSubset>X</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Lancet HIV. 2015 Aug;2(8):e308-9</RefSource>
                <PMID Version="1">26423368</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>Lancet HIV. 2015 Aug;2(8):e316</RefSource>
            </CommentsCorrections>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>Lancet HIV. 2015 Oct;2(10):e416</RefSource>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26423374</ArticleId>
            <ArticleId IdType="pii">S2352-3018(15)00114-9</ArticleId>
            <ArticleId IdType="doi">10.1016/S2352-3018(15)00114-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26371152</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>09</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6591</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>62</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Jan</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
                <ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.</ArticleTitle>
            <Pagination>
                <MedlinePgn>32-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/civ722</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The phase 2 C-SALVAGE study (Hepatitis C-Salvage Study for Patients who Failed DAA/PR Therapy) demonstrated a 96.2% sustained virologic response at 12 weeks (SVR12) rate using the NS3/4A protease inhibitor grazoprevir and the NS5A inhibitor elbasvir together with ribavirin in treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">C-SALVAGE was a prospective open-label trial of grazoprevir 100 mg once daily and elbasvir 50 mg once daily coadministered with weight-based ribavirin twice daily for 12 weeks in genotype 1-infected cirrhotic and noncirrhotic patients who had failed treatment with ≥ 4 weeks of pegylated interferon and ribavirin plus either boceprevir, telaprevir, or simeprevir. Although the primary efficacy outcome was SVR12, patients were also evaluated 24 weeks after cessation of study therapy. Population sequencing was performed at baseline and periodically in virologic failures throughout the 24-week posttherapy follow-up period.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">SVR24 rates were 76 of 79 (96.2%) overall, with all 3 relapses occurring by posttherapy week 8. Every NS3 and NS5A variant detected at baseline reappeared at the time of relapse and persisted throughout the available follow-up period. NS3_A156T emerged in virus from each patient at relapse, but rapidly disappeared over the ensuing 2 weeks in 2 patients. NS5A_Y93H emerged in virus from 2 patients at relapse and persisted for the entire follow-up period.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Grazoprevir and elbasvir with ribavirin for 12 weeks maintained HCV suppression for at least 24 weeks posttherapy without late relapses. Baseline resistance-associated variants (RAVs) stably reappeared at relapse in all 3 patients with virologic failure. NS5A_RAVs emerging at relapse persisted for the full 24-week follow-up period. If confirmed, this finding could complicate retreatment of the small number of patients failing regimens containing an NS5A inhibitor.</AbstractText>
                <AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT02105454.</AbstractText>
                <CopyrightInformation>© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Buti</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Universitario Valle Hebron and Ciberehd, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gordon</LastName>
                    <ForeName>Stuart C</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Henry Ford Health System, Detroit, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zuckerman</LastName>
                    <ForeName>Eli</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Carmel Medical Center, Haifa, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calleja</LastName>
                    <ForeName>Jose L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Gastroenterología y Hepatología, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hofer</LastName>
                    <ForeName>Harald</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilbert</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck and Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palcza</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck and Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck and Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DiNubile</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck and Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck and Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck and Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck and Co, Inc, Kenilworth, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forns</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02105454</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>09</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Infect Dis</MedlineTA>
            <NlmUniqueID>9203213</NlmUniqueID>
            <ISSNLinking>1058-4838</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">C-SALVAGE</Keyword>
            <Keyword MajorTopicYN="N">elbasvir</Keyword>
            <Keyword MajorTopicYN="N">genotype 1</Keyword>
            <Keyword MajorTopicYN="N">grazoprevir</Keyword>
            <Keyword MajorTopicYN="N">resistance-associated variants (RAVs)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26371152</ArticleId>
            <ArticleId IdType="pii">civ722</ArticleId>
            <ArticleId IdType="doi">10.1093/cid/civ722</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26303801</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>08</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>59</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6922-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01390-15</ELocationID>
            <Abstract>
                <AbstractText>Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes. Antiviral activity of elbasvir was measured in replicons derived from wild-type or resistant variants of genotypes 1a, 1b, and 3. The barrier to resistance was assessed by the number of resistant colonies selected by exposure to various elbasvir concentrations. In a phase 1b dose-escalating study, virologic responses were determined in 48 noncirrhotic adult men with chronic genotype 1 or 3 infections randomized to placebo or elbasvir from 5 to 50 mg (genotype 1) or 10 to 100 mg (genotype 3) once daily for 5 days. The NS5A gene was sequenced from plasma specimens obtained before, during, and after treatment. Elbasvir suppressed the emergence of resistance-associated variants (RAVs) in vitro in a dose-dependent manner. Variants selected by exposure to high elbasvir concentrations typically encoded multiple amino acid substitutions (most commonly involving loci 30, 31, and 93), conferring high-level elbasvir resistance. In the monotherapy study, patients with genotype 1b had greater reductions in HCV RNA levels than patients with genotype 1a at all elbasvir doses; responses in patients with genotype 3 were generally less pronounced than for genotype 1, particularly at lower elbasvir doses. M28T, Q30R, L31V, and Y93H in genotype 1a, L31V and Y93H in genotype 1b, and A30K, L31F, and Y93H in genotype 3 were the predominant RAVs selected by elbasvir monotherapy. Virologic findings in patients were consistent with the preclinical observations. NS5A-RAVs emerged most often at amino acid positions 28, 30, 31, and 93 in both the laboratory and clinical trial. (The MK-8742 P002 trial has been registered at ClinicalTrials.gov under identifier NCT01532973.). </AbstractText>
                <CopyrightInformation>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA Rongl876@gmail.com ahowe@cfenet.ubc.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curry</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McMonagle</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yeh</LastName>
                    <ForeName>Wendy W</ForeName>
                    <Initials>WW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ludmerer</LastName>
                    <ForeName>Steven W</ForeName>
                    <Initials>SW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jumes</LastName>
                    <ForeName>Patricia A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marshall</LastName>
                    <ForeName>William L</ForeName>
                    <Initials>WL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingravallo</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Stuart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pak</LastName>
                    <ForeName>Irene</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DiNubile</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA Rongl876@gmail.com ahowe@cfenet.ubc.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01532973</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26303801</ArticleId>
            <ArticleId IdType="pii">AAC.01390-15</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.01390-15</ArticleId>
            <ArticleId IdType="pmc">PMC4604396</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA. 2015 May 5;313(17):1728-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25942723</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1087-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Sep;63(3):564-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25895428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet HIV. 2015 Aug;2(8):e319-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26423374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 2003 Jun 5;310(2):333-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12781720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biotechniques. 1993 Jul;15(1):120-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8363827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2007 Jan;59(1):51-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17151003</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Jul;85(13):6645-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21525356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(7):e39652</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22792183</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2013 May;57(1):13-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2012 Oct;2(5):651-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23006585</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2012;8(8):e1002881</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22927817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2013 Jul;57(2):221-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23575197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Methods Mol Biol. 2013;1030:137-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23821266</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 2013 Sep;444(1-2):329-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23876458</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ChemMedChem. 2013 Dec;8(12):1930-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24127258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1075-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467591</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Infect Dis. 2014 Jan 1;209(1):38-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24127561</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2014 Dec 15;59(12):1657-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25266289</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2015 Jul;89(14):7385-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25972535</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26196665</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>373</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>705-13</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1501315</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an unmet medical need.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicenter, single-group, open-label study involving patients coinfected with HIV-1 and genotype 1 or 4 HCV receiving an antiretroviral regimen of tenofovir and emtricitabine with efavirenz, rilpivirine, or raltegravir. All patients received ledipasvir, an NS5A inhibitor, and sofosbuvir, a nucleotide polymerase inhibitor, as a single fixed-dose combination for 12 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 335 patients enrolled, 34% were black, 55% had been previously treated for HCV, and 20% had cirrhosis. Overall, 322 patients (96%) had a sustained virologic response at 12 weeks after the end of therapy (95% confidence interval [CI], 93 to 98), including rates of 96% (95% CI, 93 to 98) in patients with HCV genotype 1a, 96% (95% CI, 89 to 99) in those with HCV genotype 1b, and 100% (95% CI, 63 to 100) in those with HCV genotype 4. Rates of sustained virologic response were similar regardless of previous treatment or the presence of cirrhosis. Of the 13 patients who did not have a sustained virologic response, 10 had a relapse after the end of treatment. No patient had confirmed HIV-1 virologic rebound. The most common adverse events were headache (25%), fatigue (21%), and diarrhea (11%). No patient discontinued treatment because of adverse events.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ledipasvir and sofosbuvir for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4. (Funded by Gilead Sciences; ION-4 ClinicalTrials.gov number, NCT02073656.).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Naggie</LastName>
                    <ForeName>Susanna</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>From Duke Clinical Research Institute, Durham, NC (S.N.); University of Ottawa, the Ottawa Hospital, Ottawa (C.C.), and Department of Hepatology, Immunodeficiency Clinic, Toronto General Hospital, University of Toronto, Toronto (D.K.W.) - both in Canada; University of Alabama at Birmingham, Birmingham (M. Saag); Emory University, Emory Healthcare, Atlanta (K.W.); Ruane Medical and Liver Health Institute (P.R.) and Kaiser Permanente Los Angeles Medical Center (W.J.T.), Los Angeles, University of California, San Francisco, San Francisco General Hospital, San Francisco (A.L.), and Gilead Sciences, Foster City (L.M.S., J.C.Y., P.G., H.D.-S., L.N., P.S.P., J.G.M.) - all in California; Weill Cornell Medical College (K.M.), Icahn School of Medicine at Mount Sinai (N.B., D.D.), New York, and James J. Peters Veterans Affairs Medical Center, Bronx (N.B.) - all in New York; Beth Israel Deaconess Medical Center (R.P.B.), Brigham and Women's Hospital and Harvard Medical School (P.E.S.), and Community Research Initiative of New England (A.E.C.) - all in Boston; University of Auckland, Auckland City Hospital, Auckland (E.G.), and Christchurch Hospital and University of Otago, Christchurch (C.A.M.S.) - both in New Zealand; University of Puerto Rico School of Medicine (J.S.-B.) and Clinical Research Puerto Rico (J.O.M.-R.) - both in San Juan; University of Miami, Miami (D.J.); University of Pennsylvania, Philadelphia (P.T.); and Johns Hopkins University School of Medicine, Baltimore (M. Sulkowski).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>Curtis</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saag</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Workowski</LastName>
                    <ForeName>Kimberly</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruane</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Towner</LastName>
                    <ForeName>William J</ForeName>
                    <Initials>WJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marks</LastName>
                    <ForeName>Kristen</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luetkemeyer</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baden</LastName>
                    <ForeName>Rachel P</ForeName>
                    <Initials>RP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sax</LastName>
                    <ForeName>Paul E</ForeName>
                    <Initials>PE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santana-Bagur</LastName>
                    <ForeName>Jorge</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stamm</LastName>
                    <ForeName>Luisa M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jenny C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>German</LastName>
                    <ForeName>Polina</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ni</LastName>
                    <ForeName>Liyun</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pang</LastName>
                    <ForeName>Phillip S</ForeName>
                    <Initials>PS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stedman</LastName>
                    <ForeName>Catherine A M</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morales-Ramirez</LastName>
                    <ForeName>Javier O</ForeName>
                    <Initials>JO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bräu</LastName>
                    <ForeName>Norbert</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jayaweera</LastName>
                    <ForeName>Dushyantha</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colson</LastName>
                    <ForeName>Amy E</ForeName>
                    <Initials>AE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tebas</LastName>
                    <ForeName>Pablo</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>David K</ForeName>
                    <Initials>DK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dieterich</LastName>
                    <ForeName>Douglas</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>ION-4 Investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02073656</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K23 AI096913</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 AI045008</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 RR025758</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UM1 AI069415</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>013TE6E4WV</RegistryNumber>
                <NameOfSubstance UI="C586541">ledipasvir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="Y">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Cooper</LastName>
                <ForeName>Curtis</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hull</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klein</LastName>
                <ForeName>Marina</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wong</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Huchet</LastName>
                <ForeName>Emmanuelle</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gane</LastName>
                <ForeName>Edward</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stedman</LastName>
                <ForeName>Catherine</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Asmuth</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brau</LastName>
                <ForeName>Norbert</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chung</LastName>
                <ForeName>Raymond</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Daar</LastName>
                <ForeName>Eric</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dietz</LastName>
                <ForeName>Craig</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dretler</LastName>
                <ForeName>Robin Henry</ForeName>
                <Initials>RH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Elion</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fessel</LastName>
                <ForeName>W J</ForeName>
                <Initials>WJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gathe</LastName>
                <ForeName>Joseph C</ForeName>
                <Initials>JC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Godofsky</LastName>
                <ForeName>Eliot</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hinestrosa</LastName>
                <ForeName>Federico</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Huhn</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jain</LastName>
                <ForeName>Mamta</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jayaweera</LastName>
                <ForeName>Dushyantha</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lalezari</LastName>
                <ForeName>Jay</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Landis</LastName>
                <ForeName>Charles</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mayer</LastName>
                <ForeName>Cynthia</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morales-Ramirez</LastName>
                <ForeName>Javier O</ForeName>
                <Initials>JO</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mounzer</LastName>
                <ForeName>Karam</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rashbaum</LastName>
                <ForeName>Bruce S</ForeName>
                <Initials>BS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruane</LastName>
                <ForeName>Peter J</ForeName>
                <Initials>PJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Santana-Bagur</LastName>
                <ForeName>Jorge L</ForeName>
                <Initials>JL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sax</LastName>
                <ForeName>Paul Edward</ForeName>
                <Initials>PE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sterling</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sulkowski</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thompson</LastName>
                <ForeName>Melanie A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wang</LastName>
                <ForeName>Chia</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Workowski</LastName>
                <ForeName>Kimberly</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Young</LastName>
                <ForeName>Benjamin</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bonacini</LastName>
                <ForeName>Maurizio</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kotler</LastName>
                <ForeName>Donald</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mills</LastName>
                <ForeName>Anthony</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Towner</LastName>
                <ForeName>William J</ForeName>
                <Initials>WJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wohl</LastName>
                <ForeName>David A</ForeName>
                <Initials>DA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wyles</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marks</LastName>
                <ForeName>Kristen</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baden</LastName>
                <ForeName>Rachel</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grant</LastName>
                <ForeName>Philip M</ForeName>
                <Initials>PM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Saag</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Salazar</LastName>
                <ForeName>Laura</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bansal</LastName>
                <ForeName>Meena</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Colson</LastName>
                <ForeName>Amy</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gallant</LastName>
                <ForeName>Joel E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siegel</LastName>
                <ForeName>Marc</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Naggie</LastName>
                <ForeName>Susanna</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Luetkemeyer</LastName>
                <ForeName>Annie</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tashima</LastName>
                <ForeName>Karen T</ForeName>
                <Initials>KT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sherman</LastName>
                <ForeName>Kenneth</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Flamm</LastName>
                <ForeName>Jason</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bredeek</LastName>
                <ForeName>Fritz</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tebas</LastName>
                <ForeName>Pablo</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wheeler</LastName>
                <ForeName>David A</ForeName>
                <Initials>DA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Friel</LastName>
                <ForeName>Timothy</ForeName>
                <Initials>T</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26196665</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1501315</ArticleId>
            <ArticleId IdType="pmc">PMC4892372</ArticleId>
            <ArticleId IdType="mid">NIHMS787045</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Apr 17;370(16):1483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Nov 15;384(9956):1756-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25078309</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2014 Jul 23-30;312(4):353-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25038354</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2006 Oct;13(10 ):683-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16970600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Jul 19;384(9939):241-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25042234</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Intern Med. 2004 Nov 22;164(21):2349-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15557414</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>AIDS. 2008 Oct 1;22(15):1979-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18784461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2012 Jul 25;308(4):370-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22820790</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Gastroenterol. 2005 Jan;100(1):56-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15654781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>AIDS. 2004 Dec 3;18(18):2391-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15622315</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2004 Jul 29;351(5):438-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15282351</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2014 Mar 18;160(6):369-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24723077</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1889-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24725239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2006;44(1 Suppl):S6-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16352363</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2015 Mar 24-31;313(12):1232-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25706232</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2009 Aug;50(2):407-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19575364</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2013 Jul 16;159(2):86-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23685940</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 15;370(20):1879-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24720702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2013 Jul;13(7):597-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23768747</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2007 Oct;47(4):527-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17692986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2013 May 7;158(9):658-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23440167</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2004 Jul 29;351(5):451-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15282352</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26196502</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>373</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>714-25</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1503153</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This was an open-label study involving 151 patients who had not received HCV treatment and 52 previously treated patients, all of whom were coinfected with HIV-1. Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 weeks or 8 weeks of daclatasvir at a standard dose of 60 mg daily (with dose adjustment for concomitant antiretroviral medications) plus 400 mg of sofosbuvir daily. Previously treated patients were assigned to undergo 12 weeks of therapy at the same doses. The primary end point was a sustained virologic response at week 12 after the end of therapy among previously untreated patients with HCV genotype 1 who were treated for 12 weeks.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients had HCV genotypes 1 through 4 (83% with genotype 1), and 14% had compensated cirrhosis; 98% were receiving antiretroviral therapy. Among patients with genotype 1, a sustained virologic response was reported in 96.4% (95% confidence interval [CI], 89.8 to 99.2) who were treated for 12 weeks and in 75.6% (95% CI, 59.7 to 87.6) who were treated for 8 weeks among previously untreated patients and in 97.7% (95% CI, 88.0 to 99.9) who were treated for 12 weeks among previously treated patients. Rates of sustained virologic response across all genotypes were 97.0% (95% CI, 91.6 to 99.4), 76.0% (95% CI, 61.8 to 86.9), and 98.1% (95% CI, 89.7 to 100), respectively. The most common adverse events were fatigue, nausea, and headache. There were no study-drug discontinuations because of adverse events. HIV-1 suppression was not compromised.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.0% after 12 weeks of treatment and 76.0% after 8 weeks. (Funded by Bristol-Myers Squibb; ALLY-2 ClinicalTrials.gov number, NCT02032888.).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wyles</LastName>
                    <ForeName>David L</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of California, San Diego, La Jolla (D.L.W.), Ruane Medical and Liver Health Institute (P.J.R.), the Jeffrey Goodman Clinic, Los Angeles LGBT Center (C.H.), and Southern California Men's Medical Group-Men's Health Foundation (A.M.), Los Angeles, the University of California, San Francisco, San Francisco (A.L.), Veterans Affairs Long Beach Healthcare System, Long Beach (T.R.M.), and Pacific Oaks Medical Group, Beverly Hills (A.S.) - all in California; Johns Hopkins University, Lutherville, MD (M.S.S.); Icahn School of Medicine at Mount Sinai, New York (D.D.); University of Cincinnati College of Medicine, Cincinnati (K.E.S.); Infectious Disease Specialists of Atlanta, Decatur, GA (R.D.); MedStar Washington Hospital Center (D.F.), Whitman-Walker Health (S.H.), and Capital Medical Associates (B.R.) - all in Washington, DC; the Cure C Consortium, Houston (J.C.G.), and Tarrant County Infectious Disease Associates, Fort Worth (C.M.) - both in Texas; Orlando Immunology Center, Orlando (F.H.), and Midway Immunology and Research Center, Fort Pierce (M.R.) - both in Florida; the University of Alabama at Birmingham, Birmingham (E.T.O.); the University of Colorado, Denver (G.R.); Lehigh Valley Health Network, Allentown, PA (J.Y.); and Bristol-Myers Squibb, Wallingford, CT (F.M., P.D.Y., P.A.), and Princeton, NJ (Z.L., E.H., S.N.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruane</LastName>
                    <ForeName>Peter J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dieterich</LastName>
                    <ForeName>Douglas</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luetkemeyer</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morgan</LastName>
                    <ForeName>Timothy R</ForeName>
                    <Initials>TR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sherman</LastName>
                    <ForeName>Kenneth E</ForeName>
                    <Initials>KE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dretler</LastName>
                    <ForeName>Robin</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fishbein</LastName>
                    <ForeName>Dawn</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gathe</LastName>
                    <ForeName>Joseph C</ForeName>
                    <Initials>JC</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henn</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hinestrosa</LastName>
                    <ForeName>Federico</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huynh</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McDonald</LastName>
                    <ForeName>Cheryl</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mills</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Overton</LastName>
                    <ForeName>Edgar Turner</ForeName>
                    <Initials>ET</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramgopal</LastName>
                    <ForeName>Moti</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rashbaum</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ray</LastName>
                    <ForeName>Graham</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scarsella</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yozviak</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zhaohui</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Philip D</ForeName>
                    <Initials>PD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noviello</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ackerman</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>ALLY-2 Investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02032888</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="Y">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Bank</LastName>
                <ForeName>Leslie</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bhamidimarri</LastName>
                <ForeName>Kalyan</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Box</LastName>
                <ForeName>Terry</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Campbell</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Desta</LastName>
                <ForeName>Taddese</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dieterich</LastName>
                <ForeName>Douglas</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dretler</LastName>
                <ForeName>Robin</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fallon</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fishbein</LastName>
                <ForeName>Dawn</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gallant</LastName>
                <ForeName>Joel</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gathe</LastName>
                <ForeName>Joseph</ForeName>
                <Initials>J</Initials>
                <Suffix>Jr</Suffix>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Henn</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hinestrosa</LastName>
                <ForeName>Federico</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Huynh</LastName>
                <ForeName>Charles</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Korenblat</LastName>
                <ForeName>Kevin</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kwo</LastName>
                <ForeName>Paul</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Landis</LastName>
                <ForeName>Charles</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Luetkemeyer</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Luketic</LastName>
                <ForeName>Velimir</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McDonald</LastName>
                <ForeName>Cheryl</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mills</LastName>
                <ForeName>Anthony</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moonka</LastName>
                <ForeName>Dilip</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morgan</LastName>
                <ForeName>Timothy</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morris</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Overton</LastName>
                <ForeName>Edgar Turner</ForeName>
                <Initials>ET</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ramgopal</LastName>
                <ForeName>Moti</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rana</LastName>
                <ForeName>Aadia</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rashbaum</LastName>
                <ForeName>Bruce</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ravendhran</LastName>
                <ForeName>Natarajan</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruane</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scarsella</LastName>
                <ForeName>Anthony</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sepe</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sherman</LastName>
                <ForeName>Kenneth E</ForeName>
                <Initials>KE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sulkowski</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wyles</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yozviak</LastName>
                <ForeName>Joseph</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zaman</LastName>
                <ForeName>Atif</ForeName>
                <Initials>A</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26196502</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1503153</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26170396</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>04</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6613</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>213</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Jan</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>206-15</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiv379</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1-4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4-infected population for HCV genotype 4 subtype prevalence, NS5A polymorphisms at residues associated with daclatasvir resistance (positions 28, 30, 31, or 93), and their effects on daclatasvir activity in vitro and clinically.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We performed phylogenetic analysis of genotype 4 NS5A sequences from 186 clinical trial patients and 43 sequences from the European HCV database, and susceptibility analyses of NS5A polymorphisms and patient-derived NS5A sequences by using genotype 4 NS5A hybrid genotype 2a replicons.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The clinical trial patients represented 14 genotype 4 subtypes; most prevalent were genotype 4a (55%) and genotype 4d (27%). Daclatasvir 50% effective concentrations for 10 patient-derived NS5A sequences representing diverse phylogenetic clusters were ≤0.080 nM. Most baseline sequences had ≥1 NS5A polymorphism at residues associated with daclatasvir resistance; however, only 3 patients (1.6%) had polymorphisms conferring ≥1000-fold daclatasvir resistance in vitro. Among 46 patients enrolled in daclatasvir trials, all 20 with baseline resistance polymorphisms achieved a sustained virologic response.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Circulating genotype 4 subtypes are genetically diverse. Polymorphisms conferring high-level daclatasvir resistance in vitro are uncommon before therapy, and clinical data suggest that genotype 4 subtype and baseline polymorphisms have minimal impact on responses to daclatasvir-containing regimens.</AbstractText>
                <CopyrightInformation>© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Nannan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernandez</LastName>
                    <ForeName>Dennis</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueland</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xiaoyan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sims</LastName>
                    <ForeName>Karen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Philip D</ForeName>
                    <Initials>PD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, Connecticut.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015967" MajorTopicYN="N">Gene Expression Regulation, Viral</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HCV</Keyword>
            <Keyword MajorTopicYN="N">NS5A</Keyword>
            <Keyword MajorTopicYN="N">daclatasvir</Keyword>
            <Keyword MajorTopicYN="N">polymorphism</Keyword>
            <Keyword MajorTopicYN="N">resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26170396</ArticleId>
            <ArticleId IdType="pii">jiv379</ArticleId>
            <ArticleId IdType="doi">10.1093/infdis/jiv379</ArticleId>
            <ArticleId IdType="pmc">PMC4690147</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Gastroenterol. 2004 Jan;38(1):68-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14679330</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2003 Dec;125(6):1808-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14724833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17142229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jan;59(1):318-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24115039</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 Feb;146(2):420-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24184132</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Mar;60(3):490-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24444658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2014 Mar 13;57(5):2033-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24320933</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 May;146(5):1176-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24631495</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2083-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24604476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMJ. 2014;348:g3308</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25002352</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2014 Aug;108:181-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24911972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Aug 2;384(9941):403-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24907225</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2014;19(5):479-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24448487</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Nov 1;384(9954):1597-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25078304</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Dec;61(6):1220-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25038486</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 May;62(5):1040-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25450208</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 May;62(5):1204-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25559328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 May;62(5):1047-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25596313</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gut. 2015 Jun;64(6):948-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25080450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Jul;63(1):30-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25703086</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Jun 20;385(9986):2502-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25837829</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2011 Jul;31 Suppl 2:18-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21651701</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2007 Jul;14(7):460-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17576387</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2008 Apr;47(4):1371-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18240152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2009 Dec;47(12):3832-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19794040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 May;84(10):5277-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20200247</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1956-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21837752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22203595</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Jun;55(6):1692-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22234905</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2012 Aug;54(4):352-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22658798</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Oct;56(10):5365-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22869572</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2013 Jan;144(1):59-61.e6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000598</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Jan;57(1):611-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23089758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Saudi J Gastroenterol. 2013 Jan-Feb;19(1):28-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23319035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pan Afr Med J. 2013;14:44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23560127</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Sep;58(3):902-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23504694</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25847509</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>62</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.</ArticleTitle>
            <Pagination>
                <MedlinePgn>129-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.27836</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Retreatment of patients who have not achieved sustained virological response (SVR) after treatment with investigational direct-acting antiviral agents (DAAs) has not been extensively studied. We conducted an open-label trial to assess the efficacy and safety of sofosbuvir (SOF) plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in patients with genotype 1 hepatitis C virus (HCV) who participated in previous studies of one or more Gilead investigational DAAs in combination with RBV with or without Peg-IFN. We enrolled 80 patients at 40 sites. All patients received SOF 400 mg once daily plus Peg-IFN-α 180 μg/week and weight-based ribavirin (1,000 or 1,200 mg/day) for 12 weeks. The efficacy endpoint was the proportion of patients with SVR 12 weeks after discontinuation of therapy (SVR12). Of the 80 patients enrolled, 36 (45%) had received two or more courses of earlier treatment for HCV and 74 (93%) had at least one resistance-associated variant (RAV) at baseline. SVR12 was achieved by 63 of the 80 patients (79%) treated. Rates of SVR12 were similar across patient subgroups. Presence of RAVs at baseline did not appear to be associated with treatment failure. Seventy-one of eighty patients (89%) experienced at least one adverse event (AE), but most events were mild to moderate in severity. The most common AEs were fatigue, headache, and nausea. No patients discontinued all treatment because of AEs.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that SOF plus Peg-IFN and RBV for 12 weeks is effective and safe in patients who have not achieved SVR with earlier regimens of one or more DAAs plus Peg-IFN and RBV.</AbstractText>
                <CopyrightInformation>© 2015 by the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université Paris Descartes, Hôpital Cochin, Inserm UMS20, Institut Pasteur, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>John Hopkins University, Baltimore, MD.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassanein</LastName>
                    <ForeName>Tarek</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Southern California Liver Center, Coronado, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Aukland City Hospital, Auckland, NZ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Lin</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doehle</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanwar</LastName>
                    <ForeName>Bittoo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramanian</LastName>
                    <ForeName>G Mani</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Symonds</LastName>
                    <ForeName>William T</ForeName>
                    <Initials>WT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Inc., Foster City, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahass</LastName>
                    <ForeName>Ronald G</ForeName>
                    <Initials>RG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Disease Care, Hillsborough, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bennett</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Associates Research Group, San Diego, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobson</LastName>
                    <ForeName>Ira M</ForeName>
                    <Initials>IM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Weill Cornell Medical College, New York, NY.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>05</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Gastroenterol Hepatol. 2015 May;12(5):252</RefSource>
                <PMID Version="1">25895827</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25847509</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.27836</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25659285</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1474-547X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>385</Volume>
                    <Issue>9973</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Mar</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Lancet (London, England)</Title>
                <ISOAbbreviation>Lancet</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1098-106</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(14)62483-1</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(14)62483-1</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although interferon-free regimens are approved for patients co-infected with HIV and genotype-2 or genotype-3 hepatitis C virus (HCV), interferon-based regimens are still an option for those co-infected with HIV and HCV genotypes 1 or 4. These regimens are limited by clinically significant toxic effects and drug interactions with antiretroviral therapy. We aimed to assess the efficacy and safety of an interferon-free, all-oral regimen of sofosbuvir plus ribavirin in patients with HIV and HCV co-infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We did this open-label, non-randomised, uncontrolled, phase 3 study at 45 sites in seven European countries and Australia. We enrolled patients (aged ≥18 years) co-infected with stable HIV and chronic HCV genotypes 1-4, including those with compensated cirrhosis. Once-daily sofosbuvir (400 mg) plus twice-daily ribavirin (1000 mg in patients with bodyweights &lt;75 kg and 1200 mg in those with weights ≥75 kg) was given for 24 weeks to all patients except treatment-naive patients with genotype-2 HCV, who received a 12-week regimen. The primary efficacy endpoint was sustained virological response 12 weeks after treatment. We did analysis by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT01783678.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Feb 7, 2013, and July 29, 2013, we enrolled 275 eligible patients, of whom 262 (95%) completed treatment; 274 patients were included in the final analysis. Overall rates of sustained virological response 12 weeks after treatment were 85% (95% CI 77-91) in patients with genotype-1 HCV, 88% (69-98) in patients with genotype-2 HCV, 89% (81-94) in patients with genotype-3 HCV, and 84% (66-95) in patients with genotype-4 HCV. Response rates in treatment-naive patients with HCV genotypes 2 or 3 (89% [95% CI 67-99] and 91% [81-97], respectively) were similar to those in treatment-experienced patients infected with those genotypes (83% [36-100] and 86% [73-94], respectively). There was no emergence of sofosbuvir-resistance mutations in patients with HCV viral relapse. Six (2%) patients discontinued treatment because of adverse events. The most common adverse events were fatigue, insomnia, asthenia, and headache. Four (1%) patients had serious adverse events regarded as related to study treatment. Additionally, four (1%) patients receiving antiretroviral treatment had a transient HIV viral breakthrough; however, none required changes in antiretroviral regimen.</AbstractText>
                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Sofosbuvir and ribavirin provided high rates of sustained virological response after 12 weeks of treatment in treatment-naive and treatment-experienced patients co-infected with HIV and HCV genotypes 1-4. The characteristics of this interferon-free combination regimen make sofosbuvir plus ribavirin a useful treatment option for this patient population.</AbstractText>
                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Gilead Sciences.</AbstractText>
                <CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Molina</LastName>
                    <ForeName>Jean-Michel</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Paris Diderot, Paris 7 and Department of Infectious Diseases, Saint-Louis Hospital, Paris, France. Electronic address: jean-michel.molina@sls.aphp.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Orkin</LastName>
                    <ForeName>Chloe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barts Health National Health Service Trust, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iser</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Unit, Alfred Hospital, Melbourne, VIC, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zamora</LastName>
                    <ForeName>Francisco-Xavier</ForeName>
                    <Initials>FX</Initials>
                    <AffiliationInfo>
                        <Affiliation>HIV Unit, Internal Medicine Service, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Chelsea and Westminster Hospital, St Stephens Centre, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stephan</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Unit at Medical Department, Hospital of the Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Massetto</LastName>
                    <ForeName>Benedetta</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaggar</LastName>
                    <ForeName>Anuj</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ni</LastName>
                    <ForeName>Liyun</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramanian</LastName>
                    <ForeName>G Mani</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puoti</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, AO Ospedale Niguarda Ca' Granda, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rockstroh</LastName>
                    <ForeName>Jürgen K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Internal Medicine I, University Hospital of Bonn, Bonn, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>PHOTON-2 study team</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01783678</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet</MedlineTA>
            <NlmUniqueID>2985213R</NlmUniqueID>
            <ISSNLinking>0140-6736</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Lancet. 2015 Mar 21;385(9973):1052-4</RefSource>
                <PMID Version="1">25659286</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Cotte</LastName>
                <ForeName>Laurent</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Durant</LastName>
                <ForeName>Jacques</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Girard</LastName>
                <ForeName>Pierre-Marie</ForeName>
                <Initials>PM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Katlama</LastName>
                <ForeName>Christine</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Molina</LastName>
                <ForeName>Jean-Michel</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yazdanpanah</LastName>
                <ForeName>Yazden</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ingiliz</LastName>
                <ForeName>Patrick</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Klinker</LastName>
                <ForeName>Hartwig</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lutz</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mauss</LastName>
                <ForeName>Stefan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Petersen</LastName>
                <ForeName>Jorg</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rockstroh</LastName>
                <ForeName>Jürgen</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stephan</LastName>
                <ForeName>Christoph</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Antinori</LastName>
                <ForeName>Andrea</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chirianni</LastName>
                <ForeName>Antonio</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Di Perri</LastName>
                <ForeName>Giovanni</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lazzarin</LastName>
                <ForeName>Adriano</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maggiolo</LastName>
                <ForeName>Franco</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Puoti</LastName>
                <ForeName>Massimo</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rizzardini</LastName>
                <ForeName>Giuliano</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berenguer</LastName>
                <ForeName>Juan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crespo</LastName>
                <ForeName>Manuel</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gonzalez-Garcia</LastName>
                <ForeName>Juan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mallolas</LastName>
                <ForeName>Josep</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pineda</LastName>
                <ForeName>Juan Antonio</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Quereda</LastName>
                <ForeName>Carmen</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rubio</LastName>
                <ForeName>Rafael</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bell</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bhagani</LastName>
                <ForeName>Sanjay</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cooke</LastName>
                <ForeName>Graeme</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fisher</LastName>
                <ForeName>Martin</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kulasegaram</LastName>
                <ForeName>Ranajababu</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nelson</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Orkin</LastName>
                <ForeName>Chloe</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baker</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bloch</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Iser</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Matthews</LastName>
                <ForeName>Gail</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sasadeusz</LastName>
                <ForeName>Joseph</ForeName>
                <Initials>J</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25659285</ArticleId>
            <ArticleId IdType="pii">S0140-6736(14)62483-1</ArticleId>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)62483-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25614962</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>06</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>61</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1127-35</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.27726</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all-oral regimens requiring 24-week treatment and the addition of ribavirin (RBV). This phase III study (ALLY-3; ClinicalTrials.gov: NCT02032901) evaluated the 12-week regimen of daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus sofosbuvir (SOF; pangenotypic NS5B inhibitor) in patients infected with genotype 3. Patients were either treatment naïve (n = 101) or treatment experienced (n = 51) and received DCV 60 mg plus SOF 400 mg once-daily for 12 weeks. Coprimary endpoints were the proportions of treatment-naïve and treatment-experienced patients achieving a sustained virological response (SVR) at post-treatment week 12 (SVR12). SVR12 rates were 90% (91 of 101) and 86% (44 of 51) in treatment-naïve and treatment-experienced patients, respectively; no virological breakthrough was observed, and ≥99% of patients had a virological response (VR) at the end of treatment. SVR12 rates were higher in patients without cirrhosis (96%; 105 of 109) than in those with cirrhosis (63%; 20 of 32). Five of seven patients who previously failed treatment with an SOF-containing regimen and 2 of 2 who previously failed treatment with an alisporivir-containing regimen achieved SVR12. Baseline characteristics, including gender, age, HCV-RNA levels, and interleukin-28B genotype, did not impact virological outcome. DCV plus SOF was well tolerated; there were no adverse events (AEs) leading to discontinuation and only 1 serious AE on-treatment, which was unrelated to study medications. The few treatment-emergent grade 3/4 laboratory abnormalities that were observed were transient.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A 12-week regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated. Additional evaluation to optimize efficacy in genotype 3-infected patients with cirrhosis is underway.</AbstractText>
                <CopyrightInformation>© 2015 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville, FL.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>James N</ForeName>
                    <Initials>JN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lalezari</LastName>
                    <ForeName>Jacob P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pockros</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gitlin</LastName>
                    <ForeName>Norman</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Freilich</LastName>
                    <ForeName>Bradley F</ForeName>
                    <Initials>BF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Younes</LastName>
                    <ForeName>Ziad H</ForeName>
                    <Initials>ZH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harlan</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghalib</LastName>
                    <ForeName>Reem</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oguchi</LastName>
                    <ForeName>Godson</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thuluvath</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ortiz-Lasanta</LastName>
                    <ForeName>Grisell</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rabinovitz</LastName>
                    <ForeName>Mordechai</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernstein</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bennett</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hawkins</LastName>
                    <ForeName>Trevor</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ravendhran</LastName>
                    <ForeName>Natarajan</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheikh</LastName>
                    <ForeName>Aasim M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varunok</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kowdley</LastName>
                    <ForeName>Kris V</ForeName>
                    <Initials>KV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hennicken</LastName>
                    <ForeName>Delphine</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rana</LastName>
                    <ForeName>Khurram</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Eric A</ForeName>
                    <Initials>EA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>ALLY-3 Study Team</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02032901</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>UL1 TR001427</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Turk J Gastroenterol. 2016 Jan;27(1):89-90</RefSource>
                <PMID Version="1">26728866</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Gastroenterology. 2016 May;150(5):1241-3</RefSource>
                <PMID Version="1">27018182</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25614962</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.27726</ArticleId>
            <ArticleId IdType="pmc">PMC4409820</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1993-2001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24795201</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2009 Oct;51(4):655-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19665246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Virol. 2010 Oct;82(10):1647-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20827760</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2011 Jul;31 Suppl 2:1-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21651699</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2011 Oct;18(10):e516-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21914071</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Jan;57(1):611-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23089758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Virol. 2013 May;57(1):13-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23384816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1867-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Virol. 2013 Oct;3(5):514-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2014 Feb;34 Suppl 1:18-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24373074</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Jan 16;370(3):211-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24428467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA Intern Med. 2014 Feb 1;174(2):204-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24193887</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25467591</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1474-547X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>385</Volume>
                    <Issue>9973</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Mar</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Lancet (London, England)</Title>
                <ISOAbbreviation>Lancet</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1075-86</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(14)61795-5</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(14)61795-5</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is a high medical need for an interferon-free, all-oral, short-duration therapy for hepatitis C virus (HCV) that is highly effective across diverse patient populations, including patients with cirrhosis or previous null response to pegylated interferon (peginterferon) plus ribavirin (PR-null responders). We aimed to assess the efficacy, safety, and effective treatment duration of grazoprevir (an HCV NS3/4A protease inhibitor) combined with elbasvir (an HCV NS5A inhibitor) with or without ribavirin in patients with HCV genotype 1 infection with baseline characteristics of poor response.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The C-WORTHY trial is a randomised, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin; here we report findings for two cohorts of previously untreated patients with cirrhosis (cohort 1) and those with previous PR-null response with or without cirrhosis (cohort 2) enrolled in part B of the study. Eligible patients were adults aged 18 years or older with chronic HCV genotype 1 infection and HCV RNA concentrations of 10 000 IU/mL or higher in peripheral blood. We randomly assigned patients to receive grazoprevir (100 mg daily) and elbasvir (50 mg daily) with or without ribavirin for 12 or 18 weeks. Randomisation was done centrally with an interactive voice response system; patients and study investigators were masked to treatment duration up to week 12 but not to treatment allocation. The primary endpoint was the proportion of patients achieving HCV RNA less than 25 IU/mL at 12 weeks after end of treatment (SVR12), assessed by COBAS TaqMan version 2.0. This study is registered with ClinicalTrials.gov, number NCT01717326.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">We describe findings for 253 patients enrolled in cohort 1 (n=123) or cohort 2 (n=130). In cohort 1, we randomly assigned 60 patients to the 12-week regimen (31 with ribavirin and 29 with no ribavirin) and 63 to the 18-week regimen (32 with ribavirin and 31 with no ribavirin); in cohort 2, we randomly assigned 65 patients to the 12-week regimen (32 with ribavirin and 33 with no ribavirin) and 65 to the 18-week regimen (33 with ribavirin and 32 with no ribavirin. High SVR12 rates were achieved irrespective of the use of ribavirin or extension of the treatment duration from 12 to 18 weeks; SVR12 rates ranged from 90% (95% CI 74-98; 28/31; cohort 1, 12 weeks, ribavirin-containing) to 100% (95% CI 89-100; 33/33; cohort 2, 18 weeks, ribavirin-containing). Among patients treated for 12 weeks with grazoprevir plus elbasvir without ribavirin, 97% (95% CI 82-100, 28/29) of patients in cohort 1 and 91% (76-98, 30/33) of patients in cohort 2 achieved SVR12. Adverse events reported in more than 10% of patients were fatigue (66 patients, 26% [95% CI 21-32]), headache (58 patients, 23% [95% CI 18-29]), and asthenia (35 patients, 14% [95% CI 10-19]).</AbstractText>
                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Treatment with grazoprevir plus elbasvir, both with and without ribavirin and for both 12 and 18 weeks' treatment duration, showed high rates of efficacy in previously untreated patients with cirrhosis and previous PR-null responders with and without cirrhosis. These results support the phase 3 development of grazoprevir plus elbasvir.</AbstractText>
                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Merck &amp; Co, Inc.</AbstractText>
                <CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA. Electronic address: lawitz@txliver.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Auckland Clinical Studies, Grafton, Auckland, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pearlman</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Atlanta Medical Center, Emory School of Medicine and Medical College of Georgia, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tam</LastName>
                    <ForeName>Edward</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>LAIR Centre, Vancouver, BC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghesquiere</LastName>
                    <ForeName>Wayne</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vancouver Island Health Authority and University of British Columbia, Victoria, BC, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guyader</LastName>
                    <ForeName>Dominique</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology, Rennes University Hospital, Rennes 1 University, Rennes, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alric</LastName>
                    <ForeName>Laurent</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>CHU Purpan, Digest Dept, UMR 152, IRD Toulouse 3 University, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bronowicki</LastName>
                    <ForeName>Jean-Pierre</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U954, Centre Hospitalier Universitaire de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lester</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California, Davis Medical Center, Sacramento, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sievert</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Monash University and Monash Health, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghalib</LastName>
                    <ForeName>Reem</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Clinical Research Institute, Arlington, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balart</LastName>
                    <ForeName>Luis</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tulane University School of Medicine, New Orleans, LA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sund</LastName>
                    <ForeName>Fredrik</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Uppsala University, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lagging</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biomedicine, University of Gothenburg, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dutko</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaughnessy</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Peggy</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haber</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01717326</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet</MedlineTA>
            <NlmUniqueID>2985213R</NlmUniqueID>
            <ISSNLinking>0140-6736</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9008-11-1</RegistryNumber>
                <NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Lancet. 2015 Mar 21;385(9973):1050-2</RefSource>
                <PMID Version="1">25468162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>Lancet. 2015 Mar 21;385(9973):1074</RefSource>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25467591</ArticleId>
            <ArticleId IdType="pii">S0140-6736(14)61795-5</ArticleId>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)61795-5</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25467560</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1474-547X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>385</Volume>
                    <Issue>9973</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Mar</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Lancet (London, England)</Title>
                <ISOAbbreviation>Lancet</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1087-97</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(14)61793-1</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(14)61793-1</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Both hepatitis C virus (HCV) mono-infected and HIV/HCV co-infected patients are in need of safe, effective, all-oral HCV regimens. In a phase 2 study we aimed to assess the efficacy and safety of grazoprevir (MK-5172; HCV NS3/4A protease inhibitor) and two doses of elbasvir (MK-8742; HCV NS5A inhibitor) in patients with HCV mono-infection and HIV/HCV co-infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The C-WORTHY study is a phase 2, multicentre, randomised controlled trial of grazoprevir plus elbasvir with or without ribavirin in patients with HCV; here, we report findings for previously untreated (genotype 1) patients without cirrhosis who were HCV mono-infected or HIV/HCV co-infected. Eligible patients were previously untreated adults aged 18 years or older with chronic HCV genoype 1 infection and HCV RNA at least 10 000 IU/mL in peripheral blood without evidence of cirrhosis, hepatocellular carcinoma, or decompensated liver disease. In part A of the study we randomly assigned HCV-mono-infected patients to receive 12 weeks of grazoprevir (100 mg) plus elbasvir (20 mg or 50 mg) with or without ribavirin (arms A1-3); in part B we assigned HCV-mono-infected patients to 8 or 12 weeks of grazoprevir (100 mg) plus elbasvir (50 mg) with or without ribavirin (arms B1-3) and HIV/HCV co-infected patients to 12 weeks of therapy with or without ribavirin. The primary endpoint was the proportion of patients achieving HCV RNA less than 25 IU/mL 12 weeks after end of treatment (SVR12). Randomisation was by presence or absence of ribavirin, 8 or 12 weeks of treatment, and dosage of elbasvir. Patients were stratified by gentoype 1a versus 1b. The patients, investigators, and study site personnel were masked to treatment group assignements but the funder was not. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT01717326.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">218 patients with HCV mono-infection (n=159) and HIV/HCV co-infection (n=59) were enrolled. SVR12 for patients treated for 12 weeks with or without ribavirin ranged from 93-98% in mono-infected and 87-97% in co-infected patients. SVR12 rates in mono-infected and co-infected patients treated for 12 weeks without ribavirin were 98% (95% CI 88-100; 43/44) and 87% (95% CI 69-96; 26/30), respectively, and with ribavirin were 93% (95% CI 85-97; 79/85) and 97% (95% CI 82-100; 28/29), respectively. Among mono-infected patients with genotype 1a infection treated for 8 weeks, SVR12 was 80% (95% CI 61-92; 24/30). Five of six patients who discontinued early for reasons other than virological failure had HCV RNA less than 25 IU/mL at their last study visit. Virological failure among patients treated for 12 weeks occurred in seven patients (7/188, 4%) and was associated with emergence of resistance-associated variants to one or both drugs. The safety profile of grazoprevir plus elbasvir with or without ribavirin was similar in mono-infected and co-infected patients. No patient discontinued due to an adverse event or laboratory abnormality. The most common adverse events were fatigue (51 patients, 23%), headache (44, 20%), nausea (32, 15%), and diarrhoea (21, 10%).</AbstractText>
                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Once-daily grazoprevir plus elbasvir with or without ribavirin for 12 weeks in previously untreated HCV-mono-infected and HIV/HCV-co-infected patients without cirrhosis achieved SVR12 rates of 87-98%. These results support the ongoing phase 3 development of grazoprevir plus elbasvir.</AbstractText>
                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Merck &amp; Co, Inc.</AbstractText>
                <CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sulkowski</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: msulkowski@jhmi.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hezode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gerstoft</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vierling</LastName>
                    <ForeName>John M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor College of Medicine, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mallolas</LastName>
                    <ForeName>Josep</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases Service, Hospital Clínic-Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Paris Descartes, Hospital Cochin, APHP and INSERM, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kugelmas</LastName>
                    <ForeName>Marcelo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>South Denver Gastroenterology, Englewood, CO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murillo</LastName>
                    <ForeName>Abel</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Advanced Medical &amp; Pain Management Research Clinic, Miami, FL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weis</LastName>
                    <ForeName>Nina</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahass</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>ID Care, Hillsborough, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibolet</LastName>
                    <ForeName>Oren</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, Tel-Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serfaty</LastName>
                    <ForeName>Lawrence</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Saint Antoine, APHP and INSERM UMR_938, Université Pierre &amp; Marie Curie, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourliere</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'hépato-gastroentérologie, Hôpital Saint-Joseph, Marseille, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeJesus</LastName>
                    <ForeName>Edwin</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Orlando Immunology Center, Orlando, FL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zuckerman</LastName>
                    <ForeName>Eli</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, Carmel Medical Center, Technion Faculty of Medicine, Haifa, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dutko</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaughnessy</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Peggy</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barr</LastName>
                    <ForeName>Eliav</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haber</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01717326</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lancet</MedlineTA>
            <NlmUniqueID>2985213R</NlmUniqueID>
            <ISSNLinking>0140-6736</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Lancet. 2015 Mar 21;385(9973):1050-2</RefSource>
                <PMID Version="1">25468162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Ann Transl Med. 2016 Oct;4(Suppl 1):S12</RefSource>
                <PMID Version="1">27867980</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25467560</ArticleId>
            <ArticleId IdType="pii">S0140-6736(14)61793-1</ArticleId>
            <ArticleId IdType="doi">10.1016/S0140-6736(14)61793-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25322962</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>61</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>769-75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.27567</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment-experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates. We assessed the efficacy and safety of sofosbuvir plus peginterferon and ribavirin (SOF+Peg-IFN+RBV) administered for 12 weeks to treatment-experienced patients with HCV genotypes 2 and 3, with and without cirrhosis. We enrolled 47 patients in this open-label, nonrandomized, uncontrolled phase 2 study. The primary endpoint was the proportion of patients with SVR at 12 weeks after cessation of study treatment (SVR12). The overall rate of SVR12 was 89% (95% confidence interval [CI]: 77-97). Rates of SVR12 were higher in patients with genotype 2 than in those with genotype 3, 96% (95% CI: 78-100) and 83% (95% CI: 62-95), respectively. Rates of SVR12 were similar in patients with and without cirrhosis: for genotype 2, 93% of patients with cirrhosis and 100% of patients without cirrhosis achieved SVR12, and for genotype 3, the SVR12 rate was 83% in patients both with and without cirrhosis. One patient discontinued study treatment because of an adverse event and four patients experienced serious adverse events. The most common adverse events were influenza-like illness, fatigue, anemia, and neutropenia.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In treatment-experienced patients with HCV genotypes 2 and 3, 12-week administration of SOF+Peg-IFN+RBV provided high SVR rates, irrespective of cirrhosis status. No safety concerns were identified.</AbstractText>
                <CopyrightInformation>© 2014 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, San Antonio, TX; University of Texas Health Science Center, San Antonio, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poordad</LastName>
                    <ForeName>Fred</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyland</LastName>
                    <ForeName>Robert H</ForeName>
                    <Initials>RH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>An</LastName>
                    <ForeName>Di</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Symonds</LastName>
                    <ForeName>William T</ForeName>
                    <Initials>WT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Membreno</LastName>
                    <ForeName>Fernando E</ForeName>
                    <Initials>FE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q46947FE7K</RegistryNumber>
                <NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25322962</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.27567</ArticleId>
            <ArticleId IdType="pmc">PMC4365682</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2002 Sep 26;347(13):975-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12324553</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Nov;61(1 Suppl):S45-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25086286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2009 Apr;49(4):1335-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19330875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2009 May;136(5):1618-28.e2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19208349</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2010 Oct;65(10):2063-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20688770</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Pharmacol Ther. 2012 Sep;92(3):294-305</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22850602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Top Antivir Med. 2012 Oct-Nov;20(4):139-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23154254</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 Jan 3;368(1):34-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23281974</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2013 May;13(5):401-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23499158</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1867-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 May 16;368(20):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23607594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23395996</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2013 Oct;20(10):669-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24010641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Feb;60(2):392-420</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24331294</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 May 22;370(21):1993-2001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24795201</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jun;59(6):2403-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24155107</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2014 Jul;60(1):98-105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24615981</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2014 Dec 15;59(12):1666-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25266287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2007 Jul 12;357(2):124-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17625124</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25266287</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6591</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>59</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Dec</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
                <ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1666-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciu697</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sofosbuvir is a chain-terminating nucleotide analogue inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase that is efficacious in subjects with HCV genotype 1-6 infection. Sofosbuvir resistance is primarily conferred by the S282T substitution in NS5B.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">NS5B sequencing and susceptibility testing of HCV from subjects infected with genotypes 1-6 who participated in phase 2 and 3 sofosbuvir clinical trials was performed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">No NS5B variants present at baseline among 1645 sofosbuvir-treated subjects were associated with treatment failure; sofosbuvir susceptibility was within 2-fold of reference. Among 282 subjects who did not achieve sustained virologic response, no novel sofosbuvir resistance-associated variants were identified, and the NS5B changes observed did not confer significant reductions in sofosbuvir susceptibility. In 1 subject with S282T observed at relapse 4 weeks after sofosbuvir monotherapy, the resistant variant (13.5-fold reduced sofosbuvir susceptibility, replication capacity &lt;2% of control) became undetectable by deep sequencing 12 weeks after treatment. L159F and V321A were identified as treatment-emergent variants but did not confer resistance to sofosbuvir in the replicon system.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data demonstrate a uniform susceptibility of subject-derived HCV to sofosbuvir, and also show that selection of sofosbuvir-resistant HCV is exceedingly rare and is associated with a significant reduction in viral fitness.</AbstractText>
                <CopyrightInformation>© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia S</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvory-Sobol</LastName>
                    <ForeName>Hadas</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parkin</LastName>
                    <ForeName>Neil</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Data First Consulting Inc, Belmont, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hebner</LastName>
                    <ForeName>Christy</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gontcharova</LastName>
                    <ForeName>Viktoria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Ross</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ouyang</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Simin</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ku</LastName>
                    <ForeName>Karin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiu</LastName>
                    <ForeName>Sophia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>Edward</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Auckland, Auckland City Hospital, New Zealand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobson</LastName>
                    <ForeName>Ira M</ForeName>
                    <Initials>IM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Weill Cornell Medical College, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida, Gainesville.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Texas Liver Institute, San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wyles</LastName>
                    <ForeName>David L</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Infectious Diseases, University of California, San Diego.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bekele</LastName>
                    <ForeName>Neby</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Symonds</LastName>
                    <ForeName>William T</ForeName>
                    <Initials>WT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mo</LastName>
                    <ForeName>Hongmei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gilead Sciences, Foster City.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>UL1 TR000064</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Infect Dis</MedlineTA>
            <NlmUniqueID>9203213</NlmUniqueID>
            <ISSNLinking>1058-4838</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GS-7977</Keyword>
            <Keyword MajorTopicYN="N">HCV</Keyword>
            <Keyword MajorTopicYN="N">NS5B polymerase</Keyword>
            <Keyword MajorTopicYN="N">antiviral resistance</Keyword>
            <Keyword MajorTopicYN="N">sofosbuvir</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25266287</ArticleId>
            <ArticleId IdType="pii">ciu697</ArticleId>
            <ArticleId IdType="doi">10.1093/cid/ciu697</ArticleId>
            <ArticleId IdType="pmc">PMC6433438</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24936600</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>58</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5155-63</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.02788-14</ELocationID>
            <Abstract>
                <AbstractText>A comparison of the daclatasvir (DCV [BMS-790052]) resistance barrier on authentic or hybrid replicons containing NS5A from hepatitis C virus (HCV) genotypes 1 to 6 (GT-1 to -6) was completed using a replicon elimination assay. The data indicated that genotype 1b (GT-1b) has the highest relative resistance barrier and genotype 2a (GT-2a M31) has the lowest. The rank order of resistance barriers to DCV was 1b&gt;4a≥5a&gt;6a≅1a&gt;2a JFH&gt;3a&gt;2a M31. Importantly, DCV in combination with a protease inhibitor (PI) eliminated GT-2a M31 replicon RNA at a clinically relevant concentration. Previously, we reported the antiviral activity and resistance profiles of DCV on HCV genotypes 1 to 4 evaluated in the replicon system. Here, we report the antiviral activity and resistance profiles of DCV against hybrid replicons with NS5A sequences derived from HCV GT-5a and GT-6a clinical isolates. DCV was effective against both GT-5a and -6a hybrid replicon cell lines (50% effective concentrations [EC50s] ranging from 3 to 7 pM for GT-5a, and 74 pM for GT-6a). Resistance selection identified amino acid substitutions in the N-terminal domain of NS5A. For GT-5a, L31F and L31V, alone or in combination with K56R, were the major resistance variants (EC50s ranging from 2 to 40 nM). In GT-6a, Q24H, L31M, P32L/S, and T58A/S were identified as resistance variants (EC50s ranging from 2 to 250 nM). The in vitro data suggest that DCV has the potential to be an effective agent for HCV genotypes 1 to 6 when used in combination therapy.</AbstractText>
                <CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA chunfu.wang@bms.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Lingling</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Boyle</LastName>
                    <ForeName>Donald R</ForeName>
                    <Initials>DR</Initials>
                    <Suffix>2nd</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jin-Hua</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rigat</LastName>
                    <ForeName>Karen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nower</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Applied Genomics, Bristol-Myers Squibb Research and Development, Hopewell, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kienzle</LastName>
                    <ForeName>Bernadette</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Applied Genomics, Bristol-Myers Squibb Research and Development, Hopewell, New Jersey, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roberts</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24936600</ArticleId>
            <ArticleId IdType="pii">AAC.02788-14</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.02788-14</ArticleId>
            <ArticleId IdType="pmc">PMC4135806</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Gen Virol. 2004 Nov;85(Pt 11):3173-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15483230</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Can J Gastroenterol. 2013 Jan;27(1):e8-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23378985</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 1999 Sep 15;262(1):250-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10489358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17142229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 Jun;83(11):5760-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19321623</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2010 Dec;17(12):825-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20723038</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2011 Mar;140(3):1032-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21111742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Mar;57(3):1291-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23274664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 May;57(5):2054-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23403428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol Methods. 2013 Oct;193(1):68-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23684844</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 2013 Sep;444(1-2):343-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23896639</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2013 Sep;58(3):902-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23504694</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Jan 16;370(3):211-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24428467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2014 Mar;146(3):812-821.e4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24262279</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2014;4:4765</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24755925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Jul;85(13):6353-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21507963</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Jul;85(14):7312-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21593143</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1956-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21837752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 19;366(3):216-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22256805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22203595</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22214777</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Mar;55(3):742-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21987462</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Jun;55(6):1692-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22234905</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22615282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2012 Sep;12(9):671-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22714001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 Jan;57(1):611-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23089758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 1995 Jun;33(6):1679-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7650216</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24795201</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>07</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>370</Volume>
                    <Issue>21</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sofosbuvir and ribavirin in HCV genotypes 2 and 3.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1993-2001</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1316145</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a study involving patients with HCV genotype 2 or 3 infection, some of whom had undergone previous treatment with an interferon-based regimen. We randomly assigned 91 patients with HCV genotype 2 infection and 328 with HCV genotype 3 infection, in a 4:1 ratio, to receive sofosbuvir-ribavirin or placebo for 12 weeks. On the basis of emerging data from phase 3 trials indicating that patients with HCV genotype 3 infection had higher response rates when they were treated for 16 weeks, as compared with 12 weeks, the study was unblinded, treatment for all patients with genotype 3 infection was extended to 24 weeks, the placebo group was terminated, and the goals of the study were redefined to be descriptive and not include hypothesis testing. The primary end point was a sustained virologic response at 12 weeks after the end of therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 419 patients who were enrolled and treated, 21% had cirrhosis and 58% had received previous interferon-based treatment. The criterion for a sustained virologic response was met in 68 of 73 patients (93%; 95% confidence interval [CI], 85 to 98) with HCV genotype 2 infection who were treated for 12 weeks and in 213 of 250 patients (85%; 95% CI, 80 to 89) with HCV genotype 3 infection who were treated for 24 weeks. Among patients with HCV genotype 3 infection, response rates were 91% and 68% among those without and those with cirrhosis, respectively. The most common adverse events were headache, fatigue, and pruritus.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Therapy with sofosbuvir-ribavirin for 12 weeks in patients with HCV genotype 2 infection and for 24 weeks in patients with HCV genotype 3 infection resulted in high rates of sustained virologic response. (Funded by Gilead Sciences; VALENCE ClinicalTrials.gov number, NCT01682720.).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zeuzem</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany (S.Z.); Royal Free Hospital and University College London School of Medicine, London (G.M.D.); Tartu University Hospital, Tartu, Estonia (R.S.); Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy (A.M.); Medical University of Bialystok, Bialystok, Poland (R.F.); Gilead Sciences, Foster City, CA (R.H.H., A.I., E.S., D.M.B., W.T.S., G.M.S., J.G.M.); Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm (O.W.); Academic Medical Center, Amsterdam (H.W.R.); Medical University of Vienna, Vienna (P.F.); Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est, INSERM Unité 955, Créteil, France (C.H.); and Hospital Universitario Val d'Hebron, Barcelona (R.E.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dusheiko</LastName>
                    <ForeName>Geoffrey M</ForeName>
                    <Initials>GM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salupere</LastName>
                    <ForeName>Riina</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mangia</LastName>
                    <ForeName>Alessandra</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flisiak</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyland</LastName>
                    <ForeName>Robert H</ForeName>
                    <Initials>RH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Illeperuma</LastName>
                    <ForeName>Ari</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svarovskaia</LastName>
                    <ForeName>Evguenia</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brainard</LastName>
                    <ForeName>Diana M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Symonds</LastName>
                    <ForeName>William T</ForeName>
                    <Initials>WT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramanian</LastName>
                    <ForeName>G Mani</ForeName>
                    <Initials>GM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McHutchison</LastName>
                    <ForeName>John G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weiland</LastName>
                    <ForeName>Ola</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reesink</LastName>
                    <ForeName>Hendrik W</ForeName>
                    <Initials>HW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferenci</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Esteban</LastName>
                    <ForeName>Rafael</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>VALENCE Investigators</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01682720</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Ferenci</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gschwantler</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stauber</LastName>
                <ForeName>Rudolf E</ForeName>
                <Initials>RE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Salupere</LastName>
                <ForeName>Riina</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zilmer</LastName>
                <ForeName>Kai</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abergel</LastName>
                <ForeName>Armando</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bourlière</LastName>
                <ForeName>Marc</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bronowicki</LastName>
                <ForeName>Jean-Pierre</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Lédinghen</LastName>
                <ForeName>Victor</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Guyader</LastName>
                <ForeName>Dominique</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Habersetzer</LastName>
                <ForeName>François</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hézode</LastName>
                <ForeName>Christophe</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Larrey</LastName>
                <ForeName>Dominque</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marcellin</LastName>
                <ForeName>Patrick</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathurin</LastName>
                <ForeName>Phillipe</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pol</LastName>
                <ForeName>Stanislas</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ratziu</LastName>
                <ForeName>Vlad</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Serfaty</LastName>
                <ForeName>Lawrence</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tran</LastName>
                <ForeName>Albert</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zarski</LastName>
                <ForeName>Jean-Pierre</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berg</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Christensen</LastName>
                <ForeName>Stefan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eisenbach</LastName>
                <ForeName>Christoph</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grüner</LastName>
                <ForeName>Norbert</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Häussinger</LastName>
                <ForeName>Dieter</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heyne</LastName>
                <ForeName>Renate</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hinrichsen</LastName>
                <ForeName>Holger</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hüppe</LastName>
                <ForeName>Dietrich</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manns</LastName>
                <ForeName>Michael P</ForeName>
                <Initials>MP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Petersen</LastName>
                <ForeName>Jörg</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Roessle</LastName>
                <ForeName>Martin</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schulze-zur-Wisch</LastName>
                <ForeName>Julian</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spengler</LastName>
                <ForeName>Ulrich</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zeuzem</LastName>
                <ForeName>Stefan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Alberti</LastName>
                <ForeName>Alfredo</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Andreone</LastName>
                <ForeName>Pietro</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Angelico</LastName>
                <ForeName>Mario</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cassola</LastName>
                <ForeName>Giovanni</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Colombo</LastName>
                <ForeName>Massimo</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Craxì</LastName>
                <ForeName>Antonio</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mangia</LastName>
                <ForeName>Alessandra</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mazzota</LastName>
                <ForeName>Francesco</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Orlandini</LastName>
                <ForeName>Alessandra</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Puoti</LastName>
                <ForeName>Massimo</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rizzetto</LastName>
                <ForeName>Mario</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Comandini</LastName>
                <ForeName>Ubaldo Visco</ForeName>
                <Initials>UV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Drenth</LastName>
                <ForeName>Joost</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>de Knegt</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reesink</LastName>
                <ForeName>Henk</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>van Hoek</LastName>
                <ForeName>Bart</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Flisiak</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Horban</LastName>
                <ForeName>Andrzej</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jablkowski</LastName>
                <ForeName>Maciej</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Krzysztof</LastName>
                <ForeName>Simon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Andrade</LastName>
                <ForeName>Raul</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Diago</LastName>
                <ForeName>Moises</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Calleja Panero</LastName>
                <ForeName>José Luis</ForeName>
                <Initials>JL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Esteban</LastName>
                <ForeName>Rafael</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Forns</LastName>
                <ForeName>Xavier</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crespo García</LastName>
                <ForeName>Javier</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>García-Samaniego</LastName>
                <ForeName>Javier</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Olveira</LastName>
                <ForeName>Antonio</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Romero-Gómez</LastName>
                <ForeName>Manuel</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Flamholc</LastName>
                <ForeName>Leo</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Norrgren</LastName>
                <ForeName>Hans</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weiland</LastName>
                <ForeName>Ola</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wejstål</LastName>
                <ForeName>Rune</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Agarwal</LastName>
                <ForeName>Kosh</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brown</LastName>
                <ForeName>Ashley</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dusheiko</LastName>
                <ForeName>Geoff</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ustianowski</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Foster</LastName>
                <ForeName>Graham</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wright</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>Fiona</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nelson</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mutimer</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ryder</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24795201</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1316145</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24448487</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>07</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2040-2058</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Antiviral therapy</Title>
                <ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.</ArticleTitle>
            <Pagination>
                <MedlinePgn>479-90</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP2729</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Daclatasvir (DCV; BMS-790052) is a picomolar inhibitor of HCV non-structural protein 5A (NS5A) and has demonstrated efficacy in patients chronically infected with HCV.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In the double-blind, randomized studies AI444021 and AI444022, 71 Japanese patients chronically infected with HCV genotype 1 (predominantly genotype 1b) received DCV (10 mg or 60 mg) plus peginterferon alfa-2b or alfa-2a and ribavirin. Virological failure occurred in 14% (5/36) of treatment-naive patients and 54% (19/35) of prior alfa/ribavirin non-responders. Resistance testing was performed on baseline samples and samples with HCV RNA≥1,000 IU/ml at week 1 through post-treatment week 24.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline NS5A resistance-associated polymorphisms had less impact on virological response rates than IL28B genotype. All patients with virological failure had NS5A DCV-resistant variants at the time of failure. The predominant NS5A variants were L31V/M/I plus Y93H; this combination was detected in 100% (5/5) of treatment-naive patients and 74% (14/19) of non-responders with failure. Emergent resistance variants in prior non-responders (four viral breakthroughs, one relapse) were more varied with novel combinations such as L31F-ΔP32 and L28M-R30Q-A92K detected. Significant loss in DCV antiviral activity was generally only seen with ≥ two resistance-associated NS5A substitutions. All DCV-resistant variants were still detected at end of study.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Virological failure in HCV genotype 1b treatment-naive Japanese patients receiving DCV plus alfa-2a/ribavirin or alfa-2b/ribavirin was associated with enrichment of NS5A resistance variants L31V/M-Y93H. In prior non-responders, emergent variants associated with failure also included NS5A-A92K or NS5A-ΔP32. As with L31-Y93 variants, these variants persisted.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT, USA. fiona.mcphee@bms.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernandez</LastName>
                    <ForeName>Dennis</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Nannan</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueland</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monikowski</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chayama</LastName>
                    <ForeName>Kazuaki</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toyota</LastName>
                    <ForeName>Joji</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Izumi</LastName>
                    <ForeName>Namiki</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yokosuka</LastName>
                    <ForeName>Osamu</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawada</LastName>
                    <ForeName>Norifumi</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osaki</LastName>
                    <ForeName>Yukio</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Eric A</ForeName>
                    <Initials>EA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>Hideaki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ishikawa</LastName>
                    <ForeName>Hiroki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumada</LastName>
                    <ForeName>Hiromitsu</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>01</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Antivir Ther</MedlineTA>
            <NlmUniqueID>9815705</NlmUniqueID>
            <ISSNLinking>1359-6535</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C471044">IL28B protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G8RGG88B68</RegistryNumber>
                <NameOfSubstance UI="C417083">peginterferon alfa-2b</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24448487</ArticleId>
            <ArticleId IdType="doi">10.3851/IMP2729</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24444658</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-0641</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>60</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hepatology</Title>
                <ISOAbbreviation>J. Hepatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.</ArticleTitle>
            <Pagination>
                <MedlinePgn>490-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhep.2013.10.019</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0168-8278(13)00744-7</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Patients with chronic hepatitis C virus (HCV) infection and prior null response (&lt;2 log HCV RNA decline after ⩾ 12 weeks of PegIFN/RBV) have limited options. We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In this randomized, phase 2a, open-label, 24-week treatment study, 101 patients received daclatasvir (60 mg) once-daily. In addition, 38 genotype 1b patients received asunaprevir (200mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3). The primary endpoint was undetectable HCV RNA 12 weeks post-treatment (sustained virologic response, SVR12).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Across all groups, mean HCV RNA was ⩾ 6 log IU/ml, and 99% of patients had a non-CC IL28B genotype. SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2). In B3, most genotype 1a patients experienced virologic breakthrough. The most common adverse events were headache, diarrhea, and asthenia. Grade 3-4 aminotransferase elevations were infrequent and not treatment-limiting.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients. Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.</AbstractText>
                <CopyrightInformation>Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lok</LastName>
                    <ForeName>Anna S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Electronic address: aslok@med.umich.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gardiner</LastName>
                    <ForeName>David F</ForeName>
                    <Initials>DF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Hopewell, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hézode</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Texas Liver Institute, University of Texas Health Sciences Center, San Antonio, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourlière</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Saint-Joseph, Marseille, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Everson</LastName>
                    <ForeName>Gregory T</ForeName>
                    <Initials>GT</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Colorado Denver, Aurora, CO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marcellin</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Beaujon, Clichy, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rodriguez-Torres</LastName>
                    <ForeName>Maribel</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fundación de Investigación, San Juan, PR, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pol</LastName>
                    <ForeName>Stanislas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Cochin, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serfaty</LastName>
                    <ForeName>Lawrence</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Saint-Antoine, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eley</LastName>
                    <ForeName>Timothy</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Hopewell, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Shu-Pang</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jianling</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wind-Rotolo</LastName>
                    <ForeName>Megan</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Wallingford, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grasela</LastName>
                    <ForeName>Dennis M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Hopewell, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pasquinelli</LastName>
                    <ForeName>Claudio</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, Hopewell, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>UL1RR024986</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Hepatol</MedlineTA>
            <NlmUniqueID>8503886</NlmUniqueID>
            <ISSNLinking>0168-8278</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G8RGG88B68</RegistryNumber>
                <NameOfSubstance UI="C417083">peginterferon alfa-2b</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S9X0KRJ00S</RegistryNumber>
                <NameOfSubstance UI="C571889">asunaprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Hepatol. 2014 Mar;60(3):471-2</RefSource>
                <PMID Version="1">24333649</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ALT</Keyword>
            <Keyword MajorTopicYN="N">AST</Keyword>
            <Keyword MajorTopicYN="N">DAA</Keyword>
            <Keyword MajorTopicYN="N">Direct-acting antiviral agents</Keyword>
            <Keyword MajorTopicYN="N">HCV</Keyword>
            <Keyword MajorTopicYN="N">HCV NS5A inhibitor</Keyword>
            <Keyword MajorTopicYN="N">Hepatitis C treatment</Keyword>
            <Keyword MajorTopicYN="N">LLOQ</Keyword>
            <Keyword MajorTopicYN="N">LOD</Keyword>
            <Keyword MajorTopicYN="N">Non-responders</Keyword>
            <Keyword MajorTopicYN="N">PegIFNα</Keyword>
            <Keyword MajorTopicYN="N">Protease inhibitor</Keyword>
            <Keyword MajorTopicYN="N">QUAD</Keyword>
            <Keyword MajorTopicYN="N">RBV</Keyword>
            <Keyword MajorTopicYN="N">SNP</Keyword>
            <Keyword MajorTopicYN="N">SVR</Keyword>
            <Keyword MajorTopicYN="N">SVR(12)</Keyword>
            <Keyword MajorTopicYN="N">SVR(24)</Keyword>
            <Keyword MajorTopicYN="N">SVR(4)</Keyword>
            <Keyword MajorTopicYN="N">Sustained virologic response</Keyword>
            <Keyword MajorTopicYN="N">alanine aminotransferase</Keyword>
            <Keyword MajorTopicYN="N">aspartate aminotransferase</Keyword>
            <Keyword MajorTopicYN="N">direct-acting antiviral</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="N">limit of detection</Keyword>
            <Keyword MajorTopicYN="N">lower limit of quantification</Keyword>
            <Keyword MajorTopicYN="N">pegylated interferon alfa-2a</Keyword>
            <Keyword MajorTopicYN="N">quadruple</Keyword>
            <Keyword MajorTopicYN="N">ribavirin</Keyword>
            <Keyword MajorTopicYN="N">single nucleotide polymorphism</Keyword>
            <Keyword MajorTopicYN="N">sustained virologic response</Keyword>
            <Keyword MajorTopicYN="N">sustained virologic response at 12weeks post-treatment</Keyword>
            <Keyword MajorTopicYN="N">sustained virologic response at 24weeks post-treatment</Keyword>
            <Keyword MajorTopicYN="N">sustained virologic response at 4weeks post-treatment</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24444658</ArticleId>
            <ArticleId IdType="pii">S0168-8278(13)00744-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhep.2013.10.019</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24154738</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6613</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>209</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Mar</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>668-75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jit562</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Serum HCV RNA from patients who experienced viral breakthrough, partial response, or nonresponse in 2 clinical trials in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by population and clonal sequence analysis as well as phenotypic assay for assessment of in vivo mericitabine resistance.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 405 patients treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, virologic breakthrough or nonresponse were not observed; 12 patients experienced a partial response. The NS5B S282T resistance mutation was not observed in any patient. A number of treatment-associated NS5B changes were observed and characterized. A novel double mutant (L159F/L320F) with impaired replication capacity was detected in one HCV genotype 1b-infected patient. Introduction of double mutant L159F/L320F into genotype 1a (H77) and 1b (Con-1) replicons, respectively, increased the EC50 for mericitabine by 3.1- and 5.5-fold and the EC90 by 3.1- and 8.9-fold. The double mutant also decreased susceptibility to sofosbuvir (GS-7977) and GS-938 but not setrobuvir, relative to wild-type.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A novel and replication-deficient double mutation (L159F/L320F) confers low-level resistance to mericitabine and cross-resistance to both sofosbuvir and GS-938.</AbstractText>
                <AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT00869661, NCT01057667.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tong</LastName>
                    <ForeName>Xiao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hoffmann-La Roche Inc, Nutley, New Jersey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Le Pogam</LastName>
                    <ForeName>Sophie</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Lewyn</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haines</LastName>
                    <ForeName>Kristin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piso</LastName>
                    <ForeName>Katherine</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baronas</LastName>
                    <ForeName>Victoria</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Jun-Mei</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>So</LastName>
                    <ForeName>Sung-Sau</ForeName>
                    <Initials>SS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klumpp</LastName>
                    <ForeName>Klaus</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nájera</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00869661</AccessionNumber>
                        <AccessionNumber>NCT01057667</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C552098">2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0W860991D6</RegistryNumber>
                <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q46947FE7K</RegistryNumber>
                <NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GS-938</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C virus</Keyword>
            <Keyword MajorTopicYN="N">mericitabine</Keyword>
            <Keyword MajorTopicYN="N">resistance</Keyword>
            <Keyword MajorTopicYN="N">setrobuvir</Keyword>
            <Keyword MajorTopicYN="N">sofosbuvir (GS-7977)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24154738</ArticleId>
            <ArticleId IdType="pii">jit562</ArticleId>
            <ArticleId IdType="doi">10.1093/infdis/jit562</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24127258</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>07</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1860-7187</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>ChemMedChem</Title>
                <ISOAbbreviation>ChemMedChem</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1930-40</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cmdc.201300343</ELocationID>
            <Abstract>
                <AbstractText>The NS5A protein plays a critical role in the replication of HCV and has been the focus of numerous research efforts over the past few years. NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens. Early work in the NS5A arena led to the discovery of our first clinical candidate, MK-4882 [2-((S)-pyrrolidin-2-yl)-5-(2-(4-(5-((S)-pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole]. While preclinical proof-of-concept studies in HCV-infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single- and multiple-dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compounds with increased potency against a number of genotypes and NS5A resistance mutations. Modification of the MK-4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virologic profiles. Herein we describe the research efforts that led to the discovery of MK-8742, a tetracyclic indole-based NS5A inhibitor, which is currently in phase 2b clinical trials as part of an all-oral, interferon-free regimen for the treatment of HCV infection. </AbstractText>
                <CopyrightInformation>Copyright © 2013 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Coburn</LastName>
                    <ForeName>Craig A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicinal Chemistry, Merck and Company, Inc. West Point, PA 19486 (USA). craig_coburn@merck.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meinke</LastName>
                    <ForeName>Peter T</ForeName>
                    <Initials>PT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fandozzi</LastName>
                    <ForeName>Christine M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graham</LastName>
                    <ForeName>Donald J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Qian</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kargman</LastName>
                    <ForeName>Stacia</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kozlowski</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCauley</LastName>
                    <ForeName>John A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nomeir</LastName>
                    <ForeName>Amin A</ForeName>
                    <Initials>AA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soll</LastName>
                    <ForeName>Richard M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vacca</LastName>
                    <ForeName>Joseph P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Dahai</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhong</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olsen</LastName>
                    <ForeName>David B</ForeName>
                    <Initials>DB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ludmerer</LastName>
                    <ForeName>Steven W</ForeName>
                    <Initials>SW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>ChemMedChem</MedlineTA>
            <NlmUniqueID>101259013</NlmUniqueID>
            <ISSNLinking>1860-7179</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000589335">2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8724FJW4M5</RegistryNumber>
                <NameOfSubstance UI="C030374">indole</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002679" MajorTopicYN="N">Pan troglodytes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antiviral agents</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C</Keyword>
            <Keyword MajorTopicYN="N">inhibitors</Keyword>
            <Keyword MajorTopicYN="N">medicinal chemistry</Keyword>
            <Keyword MajorTopicYN="N">structure-activity relationships</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24127258</ArticleId>
            <ArticleId IdType="doi">10.1002/cmdc.201300343</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23384816</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>07</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-5967</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>57</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title>
                <ISOAbbreviation>J. Clin. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>13-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2012.12.020</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1386-6532(13)00007-3</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hepatitis C virus (HCV) NS5A replication complex inhibitors (RCIs) have been shown to exhibit picomolar antiviral activity against genotype 1 (GT1) in vitro. This has translated into rapid and robust declines in HCV RNA in GT1 patients. Less is known about the susceptibility of other genotypes such as GT3 to inhibition by NS5A RCIs.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To detect and phenotype naturally occurring HCVGT3 NS5A polymorphisms against two NS5A RCIs (daclatasvir [DCV] and GS-5885) currently in clinical development.</AbstractText>
                <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">The NS5A region from 96 HCV GT3 treatment-naive patients spanning North America, Europe and Australia was determined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Phylogenetic analysis revealed a broad distribution with no significant geographic clustering. GT1 DCV resistance-associated variants (RAVs) were observed in GT3 subjects; variants (and their frequencies) included 28M/V (1%), 30A/K/S/T/V (10%), 31L/M (1%), E92A (1%) and Y93H (8.3%). A consensus sequence was used to generate a JFH1/3a-NS5A hybrid replicon and employed to assess susceptibility to NS5A RCIs. Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.006 nM), A30V (EC(50) = 0.012 nM), and E92A (EC(50) = 0.004 nM) while the NS5A-A30K and -Y93H variants exhibited reduced sensitivity to DCV (EC50 values of 23 nM and 1120 nM, respectively) and to GS-5885 (EC50 values of 1770 nM and 4300 nM, respectively).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Substitutions conferring resistance to NS5A RCIs pre-existed in treatment-naive patients infected with HCV GT3. The effectiveness of these NS5A RCIs to exert efficacy in the clinic may depend on which inhibitor is used in combination with other antivirals.</AbstractText>
                <CopyrightInformation>Copyright © 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hernandez</LastName>
                    <ForeName>Dennis</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA. dennis.hernandez@bms.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Nannan</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueland</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monikowski</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>02</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Clin Virol</MedlineTA>
            <NlmUniqueID>9815671</NlmUniqueID>
            <ISSNLinking>1386-6532</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>J Clin Virol. 2016 Apr;77:115</RefSource>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23384816</ArticleId>
            <ArticleId IdType="pii">S1386-6532(13)00007-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jcv.2012.12.020</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23089758</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>57</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.</ArticleTitle>
            <Pagination>
                <MedlinePgn>611-3</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01874-12</ELocationID>
            <Abstract>
                <AbstractText>The NS5A replication complex inhibitor daclatasvir (DCV; BMS-790052) inhibits hybrid replicons containing hepatitis C virus (HCV) genotype 3a (HCV3a) NS5A genes with 50% effective concentrations (EC(50)s) ranging from 120 to 870 pM. Selection studies with a hybrid HCV3a replicon identified NS5A residues 31 and 93 as sites for DCV-selected resistance. Our results support the potential use of DCV as a component in combination therapies for HCV3a chronic infection.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Lingling</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirk</LastName>
                    <ForeName>Melissa J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GENBANK</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>JX944789</AccessionNumber>
                        <AccessionNumber>JX944790</AccessionNumber>
                        <AccessionNumber>JX944791</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23089758</ArticleId>
            <ArticleId IdType="pii">AAC.01874-12</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.01874-12</ArticleId>
            <ArticleId IdType="pmc">PMC3535966</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2003 Dec;125(6):1808-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14724833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2012 Sep;12(9):671-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22714001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Intervirology. 2005;48(2-3):183-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15812193</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2006 May 9;103(19):7408-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16651538</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17142229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 May;84(10):5277-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20200247</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2011 Jan;31 Suppl 1:62-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21205140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Jul;85(13):6353-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21507963</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Jul;85(14):7312-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21593143</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1956-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21837752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 19;366(3):216-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22256805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22203595</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22214777</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Mar;55(3):742-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21987462</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Jun;55(6):1692-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22234905</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 1994 Jul;75 ( Pt 7):1761-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8021605</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22850513</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>56</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5230-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01209-12</ELocationID>
            <Abstract>
                <AbstractText>Three hepatitis C virus (HCV) inhibitors, asunaprevir (ASV; BMS-650032), daclatasvir (DCV; BMS-790052), and BMS-791325, each targeting a different nonstructural protein of the virus (NS3, NS5A, and NS5B, respectively), have independently demonstrated encouraging preclinical profiles and are currently undergoing clinical evaluation. Since drug-resistant variants have rapidly developed in response to monotherapy with almost all direct-acting antiviral agents (DAAs) for HCV, the need for combination therapies to effectively eradicate the virus from infected patients is clear. These studies demonstrated the additive-synergistic effects on replicon inhibition and clearance of combining NS3 protease or NS5B RNA polymerase inhibitors with the first-in-class, NS5A replication complex inhibitor daclatasvir (DCV) and reveal new resistance pathways for combinations of two small-molecule inhibitors that differ from those that develop during monotherapy. The results suggest that under a specific selective pressure, a balance must be reached in the fitness costs of substitutions in one target gene when substitutions are also present in another target gene. Further synergies and additional novel resistance substitutions were observed during triple-combination treatment relative to dual-drug therapy, indicating that, in combination, HCV inhibitors can exert cross-target influences on resistance development. Enhanced synergies in replicon inhibition and a reduced frequency of resistance together lend strong support to the utility of combinations of DAAs for the treatment of HCV, and the identification of altered resistance profiles during combination treatment provides useful information for monitoring resistance in the clinic.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pelosi</LastName>
                    <ForeName>Lenore A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research &amp; Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voss</LastName>
                    <ForeName>Stacey</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Mengping</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lemm</LastName>
                    <ForeName>Julie A</ForeName>
                    <Initials>JA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C587012">8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22850513</ArticleId>
            <ArticleId IdType="pii">AAC.01209-12</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.01209-12</ArticleId>
            <ArticleId IdType="pmc">PMC3457360</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Virol. 2002 Jun;76(12):5974-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12021330</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Jul;56(7):3670-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22508297</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2003 Nov 13;426(6963):186-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14578911</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2004 Jun;48(6):2260-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15155230</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Sep;85(Pt 9):2485-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15302943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10583-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8248148</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1994 Jun;68(6):3753-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8189513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 1996;24(2 Suppl):11-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8836884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 1999 Feb;41(1):67-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10321580</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15793110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 May 19;435(7040):374-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15902263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2005 Sep;5(9):558-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16122679</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Nov 25;280(47):39260-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16188890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2006 May;50(5):1813-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16641454</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2006 Jun;80(12):6146-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16731953</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Rev. 2006 Sep;58(3):621-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16968952</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2006 Nov 2;49(22):6614-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17064080</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Cell Biol. 2007 Sep;9(9):1089-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17721513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2008 Mar;77(3):177-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18201776</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2008 Mar;4(3):e1000032</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18369478</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18824605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2009 Feb 1;48(3):313-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19123867</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1999 Dec;73(12):9984-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10559312</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2000 Dec 8;290(5498):1972-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11110665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2001 Mar;33(3):728-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11230755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2002 Mar 29;277(13):11149-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11801599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2009 Feb;53(2):401-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18936191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Gastroenterol Rep. 2009 Feb;11(1):15-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19166654</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Best Pract Res Clin Gastroenterol. 2008;22(6):1123-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19187871</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2009 Mar;49(3):745-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19072827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 May;83(9):4395-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19244328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Ther Pat. 2009 Feb;19(2):145-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19441916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2009 Jun;16(6):377-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19472445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Investig Drugs. 2009 Jun;18(6):709-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19426125</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mol Biol. 2009 Jul 31;390(5):1048-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19505479</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Liver Dis. 2009 Aug;13(3):453-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19628161</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antiviral Res. 2009 Nov;84(2):178-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19747948</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2009 Dec;50(6):1709-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19787809</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Investig Drugs. 2010 Jan;19(1):151-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20001560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Jan;54(1):305-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19841155</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2010 Feb;65(2):202-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19903720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2010 Feb;138(2):447-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20006612</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 May;54(5):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20176898</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Investig Drugs. 2010 Aug;19(8):963-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20629614</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virol Sin. 2010 Aug;25(4):246-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20960299</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2010 Oct 30;376(9751):1467-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20951424</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):20986-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21084633</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2011 Mar 31;364(13):1195-206</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21449783</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2011 May;54(5):872-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21145818</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem Lett. 2011 May 15;21(10):2925-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21486696</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2011 Jun 23;364(25):2405-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21696307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Pharmacother. 2011 Sep;45(9):1085-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21828346</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1956-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21837752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 19;366(3):216-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22256805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2012;56 Suppl 1:S88-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22300469</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22290978</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 May;77(9):5401-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12692242</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22430955</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>56</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3359-68</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00054-12</ELocationID>
            <Abstract>
                <AbstractText>PSI-7977, a prodrug of 2'-F-2'-C-methyluridine monophosphate, is the purified diastereoisomer of PSI-7851 and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. In this study, we profiled the activity of PSI-7977 and its ability to select for resistance using a number of different replicon cells. Results showed that PSI-7977 was active against genotype (GT) 1a, 1b, and 2a (strain JFH-1) replicons and chimeric replicons containing GT 2a (strain J6), 2b, and 3a NS5B polymerase. Cross-resistance studies using GT 1b replicons confirmed that the S282T change conferred resistance to PSI-7977. Subsequently, we evaluated the ability of PSI-7977 to select for resistance using GT 1a, 1b, and 2a (JFH-1) replicon cells. S282T was the common mutation selected among all three genotypes, but while it conferred resistance to PSI-7977 in GT 1a and 1b, JFH-1 GT 2a S282T showed only a very modest shift in 50% effective concentration (EC(50)) for PSI-7977. Sequence analysis of the JFH-1 NS5B region indicated that additional amino acid changes were selected both prior to and after the emergence of S282T. These include T179A, M289L, I293L, M434T, and H479P. Residues 179, 289, and 293 are located within the finger and palm domains, while 434 and 479 are located on the surface of the thumb domain. Data from the JFH-1 replicon variants showed that amino acid changes within the finger and palm domains together with S282T were required to confer resistance to PSI-7977, while the mutations on the thumb domain serve to enhance the replication capacity of the S282T replicons.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lam</LastName>
                    <ForeName>Angela M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmasset, Inc, Princeton, New Jersey, USA. angela.lam.al1@roche.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Espiritu</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bansal</LastName>
                    <ForeName>Shalini</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Micolochick Steuer</LastName>
                    <ForeName>Holly M</ForeName>
                    <Initials>HM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niu</LastName>
                    <ForeName>Congrong</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zennou</LastName>
                    <ForeName>Veronique</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keilman</LastName>
                    <ForeName>Meg</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Yuao</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lan</LastName>
                    <ForeName>Shuiyun</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Otto</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furman</LastName>
                    <ForeName>Phillip A</ForeName>
                    <Initials>PA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>03</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E2OU15WN0N</RegistryNumber>
                <NameOfSubstance UI="D014542">Uridine Monophosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WJ6CA3ZU8B</RegistryNumber>
                <NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014542" MajorTopicYN="N">Uridine Monophosphate</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22430955</ArticleId>
            <ArticleId IdType="pii">AAC.00054-12</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.00054-12</ArticleId>
            <ArticleId IdType="pmc">PMC3370800</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2003 Dec;125(6):1808-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14724833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2006 Mar;50(3):899-909</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16495249</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 May;49(5):2059-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15855532</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2005 Jul;11(7):791-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15951748</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2006 Jan;80(1):404-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16352565</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2006 Feb 17;281(7):3793-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16316989</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16495264</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2006 May;50(5):1813-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16641454</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2006 Jun;80(12):6146-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16731953</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Chem Chemother. 2006;17(2):79-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17042329</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2006 Dec;50(12):4161-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17000745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2007 Jan;81(2):588-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17079281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 May;52(5):1604-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18285474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 Jun;52(6):2043-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18411324</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 Sep;52(9):3327-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18559648</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 Oct;52(10):3523-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18694956</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 Dec;52(12):4356-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18838588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2009 May;53(5):2129-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19273674</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 Nov;83(22):11926-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19740982</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2010 Feb;65(2):202-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19903720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Mar;84(6):2923-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20071590</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 May;54(5):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20176898</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Aug;54(8):3187-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20516278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Top Microbiol Immunol. 2000;242:55-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10592656</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 Mar;77(5):3007-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12584326</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 Mar;77(5):3181-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12584342</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 Oct;77(19):10689-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12970456</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2003 Oct;38(4):869-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14512874</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2003 Nov;47(11):3525-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14576112</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2003 Dec 5;278(49):49164-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12966103</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2010 Oct 14;53(19):7202-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20845908</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2010 Nov 5;285(45):34337-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20801890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem Lett. 2010 Dec 15;20(24):7376-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21050754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2011 Jan;55(1):76-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21060109</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Mar;85(6):2565-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21209117</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2011 May;55(5):1843-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21357300</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2011 Jun;55(6):2566-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21444700</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem Lett. 2011 Jun 15;21(12):3658-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21550240</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Dec;85(23):12334-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21957306</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2012 Jan 1;54(1):96-104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22156853</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Jan;56(1):271-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22064535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2012 Mar 22;55(6):2481-531</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22185586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Infect Dis. 2013 Jul;57(2):221-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23575197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 1999 Sep 15;262(1):250-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10489358</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22256805</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>01</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>366</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Jan</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Preliminary study of two antiviral agents for hepatitis C genotype 1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>216-24</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1104430</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had ≥2 log(10) decline in HCV RNA after ≥12 weeks of treatment with peginterferon and ribavirin). We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 weeks. The primary end point was the percentage of patients with a sustained virologic response 12 weeks after the end of the treatment period.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 4 patients in group A (36%; 2 of 9 with HCV genotype 1a and 2 of 2 with genotype 1b) had a sustained virologic response at 12 weeks after treatment and also at 24 weeks after treatment.. Six patients (all with HCV genotype 1a) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period. All 10 patients in group B had a sustained virologic response at 12 weeks after treatment, and 9 had a sustained virologic response at 24 weeks after treatment. Diarrhea was the most common adverse event in both groups. Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virologic response can be achieved with two direct-acting antiviral agents only. In addition, a high rate of sustained virologic response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01012895.).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lok</LastName>
                    <ForeName>Anna S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. aslok@med.umich.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gardiner</LastName>
                    <ForeName>David F</ForeName>
                    <Initials>DF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawitz</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martorell</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Everson</LastName>
                    <ForeName>Gregory T</ForeName>
                    <Initials>GT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghalib</LastName>
                    <ForeName>Reem</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reindollar</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rustgi</LastName>
                    <ForeName>Vinod</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McPhee</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wind-Rotolo</LastName>
                    <ForeName>Megan</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Persson</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Kurt</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dimitrova</LastName>
                    <ForeName>Dessislava I</ForeName>
                    <Initials>DI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eley</LastName>
                    <ForeName>Timothy</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Tong</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grasela</LastName>
                    <ForeName>Dennis M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pasquinelli</LastName>
                    <ForeName>Claudio</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01012895</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q46947FE7K</RegistryNumber>
                <NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Hepatol. 2012 Aug;57(2):455-7</RefSource>
                <PMID Version="1">22465738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>N Engl J Med. 2012 Jan 19;366(3):273-5</RefSource>
                <PMID Version="1">22256811</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Gastroenterology. 2012 Jul;143(1):264-5</RefSource>
                <PMID Version="1">22633765</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22256805</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1104430</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22234905</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>08</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>55</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1692-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.25581</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">The influence of naturally occurring polymorphisms on the potency of the HCV nonstructural protein 5A (NS5A) replication complex inhibitor, BMS-790052, was investigated by evaluating hybrid replicons in which the entire NS5A coding region of genotype (GT) la and 1b laboratory (lab) strains (H77c and Con1) were replaced with the corresponding regions of specimens collected from 10 GT-1a- and 6 GT-1b-infected subjects. For baseline (BL) specimens, with no previously observed resistance variants identified by population sequencing, the median 50% effective concentration (EC(50) ) values for BMS-790052 were similar for the clinically derived and lab strains. A Q30R variant was observed at viral breakthrough (VBT) in one of the GT-1a-infected subjects. Because the lowest plasma exposure of BMS-790052 observed in this subject was 117 nM and the median 50% effective concentration value for a GT-1a H77c replicon containing a Q30R substitution is ~7 nM, a rigorous investigation was initiated to determine the basis for resistance. Three approaches were used: (1) replacement of the entire H77c NS5A or (2) replacement of the N-terminal region of NS5A, with sequence from BL and day 14, and (3) substitution of specific amino acids. A BL polymorphism (E62D) did not contribute resistance to BMS-790052; however, the linked variant, Q30R-E62D, conferred high-level resistance in vitro and is likely responsible for VBT in vivo.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data show that a BL polymorphism with minimal effect on the anti-HCV effect of BMS-790052 can affect the emergence of resistance and significantly affect clinical outcome. This work establishes a clear, systematic approach to monitor resistance to NS5A inhibitors in the clinic.</AbstractText>
                <CopyrightInformation>Copyright © 2012 American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jin-Hua</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA. jinhua.sun@bms.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Boyle Ii</LastName>
                    <ForeName>Donald R</ForeName>
                    <Initials>DR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nower</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roberts</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nettles</LastName>
                    <ForeName>Richard E</ForeName>
                    <Initials>RE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Hepatology. 2013 May;57(5):2087</RefSource>
                <PMID Version="1">22745013</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Hepatology. 2013 May;57(5):2087-8</RefSource>
                <PMID Version="1">23505151</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22234905</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.25581</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22214777</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>56</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1350-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.05977-11</ELocationID>
            <Abstract>
                <AbstractText>BMS-790052, a first-in-class hepatitis C virus (HCV) replication complex inhibitor, targeting nonstructural protein 5A (NS5A), displays picomolar to nanomolar potency against genotypes 1 to 5. This exceptional potency translated into robust anti-HCV activity in clinical studies with HCV genotype 1-infected subjects. To date, all BMS-790052-associated resistance mutations have mapped to the N-terminal region of NS5A. To further characterize the antiviral activity of BMS-790052, HCV replicon elimination and colony formation assays were performed. Replicon was cleared from genotype 1a and 1b replicon cells in a time- and dose-dependent manner. Elimination of the genotype 1a replicon required longer treatment durations and higher concentrations of BMS-790052 than those for the genotype1b replicon. Single amino acid substitutions that conferred relatively low levels of resistance were observed at early time points and at low doses. Higher doses and longer treatment durations yielded mutations that conferred greater levels of resistance, including linked amino acid substitutions. Replicon cells that survived inhibitor treatment remained fully sensitivity to pegylated alpha interferon (pegIFN-α) and other HCV inhibitors. Moreover, genotype 1a replicon elimination was markedly enhanced when pegIFN-α and BMS-790052 were combined. Resistant variants observed in this study were very similar to those observed in a multiple ascending dose (MAD) monotherapy trial of BMS-790052, validating replicon elimination studies as a model to predict clinical resistance. Insights gained from the in vitro anti-HCV activity and resistance profiles of BMS-790052 will be used to help guide the clinical development of this novel HCV inhibitor.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Haichang</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jin-Hua</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Boyle</LastName>
                    <ForeName>Donald R</ForeName>
                    <Initials>DR</Initials>
                    <Suffix>2nd</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nower</LastName>
                    <ForeName>Peter T</ForeName>
                    <Initials>PT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Lingling</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Dike</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Altaf</LastName>
                    <ForeName>Aneela</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>01</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C550357">PF 00868554</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011753">Pyrones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.7.48</RegistryNumber>
                <NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q46947FE7K</RegistryNumber>
                <NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011753" MajorTopicYN="N">Pyrones</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012324" MajorTopicYN="N">RNA Replicase</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22214777</ArticleId>
            <ArticleId IdType="pii">AAC.05977-11</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.05977-11</ArticleId>
            <ArticleId IdType="pmc">PMC3294925</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2000 Dec 8;290(5498):1972-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11110665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1956-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21837752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Nov;85(Pt 11):3173-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15483230</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2005 Mar;86(Pt 3):645-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15722525</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15793110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Intervirology. 2005;48(2-3):183-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15812193</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17142229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2007 May 7;13(17):2436-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17552026</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 May;52(5):1604-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18285474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 Jun;83(11):5760-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19321623</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2010 Sep;53(3):583-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20579761</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2010 Dec;17(12):825-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20723038</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virol J. 2010;7:296</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21040548</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2011 Jan;31 Suppl 1:62-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21205140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol Methods. 2011 Jun;174(1-2):153-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21473883</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2002 Dec;76(24):13001-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12438626</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22203595</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>56</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1588-90</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.06169-11</ELocationID>
            <Abstract>
                <AbstractText>The antiviral profile of BMS-790052, a potent hepatitis C virus (HCV) replication complex inhibitor targeting nonstructural protein NS5A, is well characterized for HCV genotype-1. Here, we report that BMS-790052 inhibits hybrid replicons containing HCV genotype-4 NS5A genes with 50% effective concentrations (EC(50)s) ranging from 7 to 13 pM. NS5A residue 30 was an important site for BMS-790052-selected resistance in the hybrid replicons. Our results support the potential of BMS-790052 as a valuable component of combination therapy for HCV genotype-4 chronic infection.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Lingling</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Haichang</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Dike</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jin-Hua</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nower</LastName>
                    <ForeName>Peter T</ForeName>
                    <Initials>PT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Boyle</LastName>
                    <ForeName>Donald R</ForeName>
                    <Initials>DR</Initials>
                    <Suffix>2nd</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GENBANK</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>JQ347513</AccessionNumber>
                        <AccessionNumber>JQ347514</AccessionNumber>
                        <AccessionNumber>JQ347515</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.12.-</RegistryNumber>
                <NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22203595</ArticleId>
            <ArticleId IdType="pii">AAC.06169-11</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.06169-11</ArticleId>
            <ArticleId IdType="pmc">PMC3294917</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Gen Virol. 2004 Nov;85(Pt 11):3173-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15483230</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15793110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17142229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1956-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21837752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2011 Jun;54(6):1250-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21316497</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2011 Jul;85(14):7312-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21593143</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Dec;54(6):1924-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21809362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21809362</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>02</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>07</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>54</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1924-35</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.24594</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">The NS5A replication complex inhibitor, BMS-790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single-ascending dose study and a 14-day multiple-ascending dose (MAD) monotherapy study. However, HCV RNA remained detectable in genotype 1a-infected patients at the end of the MAD study. In contrast, viral breakthrough was observed less often in patients infected with genotype 1b, and, in several patients, HCV RNA declined and remained below the level of quantitation (&lt;25 IU/mL) through the duration of treatment. Here, we report on the results of the genotypic and phenotypic analyses of resistant variants in 24 genotype 1-infected patients who received BMS-790052 (1, 10, 30, 60, and 100 mg, once-daily or 30 mg twice-daily) in the 14-day MAD study. Sequence analysis was performed on viral complementary DNA isolated from serum specimens collected at baseline and days 1 (4, 8, and 12 hours), 2, 4, 7, and 14 postdosing. Analyses of the sequence variants (1) established a correlation between resistant variants emerging in vivo with BMS-790052 treatment and those observed in the in vitro replicon system (major substitutions at residues 28, 30, 31, and 93 for genotype 1a and residues 31 and 93 for genotype 1b); (2) determined the prevalence of variants at baseline and the emergence of resistance at different times during dosing; and (3) revealed the resistance profile and replicative ability (i.e., fitness) of the variants.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although resistance emerged during monotherapy with BMS-790052, the substantial anti-HCV effect of this compound makes it an excellent candidate for effective combination therapy.</AbstractText>
                <CopyrightInformation>Copyright © 2011 American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, CT 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jin-Hua</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Boyle</LastName>
                    <ForeName>Donald R</ForeName>
                    <Initials>DR</Initials>
                    <Suffix>2nd</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nower</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Dike</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roberts</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kienzle</LastName>
                    <ForeName>Bernadette</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bifano</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nettles</LastName>
                    <ForeName>Richard E</ForeName>
                    <Initials>RE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21809362</ArticleId>
            <ArticleId IdType="doi">10.1002/hep.24594</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21593143</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>09</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>85</Volume>
                    <Issue>14</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.</ArticleTitle>
            <Pagination>
                <MedlinePgn>7312-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00253-11</ELocationID>
            <Abstract>
                <AbstractText>BMS-790052, targeting nonstructural protein 5A (NS5A), is the most potent hepatitis C virus (HCV) inhibitor described to date. It is highly effective against genotype 1 replicons and also displays robust genotype 1 anti-HCV activity in the clinic (M. Gao et al., Nature 465:96-100, 2010). BMS-790052 inhibits genotype 2a JFH1 replicon cells and cell culture infectious virus with 50% effective concentrations (EC(50)s) of 46.8 and 16.1 pM, respectively. Resistance selection studies with the JFH1 replicon and virus systems identified drug-induced mutations within the N-terminal region of NS5A. F28S, L31M, C92R, and Y93H were the major resistance mutations identified; the impact of these mutations on inhibitor sensitivity between the replicon and virus was very similar. The C92R and Y93H mutations negatively impacted fitness of the JFH1 virus. Second-site replacements at NS5A residue 30 (K30E/Q) restored efficient replication of the C92R viral variant, thus demonstrating a genetic interaction between NS5A residues 30 and 92. By using a trans-complementation assay with JFH1 replicons encoding inhibitor-sensitive and inhibitor-resistant NS5A proteins, we provide genetic evidence that NS5A performs the following two distinct functions in HCV RNA replication: a cis-acting function that likely occurs as part of the HCV replication complex and a trans-acting function that may occur outside the replication complex. The cis-acting function is likely performed by basally phosphorylated NS5A, while the trans-acting function likely requires hyperphosphorylation. Our data indicate that BMS-790052 blocks the cis-acting function of NS5A. Since BMS-790052 also impairs JFH1 NS5A hyperphosphorylation, it likely also blocks the trans-acting function.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA. Robert.fridell@bms.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Dike</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rose</LastName>
                    <ForeName>Ronald E</ForeName>
                    <Initials>RE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>05</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21593143</ArticleId>
            <ArticleId IdType="pii">JVI.00253-11</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.00253-11</ArticleId>
            <ArticleId IdType="pmc">PMC3126594</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2005 May 19;435(7040):374-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15902263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Intervirology. 2005;48(2-3):183-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15812193</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virus Res. 2006 Feb;115(2):122-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16146661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2004 Mar;78(6):2738-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14990694</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 1995 Jun 20;210(1):202-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7793072</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1994 Jun;68(6):3753-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8189513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2009 Apr 17;381(4):634-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19249289</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15793110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2004 Dec;78(23):13306-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15542681</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1995 Jul;69(7):3980-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7769656</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 May;77(9):5401-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12692242</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Oct 28;280(43):36417-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16126720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13038-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15326295</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2002 Mar 29;277(13):11149-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11801599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17142229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 May;77(10):6055-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12719597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 2008 Feb 5;371(1):71-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17949770</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 Sep;49(9):3816-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16127058</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 2007 Jul 20;364(1):1-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17400273</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20628345</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Drug Deliv Rev. 2007 Oct 10;59(12):1200-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17825945</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 May;77(9):5428-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12692244</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 May;83(9):4395-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19244328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem Lett. 2009 Mar 15;19(6):1779-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19216075</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Sep 24;279(39):40835-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15247283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Nov 19;279(47):48576-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15339921</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2006 Nov;80(22):11082-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16956932</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochemistry. 2007 Oct 16;46(41):11550-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17880107</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virol J. 2010;7:296</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21040548</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2008 Feb;82(3):1073-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18032500</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Jul;85(Pt 7):1867-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15218171</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1999 Sep;73(9):7138-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10438800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Open Biochem J. 2009 Apr 20;3:39-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19590581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2003 Dec;125(6):1808-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14724833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Cell Biol. 2007 Sep;9(9):1089-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17721513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2004 Nov;78(21):12085-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15479852</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 Mar;83(5):2163-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19073716</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 May;77(9):5487-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12692249</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Liver Dis. 2010 Nov;30(4):333-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20960374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 1996 Jan 2;15(1):12-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8598194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2008 Nov;82(21):10519-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18715913</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1993 Jul;67(7):3835-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8389908</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2000 Dec 8;290(5498):1972-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11110665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2005 Jan;79(2):896-909</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15613318</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2005 Mar;79(5):3187-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15709040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12884-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17616579</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2007 Feb;88(Pt 2):470-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17251564</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2008 Mar;4(3):e1000032</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18369478</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1999 Dec;73(12):9984-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10559312</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2008 Mar;4(3):e1000035</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18369481</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Sep;85(Pt 9):2485-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15302943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2005 Jul;11(7):791-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15951748</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20585111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2011 Mar;140(3):1032-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21111742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2002 Jun;76(12):5974-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12021330</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2005 Nov;79(21):13594-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16227280</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 1994 Nov 30;205(1):320-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7999043</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20585111</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-6596</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>54</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Antimicrobial agents and chemotherapy</Title>
                <ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3641-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00556-10</ELocationID>
            <Abstract>
                <AbstractText>BMS-790052 is the most potent hepatitis C virus (HCV) inhibitor reported to date, with 50% effective concentrations (EC(50)s) of &lt; or = 50 pM against genotype 1 replicons. This exceptional potency translated to rapid viral load declines in a phase I clinical study. By targeting NS5A, BMS-790052 is distinct from most HCV inhibitors in clinical evaluation. As an initial step toward correlating in vitro and in vivo resistances, multiple cell lines and selective pressures were used to identify BMS-790052-resistant variants in genotype 1 replicons. Similarities and differences were observed between genotypes 1a and 1b. For genotype 1b, L31F/V, P32L, and Y93H/N were identified as primary resistance mutations. L23F, R30Q, and P58S acted as secondary resistance substitutions, enhancing the resistance of primary mutations but themselves not conferring resistance. For genotype 1a, more sites of resistance were identified, and substitutions at these sites (M28T, Q30E/H/R, L31M/V, P32L, and Y93C/H/N) conferred higher levels of resistance. For both subtypes, combining two resistance mutations markedly decreased inhibitor susceptibility. Selection studies with a 1b/1a hybrid replicon highlighted the importance of the NS5A N-terminal region in determining genotype-specific inhibitor responses. As single mutations, Q30E and Y93N in genotype 1a conferred the highest levels of resistance. For genotype 1b, BMS-790052 retained subnanomolar potency against all variants with single amino acid substitutions, suggesting that multiple mutations will likely be required for significant in vivo resistance in this genetic background. Importantly, BMS-790052-resistant variants remained fully sensitive to alpha interferon and small-molecule inhibitors of HCV protease and polymerase.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA. robert.fridell@bms.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Dike</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valera</LastName>
                    <ForeName>Lourdes</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>06</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
            <NlmUniqueID>0315061</NlmUniqueID>
            <ISSNLinking>0066-4804</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20585111</ArticleId>
            <ArticleId IdType="pii">AAC.00556-10</ArticleId>
            <ArticleId IdType="doi">10.1128/AAC.00556-10</ArticleId>
            <ArticleId IdType="pmc">PMC2935007</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Biol Chem. 2004 Nov 19;279(47):48576-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15339921</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 6;465(7294):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20410884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Intervirology. 2005;48(2-3):183-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15812193</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 May 19;435(7040):374-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15902263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Infect Dis. 2005 Sep;5(9):558-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16122679</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Oct 28;280(43):36417-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16126720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2006 Feb;87(Pt 2):323-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16432018</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2006 Jul 27;49(15):4721-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16854079</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17142229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 2007 Jul 20;364(1):1-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17400273</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2007 May 7;13(17):2416-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17552024</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2007 May 7;13(17):2461-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17552030</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochemistry. 2007 Oct 16;46(41):11550-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17880107</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2007 Nov 21;13(43):5673-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17963291</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2008 Feb;82(3):1073-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18032500</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18824605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2001 Feb;75(3):1437-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11152517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2002 Mar 8;277(10):8130-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11744739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Sep;85(Pt 9):2485-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15302943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Sep 24;279(39):40835-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15247283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2004 Oct;78(20):11393-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15452261</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 2004 Nov;85(Pt 11):3173-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15483230</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2009 Jan;50(1):184-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19022518</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2009 Jan;29 Suppl 1:57-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19207967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2009 Mar;49(3):745-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19072827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2009 Apr 17;381(4):634-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19249289</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 May;83(9):4395-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19244328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2009 Jun;16(6):377-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19472445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Gastroenterol Hepatol. 2009 Sep;6(9):509-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19713984</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2009 Dec;6(12):e1000198</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20041120</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Antimicrob Chemother. 2010 Feb;65(2):202-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19903720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2010 Feb 1;17(2):77-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20040045</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2010 Feb;138(2):447-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20006612</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15793110</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20410884</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-4687</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>465</Volume>
                    <Issue>7294</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>May</Month>
                        <Day>06</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature</Title>
                <ISOAbbreviation>Nature</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.</ArticleTitle>
            <Pagination>
                <MedlinePgn>96-100</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/nature08960</ELocationID>
            <Abstract>
                <AbstractText>The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus. The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B. Here we describe the profile of BMS-790052, a small molecule inhibitor of the HCV NS5A protein that exhibits picomolar half-maximum effective concentrations (EC(50)) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture. In a phase I clinical trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was associated with a 3.3 log(10) reduction in mean viral load measured 24 h post-dose that was sustained for an additional 120 h in two patients infected with genotype 1b virus. Genotypic analysis of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants observed had substitutions at amino-acid positions identified using the in vitro replicon system. These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nettles</LastName>
                    <ForeName>Richard E</ForeName>
                    <Initials>RE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belema</LastName>
                    <ForeName>Makonen</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Snyder</LastName>
                    <ForeName>Lawrence B</ForeName>
                    <Initials>LB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Van N</ForeName>
                    <Initials>VN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fridell</LastName>
                    <ForeName>Robert A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serrano-Wu</LastName>
                    <ForeName>Michael H</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langley</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jin-Hua</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Boyle</LastName>
                    <ForeName>Donald R</ForeName>
                    <Initials>DR</Initials>
                    <Suffix>2nd</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lemm</LastName>
                    <ForeName>Julie A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chunfu</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knipe</LastName>
                    <ForeName>Jay O</ForeName>
                    <Initials>JO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chien</LastName>
                    <ForeName>Caly</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colonno</LastName>
                    <ForeName>Richard J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grasela</LastName>
                    <ForeName>Dennis M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meanwell</LastName>
                    <ForeName>Nicholas A</ForeName>
                    <Initials>NA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamann</LastName>
                    <ForeName>Lawrence G</ForeName>
                    <Initials>LG</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>04</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nature</MedlineTA>
            <NlmUniqueID>0410462</NlmUniqueID>
            <ISSNLinking>0028-0836</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C549273">BMS-790052</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Hepatology. 2010 Sep;52(3):1162-4</RefSource>
                <PMID Version="1">20812360</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Hepatol. 2011 May;54(5):1069-72</RefSource>
                <PMID Version="1">21167889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nature. 2010 May 6;465(7294):42-4</RefSource>
                <PMID Version="1">20445618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Drug Discov. 2010 Jun;9(6):432</RefSource>
                <PMID Version="1">20514066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Microbiol. 2010 Jul;8(7):464</RefSource>
                <PMID Version="1">21394952</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002522" MajorTopicYN="N">Cercopithecus aethiops</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20410884</ArticleId>
            <ArticleId IdType="pii">nature08960</ArticleId>
            <ArticleId IdType="doi">10.1038/nature08960</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2007 Dec;6(12):991-1000</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18049473</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 May 19;435(7040):374-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15902263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2006 Apr 14;281(15):9833-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16407182</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Drug Discov. 2009 Mar;4(3):293-314</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23489127</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2007 Oct;46(4):1026-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17600342</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2006 May 9;103(19):7408-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16651538</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2006 Dec 7;355(23 ):2444-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17151366</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15793110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2004 Aug;78(15):7904-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15254163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2002 Nov;1(11):911-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12415250</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9739-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15998731</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2001 Jul 5;345(1):41-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11439948</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Aug 18;436(7053):953-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16107835</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2009 May;83(9):4395-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19244328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2004 Dec 16;432(7019):846-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15602550</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Drug Discov. 2008 Jun 1;3(6):671-676</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19750206</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):77-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18673121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Microbes Infect. 2002 Oct;4(12):1219-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12467763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2003 Jun;77(12):6753-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12767995</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2008 Jun 21;14 (23 ):3621-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18595128</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2010 Jan;84(1):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19812153</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30957170</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6613</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Apr</Month>
                        <Day>08</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of infectious diseases</Title>
                <ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">jiz154</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiz154</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">12-week grazoprevir/elbasvir is highly effective in hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of 8-week regimen for naïve patients with mild fibrosis is elusive.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">HCV-1b naïve patients with mild fibrosis were randomized to 8 (n=41) or 12 (n=41) weeks of elbasvir/grazoprevir. The primary endpoint was SVR12 (HCV RNA &lt; 12 IU/ml at post-treatment week-12).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">SVR12 was achieved by 87.8% (36/41) and 100% (41/41) in the full-analysis population and 90.0% (36/40) and 100% (41/41) in the per-protocol population in the 8-week and 12-week arms, respectively (all p=0.055). In the 8-week arm, a significantly lower SVR12 rate was observed among patients with a high viral loads (HVL,&gt;1,500,000 IU/mL, 79% vs. 100%, p=0.042) and those with baseline NS5A-Y93H RAS &gt;15% (40.0% vs. 97.1%, p=0.004). Between-group analysis demonstrated that patients with HVL and Y93H&gt;15% had a substantially lower SVR12 rate in the 8-week arm (40.0%) than the 12-week arm (100.0%). All four HCV-1b relapses had NS5A RAS Y93H&gt; 99% at post-treatment week-12.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Twelve weeks of grazoprevir/elbasvir is highly effective for HCV-1b naïve patients with mild fibrosis. A truncated 8-week grazoprevir/elbasvir regimen might be applied for those with low viral loads or without significant NS5A RAS.</AbstractText>
                <CopyrightInformation>© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Chung-Feng</ForeName>
                    <Initials>CF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital and Hepatitis Research Center and Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hung</LastName>
                    <ForeName>Chao-Hung</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hepatogastroenterology, Department of Internal Medicine, ChiaYi Chang Gung Memorial Hospital, ChiaYi, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Pin-Nan</ForeName>
                    <Initials>PN</Initials>
                    <AffiliationInfo>
                        <Affiliation>ational Cheng Kung University Hospital, Tainan, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bair</LastName>
                    <ForeName>Ming-Jong</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung City, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Yi-Hsiang</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kao</LastName>
                    <ForeName>Jia-Horng</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Shih-Jer</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Pei-Lun</ForeName>
                    <Initials>PL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Chi-Mei Medical Center, Liouying, Tainan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jyh-Jou</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology and Hepatology, Chi-Mei Medical Center, Liouying, Tainan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chien</LastName>
                    <ForeName>Rong-Nan</ForeName>
                    <Initials>RN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Cheng-Yuan</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hepatology and Gastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Chun-Yen</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsieh</LastName>
                    <ForeName>Tsai-Yuan</ForeName>
                    <Initials>TY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Tri-service General Hospital, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Chun-Han</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung City, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dai</LastName>
                    <ForeName>Chia-Yen</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital and Hepatitis Research Center and Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Jee-Fu</ForeName>
                    <Initials>JF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital and Hepatitis Research Center and Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chuang</LastName>
                    <ForeName>Wan-Long</ForeName>
                    <Initials>WL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital and Hepatitis Research Center and Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Ming-Lung</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital and Hepatitis Research Center and Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B) and Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Infect Dis</MedlineTA>
            <NlmUniqueID>0413675</NlmUniqueID>
            <ISSNLinking>0022-1899</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CHC</Keyword>
            <Keyword MajorTopicYN="N">DAA</Keyword>
            <Keyword MajorTopicYN="N">abbreviated</Keyword>
            <Keyword MajorTopicYN="N">elbasvir</Keyword>
            <Keyword MajorTopicYN="N">grazoprevir</Keyword>
            <Keyword MajorTopicYN="N">treatment</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30957170</ArticleId>
            <ArticleId IdType="pii">5430846</ArticleId>
            <ArticleId IdType="doi">10.1093/infdis/jiz154</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30127629</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1178-6973</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Infection and drug resistance</Title>
                <ISOAbbreviation>Infect Drug Resist</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1119-1135</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IDR.S156581</ELocationID>
            <Abstract>
                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">A detailed analysis of hepatitis C virus (HCV) resistance-associated substitutions (RASs) is required to understand why people fail direct-acting antiviral therapies. This study was conducted to assess RASs in an analysis of 2 trials evaluating the second-generation NS3/4A protease inhibitor grazoprevir (GZR) in combination with peginterferon/ribavirin.</AbstractText>
                <AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">From a total of 113 participants with HCV genotype 1 infection, RASs were evaluated in 25 patients who relapsed and 6 patients with on-treatment virologic breakthrough using consensus Sanger and clonal sequence analysis of NS3/NS4a genes, with in vitro testing of replicon mutants. Next-generation sequencing (NGS) was used in a subset of participants to assess minority variants and the evolution of the whole viral genome.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Baseline RASs did not predict treatment failure. Relapse was most commonly associated with RASs at D168, although additional RASs (Y56, R155 and A156) were also detected, particularly in participants with on-treatment breakthrough. Treatment-emergent RASs usually reverted to wild-type (WT), suggesting these mutations were associated with a negative fitness cost (confirmed using in vitro assays). NGS was the most sensitive assay for the detection of minor variants. Significant viral sequence divergence (up to 5.9% codons) was observed across whole genomes in association with the acquisition and reversion of RASs.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Relapse with GZR and peginterferon/ribavirin is commonly associated with single RASs in NS3 that generally revert to WT, while breakthrough follows more complex patterns of viral resistance. NGS suggests that large diverse pools of viral quasispecies that emerge with RASs facilitate rapid viral evolution.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bonsall</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK, david.bonsall@ndm.ox.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Stuart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Ym</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chase</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingravallo</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pak</LastName>
                    <ForeName>Irene</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK, david.bonsall@ndm.ox.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK, david.bonsall@ndm.ox.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowden</LastName>
                    <ForeName>Rory</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK, david.bonsall@ndm.ox.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barnes</LastName>
                    <ForeName>Eleanor</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK, david.bonsall@ndm.ox.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MR/K01532X/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Infect Drug Resist</MedlineTA>
            <NlmUniqueID>101550216</NlmUniqueID>
            <ISSNLinking>1178-6973</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">NS3/4A protease inhibitor</Keyword>
            <Keyword MajorTopicYN="N">next-generation sequencing</Keyword>
            <Keyword MajorTopicYN="N">resistance-associated substitution</Keyword>
            <Keyword MajorTopicYN="N">virologic failure</Keyword>
        </KeywordList>
        <CoiStatement>Disclosure Paul Ingravallo is an employee of Merck &amp; Co., Inc. Stuart Black, Anita YM Howe, Robert Chase and Irene Pak are former employees of Merck &amp; Co., Inc. The authors report no other conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30127629</ArticleId>
            <ArticleId IdType="doi">10.2147/IDR.S156581</ArticleId>
            <ArticleId IdType="pii">idr-11-1119</ArticleId>
            <ArticleId IdType="pmc">PMC6089106</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Viral Hepat. 2016 Feb;23(2):80-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26353843</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2013 May;57(5):2054-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23403428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2000 Feb;74(4):2046-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10644379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Genomics. 2012 Sep 13;13:475</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22974120</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virology. 2013 Sep;444(1-2):329-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23876458</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet HIV. 2015 Aug;2(8):e319-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26423374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2015 Jul 7;163(1):1-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Jun 10;8(6):e66129</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23762474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Nov;62(5):1623-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antivir Ther. 2018;23(1):53-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28594332</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1087-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2017 Jan;152(1):164-175.e4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27720838</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 May;54(5):1878-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20176898</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>F1000Res. 2015 Oct 13;4:1062</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27092241</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Sep;62(3):932-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26111063</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2012;8(3):e1002529</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22412369</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1998 Oct 2;282(5386):103-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9756471</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2992-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15710891</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26926625</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Viral Hepat. 2016 Oct;23(10):789-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27291249</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 Sep;63(3):564-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25895428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2016 Sep 15;12(9):e1005894</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27631086</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(4):e34372</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22511937</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2016 Oct;54(10):2470-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27385709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22615282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1075-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467591</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Oct 17;386(10003):1537-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26456905</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28228479</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>292</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>04</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6202-6212</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M116.772996</ELocationID>
            <Abstract>
                <AbstractText>Grazoprevir is a potent pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was developed for treating chronic HCV infection. In HCV genotype (GT) 1a, grazoprevir maintains potent activity against a majority of NS3 resistance-associated amino acid substitutions, including the highly prevalent and naturally occurring Q80K polymorphism that impacts simeprevir, another NS3/4A protease inhibitor. The basis for an unexpected difference in the clinical impact of some NS3 substitutions was investigated. Phenotypic analysis of resistance-associated substitutions identified in NS3 from GT1a-infected patients who failed therapy with grazoprevir (in combination with elbasvir, an inhibitor of HCV NS5A protein) showed that positions 56, 156, and 168 in NS3 were most impactful because they diminished protein-inhibitor interactions. Although an amino acid substitution from aspartic acid to alanine at position 168 (D168A) reduced the potency of grazoprevir, its combination with R155K unexpectedly nullified this effect. Molecular dynamics and free-energy surface studies indicated that Asp-168 is important in anchoring Arg-155 for ligand binding but is not critical for Lys-155 because of the inherent flexibility of its side chain. Moreover, modeling studies supported a strong direct cation-heterocycle interaction between the Lys-155 side chain of the double substitution, R155K/D168A, and the lone pair on the quinoxaline in grazoprevir. This unique interaction provides a structural basis for grazoprevir's higher potency than simeprevir, an inhibitor to which the double substitution confers a significant reduction in potency. Our findings are consistent with the detection of R155K/D168A in NS3 from virologic failures treated with simeprevir but not grazoprevir.</AbstractText>
                <CopyrightInformation>© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Zhuyan</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Chemistry, Modeling and Informatics and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Stuart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Merck Research Laboratories, Kenilworth, New Jersey 07033.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Chemistry, Modeling and Informatics and.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McMonagle</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Merck Research Laboratories, Kenilworth, New Jersey 07033.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingravallo</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Merck Research Laboratories, Kenilworth, New Jersey 07033.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chase</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Merck Research Laboratories, Kenilworth, New Jersey 07033.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curry</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Merck Research Laboratories, Kenilworth, New Jersey 07033.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asante-Appiah</LastName>
                    <ForeName>Ernest</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases, Merck Research Laboratories, Kenilworth, New Jersey 07033 Ernest_asanteappiah@merck.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>PDB</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>3SUD</AccessionNumber>
                        <AccessionNumber>3KEE</AccessionNumber>
                        <AccessionNumber>3SUE</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C084422">NS3 protein, hepatitis C virus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9WS5RD66HZ</RegistryNumber>
                <NameOfSubstance UI="D000069616">Simeprevir</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069616" MajorTopicYN="N">Simeprevir</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">crystal structure</Keyword>
            <Keyword MajorTopicYN="Y">drug resistance</Keyword>
            <Keyword MajorTopicYN="Y">hepatitis C virus (HCV)</Keyword>
            <Keyword MajorTopicYN="Y">molecular dynamics</Keyword>
            <Keyword MajorTopicYN="Y">protease inhibitor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28228479</ArticleId>
            <ArticleId IdType="pii">M116.772996</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M116.772996</ArticleId>
            <ArticleId IdType="pmc">PMC5391751</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Am Chem Soc. 2008 Apr 9;130(14):4607-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18338894</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16495264</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ACS Med Chem Lett. 2012 Mar 02;3(4):332-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24900473</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2014 Mar 13;57(5):1673-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24446688</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2011 Feb;140(2):667-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21056040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2000 Feb;74(4):2046-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10644379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Comput Chem. 2002 Dec;23(16):1623-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12395429</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Jan;61(1):77-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25069599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Aug 2;384(9941):403-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24907225</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet HIV. 2015 Aug;2(8):e319-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26423374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Oct;54(4):1433-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21898493</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anal Biochem. 2008 Feb 1;373(1):1-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18022380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 2004 Aug;78(15):7904-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15254163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2015 Nov;62(5):1623-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Jul 2;285(5424):110-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10390360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Pathog. 2012;8(7):e1002832</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22910833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2010 Dec;54(12):5288-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20855726</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2009 Jan;29 Suppl 1:74-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19207969</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):988-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25451053</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antimicrob Agents Chemother. 2006 Mar;50(3):899-909</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16495249</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2000 Dec 8;290(5498):1972-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11110665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2015 Mar 21;385(9973):1075-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25467591</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2015 May;62(5):1008-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25445400</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27291249</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2893</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of viral hepatitis</Title>
                <ISOAbbreviation>J. Viral Hepat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>789-97</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jvh.12552</ELocationID>
            <Abstract>
                <AbstractText>Grazoprevir (GZR) is a second-generation hepatitis C virus NS3/4A protease inhibitor. The aim of this study was to evaluate GZR plus ribavirin (RBV) in patients with HCV GT1 infection. Noncirrhotic, IL28B CC patients with HCV genotype 1 infection were randomized to GZR 100 mg once daily and RBV for 12 or 24 weeks. Patients in the 12-week arm with detectable HCV RNA at treatment week 4 (TW4) had treatment extended to 24 weeks (response-guided therapy, RGT). The primary endpoint was sustained virologic response (SVR12) at follow-up week 12 (HCV RNA &lt;25 IU/mL) in the per-protocol (PP) population (excluding patients with important protocol deviations). Twenty-six patients were randomized and 22 were included in the PP population. SVR12 was 58.3% (7 of 12) and 90% (9 of 10) in the RGT and 24-week arms, respectively. Seven PP patients had virologic failure, including one patient in the 24-week arm who relapsed after follow-up week 12. All three breakthrough patients had wild-type (WT) virus at baseline and developed breakthrough at TW6 or TW12 with Y56H, A156T and D168A/N mutations. Of the five relapse patients, four had WT at baseline (at relapse three had WT and one had V55A and D168A), and one had S122A/T at baseline and S122T at relapse. There were no serious adverse events (AEs), discontinuations due to AEs or grade 3/4 elevations in total and/or direct bilirubin. Grazoprevir plus RBV was associated with a rapid and sustained suppression of HCV RNA. These results support further evaluation of grazoprevir-based regimens (NCT01716156; protocol P039).</AbstractText>
                <CopyrightInformation>© 2016 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gane</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Auckland Clinical Studies, Auckland, New Zealand. edgane@adhb.govt.nz.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ben Ari</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Disease Center, Sheba Medical Center, Ramat Gan, Israel.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mollison</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fremantle Hepatitis Services, Fremantle Hospital, Fremantle, WA, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zuckerman</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, Carmel Medical Center Technion Faculty of Medicine, Haifa, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bruck</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baruch</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, Rambam Healthcare Campus and the Technion Faculty of Medicine, Haifa, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>A Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahl</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhanja</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>M N</ForeName>
                    <Initials>MN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01716156</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Viral Hepat</MedlineTA>
            <NlmUniqueID>9435672</NlmUniqueID>
            <ISSNLinking>1352-0504</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">adverse event</Keyword>
            <Keyword MajorTopicYN="Y">clinical trial</Keyword>
            <Keyword MajorTopicYN="Y">efficacy</Keyword>
            <Keyword MajorTopicYN="Y">randomized</Keyword>
            <Keyword MajorTopicYN="Y">resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>04</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27291249</ArticleId>
            <ArticleId IdType="doi">10.1111/jvh.12552</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25266289</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1537-6591</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>59</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Dec</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
                <ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1657-65</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciu696</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Virologic failure following treatment of hepatitis C virus (HCV) genotype 1 with direct-acting antiviral agents is often accompanied by the emergence of resistant variants. MK-5172 is an investigational once-daily protease inhibitor. We analyzed variants in treatment-naive noncirrhotic patients with virologic failure on MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV) during a phase 2 trial.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Population and selective clonal sequencing were performed at baseline and at virologic failure in the 4 MK-5172 dosing arms. MK-5172 activity was determined using a mutant replicon assay.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Six of 266 (2.3%) MK-5172 recipients satisfied prespecified criteria for virologic failure, all with genotype 1a infection. Five patients with virologic failure were in the MK-5172 100-mg arm, including 4 patients with low plasma MK-5172 levels documented during triple therapy. Variants associated with &gt;4-fold loss of potency were detected in 3 of the 4 patients with genotype 1a breakthrough while on MK-5172. The fifth patient had undetectable HCV-RNA levels at the end of triple therapy but subsequently broke through during the peg-IFN/RBV tail 16 weeks after completion of MK-5172. Three patients had D168 variants at virologic failure, including 2 with the D168A variant associated with a 95-fold loss of potency. The sole apparent relapse was actually a genotype 3a reinfection in the MK-5172 200-mg group.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Virologic failure occurred uncommonly (6/266 [2.3%]) in MK-5172/peg-IFN/RBV recipients. The most prevalent treatment-emergent variants were detected at the D168 locus. D168A variants conferring approximately 2-log reduction in MK-5172 susceptibility emerged in 2 of the 4 evaluable patients with genotype 1a breakthrough. Clinical Trials Registration. NCT01353911.</AbstractText>
                <CopyrightInformation>© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Howe</LastName>
                    <ForeName>Anita Y M</ForeName>
                    <Initials>AY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Stuart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curry</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ludmerer</LastName>
                    <ForeName>Steven W</ForeName>
                    <Initials>SW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barnard</LastName>
                    <ForeName>Richard J O</ForeName>
                    <Initials>RJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Newhard</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>Peggy M T</ForeName>
                    <Initials>PM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nickle</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilbert</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caro</LastName>
                    <ForeName>Luzelena</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DiNubile</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Office of the Chief Medical Officer, Merck, North Wales, Pennsylvania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mobashery</LastName>
                    <ForeName>Niloufar</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck Research Laboratories, West Point.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT01353911</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Infect Dis</MedlineTA>
            <NlmUniqueID>9203213</NlmUniqueID>
            <ISSNLinking>1058-4838</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8YE81R1X1J</RegistryNumber>
                <NameOfSubstance UI="C578009">MK-5172</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9008-11-1</RegistryNumber>
                <NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Clin Infect Dis. 2014 Dec 15;59(12):1675-7</RefSource>
                <PMID Version="1">25266288</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MK-5172</Keyword>
            <Keyword MajorTopicYN="N">hepatitis C genotype 1</Keyword>
            <Keyword MajorTopicYN="N">resistance-associated variants</Keyword>
            <Keyword MajorTopicYN="N">treatment-naive</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25266289</ArticleId>
            <ArticleId IdType="pii">ciu696</ArticleId>
            <ArticleId IdType="doi">10.1093/cid/ciu696</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
</Publications>